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Abstract 
 
Skeletal muscle (SKM) is the most important tissue in maintaining glucose homeostasis 
and impairments in this tissue leads to insulin resistance (IR). Activation of 5’ AMP-
activated kinase (AMPK) is viewed as a targeted approach to counteract IR. Rosemary 
extract (RE) has been reported to decrease blood glucose levels but its effects on SKM 
are not known. We hypothesized that RE acts directly on SKM to increase glucose 
uptake (GU). We found an increase in GU (184±5.07% of control, p<0.001) in L6 
myotubes by RE to levels similar to insulin and metformin. Carnosic acid (CA) and 
rosmarinic acid (RA), major polyphenols found in RE, increased GU. RE, CA, and RA 
significantly increased AMPK phosphorylation and their effects on GU was reduced by 
an AMPK inhibitor. Our study is the first to show a direct effect of RE, CA and RA on SKM 
GU by a mechanism that involves AMPK activation. 
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Chapter 1: Introduction 
 
Skeletal muscle tissue accounts for approximately 80% of insulin-mediated glucose 
uptake in the post-prandial state and therefore plays a predominant role in maintaining 
glucose homeostasis. The facilitative glucose transporters (GLUTs) enable glucose entry 
into skeletal muscle cells and represent the rate-limiting step in restoration of post-
prandial euglycemia. Insulin increases skeletal muscle glucose uptake by increasing 
translocation of intracellular stored GLUT4 glucose transporters to the plasma 
membrane through the phosphatidylinositol-3 kinase (PI3K) and Akt signaling pathway. 
Impaired PI3K-Akt signaling causes insulin resistance (IR) and combined with impaired 
pancreatic beta-cell function leads to Type 2 diabetes mellitus (T2DM), which accounts 
for 90-95% of all diabetes cases.   
The AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine 
kinase that functions as a cellular energy sensor. Importantly, skeletal muscle AMPK is 
activated by exercise/contraction and various compounds including metformin, 
thiazolidineones, and the polyphenols resveratrol  and naringenin leading to stimulation 
of glucose uptake. In recent years, AMPK has become an attractive pharmacological 
target for the treatment of insulin resistance (IR) and T2DM. Therefore, the study of 
novel compounds that activate AMPK and increase skeletal muscle glucose uptake is of 
major importance and could lead to broadening the treatment options for insulin 
resistance (IR) and T2DM.  
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Rosemary (Rosmarinus officinalis Lamiaceae) is an aromatic evergreen shrub/plant 
indigenous to the Mediterranean region and South America reported to have anti-
microbial, anti-cancer, and antioxidant properties. Additionally, effects on lipid 
metabolism and plasma glucose levels  have been reported. In vitro studies have shown 
that rosemary extract (RE) has an insulin-like effect to inhibit gluconeogenesis in 
hepatocytes. In in vivo studies, RE administration decreased plasma glucose levels in 
streptozotocin (STZ)-induced diabetic rats, alloxan-induced diabetic rabbits, genetic and 
dietary animal models of obesity and insulin resistance (IR). Direct effects of RE on 
skeletal muscle glucose transport have not been examined previously and its 
mechanism of action is not known.  
In the present thesis, the effects of RE on glucose transport in L6 rat skeletal muscle 
cells were examined. RE increased glucose uptake in L6 myotubes and increased AMPK 
phosphorylation. The effects of RE on skeletal muscle cell glucose uptake are similar to 
that seen with metformin and the polyphenol resveratrol and its mechanisms of action 
deserves further study.  
1.1  Glucose Transporters 
Glucose is a major energy source and is an important substrate for both protein and 
lipid synthesis in mammalian cells (1). It provides energy in the form of ATP through 
glycolysis and the citric acid cycle. It is also used in the synthesis of glycerol for 
triglyceride production and provides intermediates for synthesis of non-essential amino 
acids. Virtually all mammalian cells possess one or more transport systems to allow 
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glucose movement through the plasma membrane (2).The plasma membrane of cells is 
composed of a lipid bilayer impermeable to carbohydrates. Therefore, glucose does not 
freely travel across the plasma membrane and requires membrane- associated carrier 
proteins for transport. There are two main groups of glucose transporters, the sodium-
glucose cotransporters (SGLTs) and the facilitated diffusion glucose transporters 
(GLUTs). The SGLTs are predominantly found in the intestinal epithelial and renal 
tubular cells where they are responsible for sodium-dependent secondary active 
transport of glucose. In the presence of sodium, these transporters have increased 
affinity for glucose and transport glucose against its concentration gradient (2).  
 Cells take up glucose from interstitial fluid by a passive, facilitative transport 
process, driven by the downward glucose concentration gradient across the plasma 
membrane (1). The passive facilitative transport process is mediated by the family of 
facilitative glucose transporters [gene symbol, SLC2A (solute carrier family 2, facilitated 
glucose transporter), protein symbol GLUT] (3). Thirteen members of this family have 
been identified, GLUT1-12 and H+/myoinositol transporter (HMIT) with a tertiary 
structure of 12 transmembrane domains containing cytoplasmic carboxyl (C)- and amino 
(N)- terminals (1,2). These proteins are structurally conserved specifically in the putative 
transmembrane (TM) regions and are more divergent in the loops between the TM and 
in the C- and N- terminal regions (2). The GLUT proteins have distinct substrate 
specificities, kinetic properties and tissue distributions that dictate their functional roles 
(3). The characteristics of GLUT1 to GLUT4, the most extensively studied transporters, 
are shown in Table 1.  
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Table 1: Characteristics of the Major Facilitated Glucose Transporters 
Transporter Approximate Km  
for Glucose (mM) 
Tissue Distribution Characteristics 
GLUT1 20 Widely expressed: high expression in 
brain, erythrocytes, and endothelial 
cells 
Constitutive glucose 
transporter 
GLUT2 42 Kidney, small intestine epithelia, 
liver, pancreatic β-cells. 
Low-affinity; role as 
glucose sensor in β-
cells 
GLUT3 10 Neurons, placenta High affinity glucose 
transporter 
GLUT4 2-10 Skeletal & cardiac muscle; adipose 
tissue 
Insulin-responsive 
glucose transporter 
 
The GLUT1 transporter is characterized as the basal glucose transporter. GLUT1 (46kDa) 
is ubiquitously expressed with high concentrations in human erythrocytes and in 
endothelial cells lining blood vessels in the brain (1,3) (Table 1). GLUT1 has a high affinity 
(Km=20 mM) for glucose. GLUT2 is a low affinity transporter (Km = 42mM) found in the 
liver, intestine, kidney, and pancreatic β cells. This transporter plays a role in the glucose 
sensory system in pancreatic β cells and functions in the basolateral transport of 
intestinal epithelial cells. GLUT3 (45 kDa, Km = 10mM) is expressed in fetal embryonic 
tissues like placenta and neurons allowing glucose to cross the blood brain barrier (3) 
GLUT4 (48 kDa, Km = 2- 10mM) is an insulin-responsive glucose transporter present in 
skeletal muscle, cardiac muscle, and adipose tissue (Table.1).  
 While GLUT1 appears to be largely responsible for glucose transport under basal 
conditions (2), it cannot compensate for postprandial blood glucose elevations. The 
restoration of blood glucose levels following an exogenous glucose load is largely 
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achieved by increased availability of the insulin sensitive-GLUT4 transporter on the 
plasma membrane of skeletal muscle, cardiac muscle and adipose tissue. GLUT4 exhibits 
the unique characteristic of mostly being intracellularly localized in the unstimulated 
state whereas insulin or other stimuli can acutely redistribute these transporters to the 
plasma membrane (1). During the basal state, GLUT4 containing intracellular vesicles 
continually cycle between the plasma membrane and several intracellular 
compartments, where the majority of the transporters are located inside the cell (~90%) 
(2). It is believed that the unique sequences in GLUT4’s COOH- and N- terminal 
cytoplasmic domains direct its characteristic membrane trafficking capacity (2). Both 
insulin stimulation and exercise acutely increases the recruitment of GLUT4 to the cell 
surface of adipose and muscle tissue through different intracellular pathways (2). Insulin 
stimulation increases the rate of GLUT4-vesicle exocytosis and reduces the rate of 
endocytosis in adipocytes only thus resulting in an increased number of GLUT4 
transporters at the plasma membrane. Indeed, rapid translocation of GLUT4 from an 
internal pool to the plasma membrane was demonstrated to occur in response to acute 
insulin stimulation in both fat cells and muscle fibres (3).  
 Theoretically, mutations in GLUT4 could lead to impaired insulin action, termed 
insulin resistance. Polymorphisms in the GLUT4 gene, however, are extremely rare in 
insulin resistant, type 2 diabetic individuals, and have the same prevalence among 
nondiabetics (4,5). GLUT4 concentrations are reduced in adipocytes derived from obese 
insulin resistant individuals or type 2 diabetes mellitus (T2DM) but these findings are not 
reflected in skeletal muscle of obese subjects, type 1 or type 2 or gestational diabetic 
Rosemary (Rosmarinus officinalis L.) Extract 
 
6 
 
individuals or insulin resistant relatives of persons with T2DM indicating that reduction 
in GLUT4 production is not a prime cause of impaired glucose transport and handling 
(3). On the other hand, reduction in insulin-stimulated glucose uptake in skeletal muscle 
in obese and diabetic individuals appears to be associated with an impairment in insulin-
stimulated translocation of GLUT4 from intracellular vesicles to the plasma membrane 
either involving defects in the insulin signaling pathway that regulate GLUT4 
translocation or in the molecular machinery directly involved in the recruitment of 
GLUT4-containing vesicles to the plasma membrane, their docking, and their fusion with 
the membrane (6).  
 Heterozygous GLUT4 knockout mice that display decreased GLUT4 protein in muscle 
and adipose tissue show insulin resistance and propensity towards diabetes (7). 
Overexpression of GLUT4 in skeletal muscle of heterozygous GLUT4 knockout mice 
normalized insulin sensitivity and glucose tolerance (8). Mice with tissue-specific GLUT4 
deficiency exhibited insulin resistance in adipose tissue, liver (9) and muscle tissue (10). 
Levels of insulin-induced GLUT4 translocation in the skeletal muscle of type 2 diabetic 
patients are typically reduced by approximately 90% (11). These abovementioned 
studies underscore the importance of GLUT4 in the regulation of glucose homeostasis.  
 There is evidence of at least two distinct intracellular pools of recruitable GLUT4 in 
muscle and at least one of the pools can respond to stimuli other than insulin in subjects 
with insulin resistance (3). Stimuli such as muscle contraction and hypoxia activate pools 
distinct from that activated by insulin, and the glucose uptake response to exercise and 
hypoxia is normal in muscle from obese subjects and those with diabetes. Food 
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components that potentially target this latter, distinct pool of GLUT4 may prove to be 
beneficial in alleviation of tissue insulin resistance.  
1.2  Insulin 
Insulin, a protein hormone first discovered in 1922 by Banting and Best, is primarly 
involved in glucose homeostasis and is responsible for decreasing postprandial blood 
glucose elevations by promoting tissue uptake of glucose from the circulation and 
inhibiting endogenous glucose production (EGP) by the liver (12). It is produced by the 
β-cells in the islets of Langerhans of the pancreas. Insulin has a half-life of approximately 
five minutes and it is cleared by receptor-mediated endocytosis and degraded by 
lysosomal insulinase. Once insulin binds to its receptor in target tissues/cells, it activates 
several signaling pathways that result in the hormone’s effects. 
Insulin plays a key role in maintaining blood glucose homeostasis, which is needed 
for proper energy metabolism. Figure 1 shows that following ingestion of a meal, there 
is a rise in blood glucose levels which is sensed by the endocrine portion of the pancreas 
specifically the β cells of the islets of Langerhans. In reponse to elevated blood glucose 
levels, the β cells release insulin into the circulation which binds to its receptors located 
on skeletal muscle, adipose tissue and liver, its main target tissues and collectively 
restore physiological blood glucose levels. Insulin promotes glucose uptake and 
utilization by skeletal muscle as well as storage of glucose as glycogen in this tissue. In 
adipose tissue, insulin stimulates glucose uptake and storage as triglycerides (13,14).  
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Figure 1: Role of Insulin in Glucose Homeostasis   
In the liver, insulin inhibits glucose production by inhibiting gluconeogenesis and 
glycogenolysis. The end result of these actions of insulin is to restore and maintain 
plasma glucose levels within a physiological range of four to seven millimolar (80-115 
mg/dL).   
1.3 Insulin Resistance 
Insulin resistance (IR) is a condition in which major insulin target tissues such as skeletal 
muscle, fat and liver display diminished responsiveness to normal circulating levels of 
insulin. In other words, IR is the failure to respond to physiological plasma 
concentrations of insulin and this state is commonly associated with obesity, aging, 
sedentary lifestyle as well as a genetic predisposition (15). In skeletal muscle, insulin’s 
stimulation of glucose uptake, utilization for energy production and storage as muscle 
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glycogen is compromised in insulin-resistant state (16). Insulin’s action on adipose tissue 
to promote glucose uptake and storage as lipids as well as suppressing lipolysis via the 
inhibition of hormone sensitive lipase (HSL) is compromised when this tissue becomes 
insulin-resistant. Additionally, the suppression of glucose production and release by 
inhibiting gluconeogenesis and glycogenolysis in liver is compromised in an insulin-
resistant state. As a result of tissue (skeletal muscle, adipose tissue and liver) insulin 
resistance, there is chronic elevation of plasma glucose levels (hyperglycemia). Chronic 
hyperglycemia can lead to short-term complications including diabetic ketoacidosis; as 
well as long-term complications including macrovascular/microvascular damage, 
cardiovascular disease, retinopathy, neuropathy and nephropathy (16,17). Moreover, 
chronic hyperglycemia not only exacerbates target tissue IR but dramatically contributes 
to pancreatic β cell exhaustion and loss of function (discussed in section 1.8).  
1.3.1 Skeletal Muscle Insulin Resistance 
Skeletal muscle is quantitatively the most important tissue in glucose homeostasis, 
accounting for 75 to 80% of postprandial glucose uptake and disposal (13) and therefore 
skeletal muscle insulin resistance (IR) will lead to major imbalances in blood glucose 
levels instigating hyperglycemia, impaired glucose tolerance (IGT) and T2DM. It has been 
consistently demonstrated that T2DM individuals are severely resistant to insulin 
compared to age-, weight- and sex-matched controls (18-20) and 85-90% of the 
impairment in total body glucose disposal has been demonstrated to be a result of 
muscle IR (21). In addition, there is evidence to indicate that skeletal muscle IR precedes 
hepatic IR and dysfunctional pancreatic islet-induced insulin deficiency by decades (22).  
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About 75-80% of insulin stimulated glucose disposal is converted to glycogen, 
whereas the remaining 20-25% is oxidized to carbon dioxide (C02) and water (H20) (23). 
Previous studies have demonstrated that in the state of T2DM, impaired glycogen 
synthesis secondary to reduced glycogen synthase activity is the earliest metabolic 
defect (24,25). In muscle tissue, glucose enters myocytes through the facilitated GLUTs 
through mass action.  Once inside the cell, glucose is converted to glucose-6-phosphate 
by hexokinase followed by isomerization to glucose-1-phosphate, activation to uridine 
5-diphosphate glucose and turned into glycogen by glycogen synthase. Insulin 
modulates glycogen accumulation through a coordinated increase in glucose transport 
and glycogen synthesis. The hormone increases muscle glucose uptake by causing 
increased translocation of GLUT4 to the plasma membrane as well as inducing GLUT4 
protein synthesis thereby increasing the number and overall plasma membrane 
availability of GLUT4 transporters. The hormone activates glycogen synthase by 
dephosphorylation through inhibition of kinases such as protein kinase A (PKA) and 
glycogen synthase kinase 3 (GSK3) (26) and activation of protein phosphatase 1 (PP1) 
(27).  In terms of muscle IR, emerging evidence indicates that decreased glycogen 
content is mainly attributable to impairments in insulin-stimulated glucose transport 
and to a much lesser extent to decreased phosphorylation activity (22). Glucose 
transport is the rate-limiting step in non-oxidative and oxidative muscle glucose 
utilization and storage as glycogen; and therefore aberrations in the signaling pathway 
underlying glucose uptake are a primary cellular explanation of muscle IR (signaling 
pathway discussed in section 1.4). 
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1.3.2 Adipose Tissue Insulin Resistance  
As mentioned before, insulin acts on adipose tissue to promote glucose uptake and 
storage as lipids and inhibits lipolysis. Adipose tissue accounts for 4-5% of whole body 
glucose disposal in the postprandial state, therefore from a quantitative standpoint; lack 
of insulin action on this tissue may seemingly appear to be irrelevant for glucose 
homeostasis. On the contrary, deranged adipocyte metabolism plays a very important 
role in the pathogenesis of T2DM (28). Lack of insulin action on adipose tissue to exhibit 
antilipolytic effects by inhibiting HSL leads to increased plasma free fatty acid (FFA) 
levels (29-31). Elevated FFA levels have been consistently implicated in skeletal muscle 
and liver IR (32,33). Chronically elevated FFA levels have various effects in terms of 
glucose homeostasis including inhibition of muscle glucose transport and glucose 
utilization; inhibition of muscle and liver glycogen synthase; increased expression and 
activity of phosphophenolpyruvate carboxykinase (PEPCK) and pyruvate carboxylase, 
the rate-limiting enzymes involved in gluconeogenesis (34). Therefore, elevated FFA 
levels secondary to insulin resistant adipose tissue counteracts the effects of insulin on 
muscle and liver instigating and exacerbating muscle and hepatic IR.  
1.3.3 Liver Insulin Resistance  
In the fasting state, the liver is the main source of endogenous glucose production (EGP) 
especially for the brain (13). The liver is responsible for 80-90% of EGP while the kidney 
generates the remaining 10-20%. It is evident from various epidemiological studies that 
individuals with T2DM have increased basal EGP compared to healthy counterparts with 
concomitant higher fasting plasma insulin levels suggesting that this tissue is resistant to 
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the action of insulin (13,28). The increased hepatic glucose production (HGP) in the state 
of hepatic IR is primarily caused by a deregulation of insulin-induced inhibition of 
hepatic gluconeogenesis and glycogenolysis.  
Thus, insulin resistance occurs in skeletal muscle, adipose tissue and liver and 
these tissues collectively impair glucose homeostasis. Chronically elevated plasma 
glucose levels (hyperglycemia) trigger pancreatic β cell-induced elevations of plasma 
insulin levels (hyperinsulinemia), a condition that further desensitizes tissues to insulin, 
which is followed by reduced insulin secretion as a result of β cell exhaustion. Therefore 
it is evident that there is a vicious cycle of impaired insulin action and insulin secretion 
that collectively lead to T2DM. Although, there is ongoing research trying to determine 
whether the initial defect in the natural history of T2DM is insulin resistance or 
pancreatic β-cell dysfunction, it still remains unclear (discussed in section 1.8).  
1.4  Insulin Signaling Cascade 
The insulin receptor is a plasma membrane intrinsic tyrosine kinase receptor belonging 
to a subfamily of receptor tyrosine kinases which also includes the insulin-like growth 
factor (IGF)-1 receptor and the insulin receptor-related receptor (IRR) (13). The receptor 
is a heterotetramer composed of two α and two β subunits linked by a disulfide bond. 
The α subunits are localized in the extracellular fluid and contain the insulin-binding 
domain while the β subunits extent from the extracellular fluid into the cytosolic surface 
where the tyrosine kinase domain is located. The action of insulin on its target tissues is 
initiated by insulin binding to its receptor and increasing the receptor’s tyrosine kinase 
activity towards intracellular substrates (35,36) (Figure 2). When insulin binds to the α 
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subunits of the receptor, it leads to a conformational change that allows 
autophosphorylation of the β subunits resulting in increased activity of the intrinsic 
tyrosine kinase domain of the receptor. Once activated, the insulin receptor 
phosphorylates a number of intracellular substrates on tyrosine including members of 
the insulin receptor substrate family (IRS1/2/3/4) and the Shc adaptor proteins, Gab-1 
and Cbl. Tyrosine phosphorylation of these proteins creates recognition sites for 
additional effector molecules containing Src Homology 2 (SH2) domains such as p85, the 
regulatory subunit of phosphatidylinositol 3-kinase (PI3K). Binding of the p85 regulatory 
subunit of PI3K to IRS activates its catalytic subunit, p110. Activated PI3K generates the 
lipid phosphatidylinositol 3,4,5-trisphosphate (PIP3) and increased levels of this 
intermediate bind PKB/Akt and phosphatidylinositol-3,4,5-phosphate-dependent kinase-
1 (PDK-1) by their pleckstrin homologous (PH) domains (15). PKB/Akt and PDK-1 
colocalize to the plasma membrane and this allows phosphorylation of PKB/Akt on 
threonine308 by PDK-1. PKB/Akt mediates many of insulin’s actions in its target cells 
such as glucose uptake, glycolysis, glycogen synthesis as well as protein synthesis (37). 
As shown in Figure 2, activation of the PI3K-Akt signaling cascade by insulin leads to 
GLUT4 glucose transporter translocation and increased glucose uptake. 
 Akt (PKB) substrates that have been well established include glycogen synthase 
kinase-3; the Rab GTPase activating protein AS160/TBC1D4 responsible for regulating 
glucose transport; the Rheb GTPase activating complex, tumor suppressor tuberous 
sclerosis complex 1/2 (TSC1/2) responsible for regulating mammalian target of 
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rapamycin (mTOR) and protein synthesis; and forkhead box protein (FOXO) transcription 
factors regulating expression of gluconeogenic and other genes (38,39).  
 Insulin-stimulated phosphorylation of the Akt (PKB) substrate, AS160/TBC1D4 
leads to inhibition of its Rab-GTPase activating protein (Rab-GAP) activity and has 
emerged as a key component of regulation of GLUT4 trafficking, although its site of 
action is uncertain (40,41). Insulin stimulation dramatically increases the translocation 
rate of GLUT4-containing intracellular vesicles to the plasma membrane via exocytosis 
and also has effects on decreasing the rate of GLUT4 internalization (42). Therefore, the 
end result of this signaling pathway is to increase plasma membrane GLUT4 number and 
activity (Figure 2). Increased plasma membrane availability of GLUT4 provides a route 
for glucose entry into skeletal muscle and adipose cells driven by a concentration 
gradient that is maintained by hexokinase (phosphorylates glucose and traps it inside 
cell). Phosphorylated glucose can either enter the pathway that leads to glycogen 
synthesis (anabolic) or glucose metabolism (catabolic) which is ultimately determined by 
the energy needs of cell. 
 Another well-established insulin signaling pathway is the Ras-MAPK pathway , 
not discussed in this thesis since it mainly mediates insulin’s growth, and proliferation 
and not metabolic/glucose transport effects. 
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Figure 2: Insulin stimulates the PI3K-Akt signaling cascade in skeletal muscle leading to 
increased glucose uptake.  IRS, Insulin receptor substrate; PI3K, phosphatidylinositol-3-
kinase; Akt (PKB), protein kinase B; GLUT4, glucose transporter; pY, phosphorylated 
tyrosine residues.  
1.4.1 Importance of Insulin Receptor Substrate in Insulin Signaling   
The insulin receptor substrate (IRS) family of proteins consists of at least four isoforms 
(IRS-1 to -4) which differ in their tissue distribution, cellular localization and function. 
IRS-1 (180kDa) mainly regulates metabolic processes including involvement in protein 
synthesis and glucose transport in skeletal muscle and adipose tissue, while IRS-2 
(185kDa), expressed in liver, adipose and muscle tissue performs a broad range of 
cellular activity. IRS-3 and IRS-4 are predominantly expressed in adipose and 
neuroendocrine tissue and suggested to exert a negative regulation on IRS-1 and IRS-2 
(15). Intact IRS signaling is crucial for insulin action and aberrations in IRS activity results 
in functional disturbances. Overexpression of human recombinant IRS-1 in L6 skeletal 
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muscle cells increased basal and insulin-stimulated glucose uptake, and increased 
plasma membrane content of GLUT4 indicating its role in this signaling pathway (43). 
Moreover, insulin-stimulated IRS-1 associated PI3K activity was increased in cells 
overexpressing recombinant IRS-1 compared to control cells (43). In L6 myotubes, small 
interfering RNA (siRNA)-induced IRS-1 gene silencing caused a marked reduction in 
insulin-induced glucose uptake and GLUT4 translocation (44). In primary skeletal muscle 
cells derived from patients with impaired glucose tolerance (prediabetes), the level of 
insulin-induced glucose uptake was reduced by 30-50% compared to that of control 
(45). This decrease in glucose uptake was associated with reduced IRS-2 tyrosine 
phosphorylation and impaired IRS-2 activation of PI3K in response to insulin. Moreover, 
skeletal muscle biopsies from type 2 diabetic subjects displayed impaired insulin action 
on IRS-1 and PI3K without these defects being associated with reduced protein 
expression of the insulin receptor, IRS-1 or the p85 subunit of PI3K (46).  
IRS-1/2 knockout mice developed peripheral IR and T2DM (47,48) indicating the 
importance of IRS in the insulin signaling pathway in vivo.  
Insulin-stimulated 2-deoxyglucose uptake was 53% lower in intact muscle strips 
from obese subjects compared to control subjects (49). Furthermore, insulin-stimulated 
IRS-1 phosphorylation and PI3K activity was reduced in obese subjects compared to 
control subjects (49). In lean type 2 diabetic subjects, insulin-stimulated IRS-1 
phosphorylation and PI3K activity was significantly decreased compared to healthy 
individuals (50). The reduced IRS-1 phosphorylation in lean type 2 diabetic individuals 
was not related to changes in IRS-1 protein content which was similar between the 
Rosemary (Rosmarinus officinalis L.) Extract 
 
17 
 
groups (50). Insulin-stimulated muscle disposal was decreased in normoglycemic 
relatives of type 2 diabetic patients compared to those without family history of 
diabetes (51). Moreover, there was decreased insulin-stimulated IRS-1 phosphorylation 
and association of PI3K activity with IRS-1 in skeletal muscle of normoglycemic subjects 
with history of diabetes compared to control group (51) providing stronger support for 
the importance of IRS in the insulin signaling pathway. Therefore, obese and T2DM 
individuals display reductions in IRS phosphorylation and IRS-associated PI3K activity 
which results in comparable reductions in insulin-stimulated glucose uptake in muscle 
tissue.  
Thus, in vitro studies in different cell lines, and in vivo studies in different animal 
models and in humans support the critical importance of insulin substrate receptor (IRS) 
in the insulin signaling pathway.   
1.4.2  Importance of Phosphatidylinositiol-3-kinase in Insulin Signaling  
Phosphatidylinositol-3-kinase (PI3K) is composed of a p110 catalytic subunit and a p85 
regulatory subunit that has two SH2 domains which interact with specific 
phosphotyrosine-containing motifs, pYMXM and pYXXM, in the IRS proteins (15). This 
family of proteins consists of 14 members divided into four classes where class I, II, and 
III are lipid kinases and class IV are related protein kinases (15). Importantly, only the 
heterodimeric p85/p110 PI3K of the class I family of proteins is responsive to insulin 
(13,37). Class I is further subdivided into class 1A which encompasses the p110α and 
p110β catalytic subunits whereas class 1B contains the p110γ subunit. There are various 
isoforms of the regulatory p85 subunit including p85α, p55α, p85β, and p55γ (37). 
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Treatment of 3T3-L1 adipocytes with LY294002, a potent inhibitor of PI3K, blocked 
insulin-stimulated glucose uptake by inhibiting translocation of GLUT4 to the plasma 
membrane (52). Treatment of rat adipocytes with wortmannin, another inhibitor of 
PI3K, abolished insulin-stimulated PI3K activation and subsequent insulin-stimulated 2-
deoxyglucose uptake (53). Many other studies with PI3K inhibitors including LY29002, 
and wortmannin, showed similar abolishment of insulin-stimulated glucose uptake in 
skeletal muscle cells indicating the importance of PI3K in this action of insulin (54).  
The expression of a constitutively activated mutant of PI3K catalytic subunit 
p110 in 3T3-L1 adipocytes caused plasma membrane translocation of GLUT4 which was 
abolished with co-treatment with wortmannin (55). Overexpression of p110α in 3T3-L1 
cells caused a 1.4 fold increase in basal glucose transport rate compared to control cells 
which was associated with increased plasma membrane translocation of GLUT4 (56). 
These studies demonstrate that PI3K, specifically the catalytic p110 subunit, is crucial for 
GLUT4 translocation in vitro.  
Mice with double heterozygous loss of p110α +/- p110β+/- had an observed 40% 
reduction in insulin-induced IRS-1 associated PI3K activity and 50% reduction in PI3K 
activity in muscle tissue and displayed mild glucose tolerance and hyperinsulinemia 
compared to wild-type mice (57). Similarly, it was demonstrated that mice deficient in 
p85α and p85β regulatory subunits of PI3K had impaired PI3K signaling in muscle and 
exhibited muscle insulin resistance and whole-body glucose intolerance (prediabetes) 
(58).  
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Furthermore, human skeletal muscle cells isolated from type 2 diabetic subjects 
had decreased IRS-1 tyrosine phosphorylation, decreased association of PI3K with IRS-1 
and decreased PI3K activity in response to insulin compared to control cells from 
healthy subjects (59). These in vivo studies not only underscore the important role of 
the p110 subunit of PI3K in the context of glucose transport in muscle but also 
demonstrate that the regulatory p85 subunit is crucial for the overall activity of PI3K. 
Altogether the abovementioned in vitro and in vivo studies clearly indicate the 
importance of PI3K in basal- and insulin-stimulated glucose uptake. Thus, PI3K activity is 
crucial for intact insulin signaling.  
1.4.3 Importance of Protein Kinase B (Akt /PKB) in Insulin Signaling  
Protein Kinase B (PKB/Akt) is a serine/threonine kinase with three mammalian isoforms 
identified including Akt1, Akt2, and Akt3. Akt1 is ubiquitously expressed in mammalian 
tissue while Akt2 is also expressed in the majority of tissues albeit at lower levels than 
the former isoform. Importantly, Akt2 is predominantly found in insulin-reponsive 
tissues including skeletal muscle, liver and adipose tissue. Lastly, Akt3 displays a low 
level expression in mammalian tissue excluding the testes and brain (1). Akt requires 
phosphorylation of two of its residues including threonine residue (Thr308) and serine 
residue (Ser473) for full activation (15). While under basal conditions, the majority of 
Akt is localized in the cytosol, upon PI3K activation, Akt translocates to the plasma 
membrane and becomes activated by PI3K. Activated Akt will detach from the plasma 
membrane and migrate through the cytosol and into the nucleus (15). The expression of 
constitutively active PKB/Akt in 3T3-L1 adipocytes induced glucose uptake in the 
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absence of insulin by stimulating translocation of GLUT4 to the plasma membrane (60). 
Katome et al. used a small interference RNA (siRNA) approach to investigate the role of 
PKB/Akt in insulin-stimulated glucose uptake. It was shown that constitutively active 
PKBα/Akt1 stimulates glucose uptake in both Chinese hamster ovary and 3T3-L1 cells 
overexpressing GLUT4, whereas inhibition of PKB/Akt function by siRNA markedly 
reduces insulin-stimulated glucose uptake (61). Akt2-null adipocytes derived from 
immortalized mouse embryo fibroblasts (MEFs) displayed significantly reduced insulin-
stimulated hexose uptake, and plasma membrane GLUT4 translocation which was 
restored with re-expression of Akt2 (62). Many studies in muscle cells also showed 
similar abolishment of insulin-stimulated glucose uptake indicating the importance of 
Akt in this action (17,38). 
Mice with homozygous deletion of Akt2 presented with fasting hyperglycemia 
and insulin-stimulated 2-deoxyglucose uptake was impaired in muscle tissue in vitro 
(63). Similarly, Akt2-null mice exhibited impaired insulin-stimulated muscle glucose 
uptake which was accompanied by elevated plasma glucose levels (hyperglycemia) (64).  
Insulin-induced glucose uptake was reduced by 60% in adipocytes from type 2 
diabetic patients compared to healthy controls (65). Moreover, adipocytes isolated from 
type 2 diabetic patients had decreased insulin-induced total serine phosphorylation and 
activation of Akt (PKB) (65). A recent study in humans detected a missense mutation in 
the kinase domain of PKBβ (AKT2) in a family of severely insulin resistant patients (66).  
Rosemary (Rosmarinus officinalis L.) Extract 
 
21 
 
Thus, it can be seen from the abovementioned studies that Akt plays a crucial 
role in insulin-induced GLUT4-plasma membrane translocation and loss of Akt function 
leads to insulin resistance and type 2 diabetes mellitus (discussed in section 1.8).  
It is well established from in vitro and in vivo studies that IRS, PI3K, and Akt are 
important proteins involved in insulin’s actions on glucose homeostasis and 
manipulating the levels of these proteins in different experimental models have proven 
to significantly alter insulin-stimulated glucose uptake. More importantly, there is 
unequivocal evidence to show that IRS, PI3K, and Akt activity is reduced in the insulin-
resistant state both in vitro and in vivo. In terms of changes in the protein expression of 
IRS, PI3K, and Akt in the insulin resistant state, there is conflicting results from different 
studies. In the next section, the underlying mechanisms involved in reduced IRS, PI3K 
and Akt activity will be discussed.  
1.5  Mechanisms Underlying Insulin Resistance 
Although, there is evidence from genetic studies that indicate certain mutations in the 
insulin receptor can invariably cause IR, the majority of IR cases arise from post-receptor 
changes (3). As seen from the previous discussion, the insulin receptor is a tyrosine 
kinase and its activation lead to activation of the serine/threonine kinase Akt. Certain 
tyrosine kinase phosphatases have been implicated in insulin resistance. Glucose 
transport in insulin resistant muscle is activated normally by inhibitors of tyrosine 
phosphatases (vanadate) (3). Vanadate stimulates glucose transport by increasing 
translocation of GLUT1 and 4 in muscle and fat cells. Several organo-vanadium 
compounds have been found to improve insulin sensitivity in both muscle and liver in 
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type 2 diabetic subjects and to reduce insulin requirements in those with type 1 
diabetes (3). Studies have shown that the insulin signal is attenuated through the 
activation of particular serine/threonine kinases. Under physiological conditions, there is 
a negative feedback mechanism that uncouples IRS-1 protein from its upstream and 
downstream effector molecules and abrogates insulin signal transduction. Chronic 
hyperinsulinemia in skeletal muscle cells and adipocytes was shown to induce serine 
phosphorylation of IRS-1 (22). Thus, the inhibitory serine phosphorylation of IRS-1 may 
be one of the ways the cell attempts to nullify insulin’s signal transduction after steady 
state plasma glucose levels are achieved. However, over-stimulation of pathways that 
lead to serine phosphorylation of IRS-1 in pathological conditions has been shown to 
cause insulin resistance. Several signaling molecules including glycogen synthase kinase 
3 (GSK3), mammalian target of rapamycin (mTOR), p70S6K, c-Jun N-terminal kinase 
(JNK), protein kinase C (PKC), and inhibitor of B (IB) kinase (IKK) have been 
implicated in causing tissue IR (Figure 3). The abovementioned enzymes cause IR by 
phosphorylating IRS-1 protein on specific serine residues which consequently inhibits 
tyrosine phosphorylation of IRS-1 and leads to decreased insulin-stimulated glucose 
uptake in skeletal muscle and adipose tissue. Serine phosphorylation of IRS-1 renders it 
a worse substrate for the insulin receptor thereby intervening IRS-1 tyrosine 
phosphorylation by the insulin receptor and subsequent association with its 
downstream effector PI3K. Specific serine residues of IRS-1 have been implicated in 
insulin resistance including Ser307, Ser612, Ser636/639, Ser1101 which are differentially 
phosphorylated by the abovementioned serine/threonine kinases (15).  
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Figure 3: Mechanism of insulin resistance in skeletal muscle. Akt, protein kinase B; 
AS160, Akt substrate of 160 kDa; GLUT4, glucose transporter 4; GSK3, glycogen synthase 
kinase 3; IKK, inhibitor of IҡB; IRS-1, insulin receptor substrate-1; JNK, c-Jun-N-terminal 
kinase; mTOR, mammalian target of rapamycin; PDK-1, phosphoinositide-dependent 
kinase-1; PI3K, phosphatidylinositol-3-kinase; PIP3, phosphatidylinositol (3,4,5)-
triphosphate; PKC, protein kinase C; S6K, ribosomal protein S6 kinase.  
 Factors such as nonesterified free fatty acids (FFA), and its metabolic derivatives, as 
well as certain inflammatory cytokines phosphorylate and activate the abovementioned 
serine/threonine kinases. More importantly, elevated FFA levels, and inflammatory 
cytokines are strongly associated with tissue IR. In section 1.7.4, the role of FFAs and 
inflammatory cytokines will be discussed briefly.  
Although the insulin signaling pathway is compromised in IR primarily through 
the action of various serine/threonine kinases, there is an insulin-independent pathway 
that regulates glucose and lipid metabolism and more importantly has been shown to 
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play a role in cellular glucose transport (Figure. 4, refer to page 27). This pathway 
involves 5`-adenosine monosphosphate activated protein kinase (AMPK) which will be 
discussed below.  
1.6 5’-Adenosine Monophosphate Activated Protein Kinase 
5’-adenosine monosphosphate activated protein kinase (AMPK), a heterotrimeric 
protein, acts as a sensor of cellular fluctuations in energy status (67). It participates in 
the regulation of cellular metabolic processes, integration of nutritional and hormonal 
activity in peripheral tissues and the hypothalamus, as well as modulation of adipokines’ 
effects on glucose and lipid metabolism. In general terms, activated AMPK at the cellular 
level inhibits anabolic pathways (ATP-consuming) and promotes catabolic pathways 
(ATP generating) through combined effects on enzymatic activity and expression (38). 
Various stimuli such as heat shock, ischemia, hypoxia, glucose deprivation, 
hypoglycemia, metabolic inhibitors such as arsenate & oligomycin, exercise, muscle 
contraction, and hyperosmotic stress have been shown to activate AMPK albeit in 
different mechanistic ways (67). AMPK is comprised of three subunits including a 
catalytic α, and regulatory β and γ subunits. There are two mammalian α subunit 
isoforms weighing 63 kDA (α1 and α2), two β subunits weighing 30 kDa (β1 and β2), and 
three γ subunits ranging between 37-63 kDa (γ1, γ2, γ3), which give rise to atleast 12 
possible isoform combinations (68). The α subunit of AMPK contains the 
serine/threonine kinase catalytic domain. Although, AMPK has several residues that can 
be phosphorylated including Thr172, Thr258, and Ser485 (α1)/491 (α2), phosphorylation 
of the Thr172 residue located on the activation loop of the catalytic domain, by 
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upstream kinases is mandatory for activation of this enzyme (67). The β subunit contains 
a glycogen-binding domain, a COOH-terminus required for complex formation with the 
other two subunits, and multiple phosphorylation sites while the γ subunit has variable 
N-terminal regions followed by cystathionine-β-synthase (CBS) domains which act in 
pairs to form the Bateman domain, a binding site for 5`-adenosine monophosphate (5’-
AMP). Although AMPK expression is found in most mammalian cells, there is a pattern 
of isoform expression that is tissue-specific with the α1, β1 and γ1 isoforms being the 
predominant form of AMPK in most cell types and α2, β2, γ2, γ3 highly expressed in 
cardiac and skeletal muscle cells (67).  
The activation of AMPK occurs through binding of 5’-AMP as well as 
phosphorylation of threonine 172 (Thr172) residue on the catalytic α subunit catalyzed 
by upstream AMPK kinase (AMPKK) and inhibition of dephosphorylation of Thr172 by 
protein phosphatases. Cellular 5’-AMP levels rise under conditions that lead to depletion 
of ATP levels resulting in an increased ADP to ATP ratio. The majority of AMP is 
produced by the adenylate kinase reaction (2ADP <--> ATP + AMP) when the cell under 
energy stress is attempting to recover ATP from anaerobic processes. Binding of AMP to 
AMPK renders it a better substrate for upstream AMPKK and a worse substrate for 
protein phosphatases especially protein phosphatase-2C. AMP also causes allosteric 
activation of the upstream kinase AMPKK. The combined effect of these mechanisms 
allows for more than a 200 fold activation of AMPK. At least two protein kinases 
(AMPKK) have been implicated in Thr172 phosphorylation of AMPK in vivo including liver 
kinase B1 (LKB1) and Ca2+/calmodulin-dependent kinase kinase (CaMKK) (67). 
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Downstream effectors of AMPK include acetyl CoA carboxylase (ACC), and peroxisome 
proliferator-activated receptor coactivator-1 (PGC-1) (69). The Akt substrate, Akt 
substrate of 160 kDa (AS160) is a novel Rab GTPase that is phosphorylated by Akt upon 
insulin stimulation (70). In L6 muscle cells, AS160 plays a key role in insulin-stimulated 
GLUT4 translocation (71). It has been recently reported that muscle contraction and 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR), an 5`-AMP analog, increased 
AS160 phosphorylation in muscle (41,72-74). Similarly in C2C12 myotubes, AICAR 
treatment acted synergistically with insulin to stimulate glucose transport (75). This 
synergistic effect was abolished upon co-treatment with compound C, an AMPK 
inhibitor (75). These abovementioned studies provide strong evidence for AS160 being a 
downstream target of AMPK. Moreover, AS160 has been suggested to be the point of 
convergence mediating GLUT4 trafficking by Akt, PKC and AMPK (71). The idea of a 
shared substrate by Akt and AMPK would not be a new finding since both molecules 
appear to have similar substrate motifs and have previously been shown to 
phosphorylate 6-phosphofructo-2-kinase/fructo-2,6-bisphosphatase on Ser466 (76). 
Various stimuli (exercise, muscle contraction, metformin) that lead to activation 
of AMPK are associated with increased glucose transport under normal conditions and 
enhanced glucose transport under insulin-resistant states in vitro and in vivo.    
Perfusion of isolated rat hindlimb AICAR caused a twofold increase in insulin-
stimulated glucose uptake (77). Electrical stimulation-induced contraction and AICAR 
treatment of isolated rat muscles significantly increased AMPK activity which was 
associated with increased glucose transport (78). Furthermore, wortmannin, a specific 
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inhibitor of PI3K, inhibited insulin-stimulated transport without having effects on AICAR- 
or contraction-stimulated transport.  While, the combination of AICAR and insulin had 
additive effects on glucose transport, the combination of AICAR and contraction did not 
(78). 
 Regular exercise improves muscle insulin sensitivity, glucose uptake and 
utilization and overall glycemic control in insulin resistant (79) and type 2 diabetic 
patients (80). This improvement in skeletal muscle glucose homeostasis in response to 
exercise is insulin-independent and partly involves AMPK activation (78,80). Indeed, 
AMPK activity is increased in response to both physical exercise (68) and electrical 
stimulation to produce muscle contractions in situ (81). Together, these findings suggest 
that exercise-induced improvement in muscle glucose uptake is in part mediated by 
AMPK activation. Therefore, exercise and simulated exercise conditions in experimental 
animal models improve plasma glucose levels by increasing skeletal muscle glucose 
uptake in an AMPK-dependent manner (Figure 4). 
 In obese, insulin-resistant Zucker rats, AICAR increased AMPK activity more than 
fivefold and increased glucose transport activity by approximately 2.4 fold while insulin 
did not have any effects on glucose transport activity in these insulin-resistant rats (82). 
In obese, insulin-resistant mice, AICAR administration improved hyperglycemia, glucose 
tolerance and increased GLUT4 expression in skeletal muscle (83). While insulin-
stimulated glucose transport was reduced in isolated muscle from obese, insulin-
resistant mice, AICAR-stimulated glucose transport was comparable to lean controls 
(83). Furthermore, high-fat fed (HFF) skeletal muscle-AMPKα2 knockout mice had 
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exacerbated glucose intolerance and insulin resistance compared to HFF control mice 
(84). Thus, these studies indicate that artificially increased AMPK activity in genetic and 
dietary animal models of IR lead to enhanced glucose handling and therefore activation 
of this kinase may provide a cellular pathway to counteract IR.  
A hypoglycemic drug used to treat insulin resistance, metformin and the polyphenol 
resveratrol found in red wine have been demonstrated to mediate their glucose 
lowering effects through AMPK activation (Figure 4). In isolated rat skeletal muscle, 
metformin activated AMPK and concomitantly stimulated glucose uptake (85). 
Metformin treatment increased skeletal muscle AMPK activity in subjects with type 2 
diabetes which was associated with improved glucose disposal rates (glucose uptake 
and utilization) (86).   
Resveratrol, a natural polyphenolic compound found in grapes and red wine 
increased AMPK and ACC phosphorylation comparable to metformin in HepG2 
hepatocytes (87). Resveratrol induced glucose uptake in rat L6 myotubes comparable to 
insulin (88). This effect of resveratrol was abolished by AMPK inhibition (88). 
Additionally, co-incubation of L6 myotubes, C2C12 myotubes and primary human 
myotubes with resveratrol prevented prolonged TNF-α and insulin-induced insulin 
resistance in these cells with attenuated serine phosphorylation of IRS1/2 (89). These in 
vitro findings indicate that the ability of resveratrol to behave as an insulin-mimetic 
requires AMPK activation (89).   
 
Rosemary (Rosmarinus officinalis L.) Extract 
 
29 
 
 
Figure 4: Role of AMPK in skeletal muscle glucose uptake in response to exercise, 
metformin & resveratrol. Akt (PKB), protein kinase B; AMPK, AMP-activated Kinase 
(heterotrimer αβγ subunits); AS160, Akt substrate of 160 kDa; GLUT4, glucose 
transporter; IRS, Insulin receptor substrate; PDK; phosphoinositide-dependent kinase-1; 
PI3K, phosphatidylinositol-3-kinase; PIP3, phosphatidylinositol (3,4,5)-trisphosphate.  
Resveratrol significantly improved insulin sensitivity in high-calorie diet-fed mice 
with concomitant increase in AMPK activity (90). In agreement, HFF mice deficient in the 
catalytic subunit of AMPKα1/2, resveratrol supplementation failed to increase insulin 
sensitivity and glucose tolerance in contrast to an improved insulin sensitivity seen in 
wildtype mice (91). In a randomized double-blind cross-over study involving healthy, 
obese men, 30 days of 150 mg/day of resveratrol treatment activated AMPK in muscle 
tissue and significantly decreased plasma glucose and insulin levels, (92). Therefore, 
resveratrol exerts its in vivo glucose lowering effects in an AMPK-dependent manner. 
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 Accumulating evidence indicates that AMPK activation by external stimuli in insulin 
resistant tissues in vitro and in vivo can improve parameters compromised in this state 
such as tissue glucose transport. It has been demonstrated that AMPK, an intracellular 
energy sensor, mediates exercise-, metformin, and polyphenol (resveratrol)-induced 
elevations in tissue glucose uptake leading to improvements in overall glucose 
homeostasis (Figure 4). Since the PI3K-Akt pathway and AMPK activation have been 
shown to converge on AS160 and regulate GLUT4 translocation in vitro and in vivo, 
activation of AMPK may prove to be a valuable therapeutic target in increasing glucose 
uptake in insulin-resistant states. Moreover, AMPK may play a role in alleviating tissue 
insulin resistance through inhibition of the mTOR/p70S6K pathway which is involved in 
downregulation of the insulin signaling pathway. Indeed, AMPKα null mice have 
impaired insulin sensitivity (76). Since AMPK has been shown to inhibit the 
mTOR/p70S6K pathway by directly phoshorylating these enzymes as well as indirectly 
inhibiting this pathway by activation of tuberous sclerosis complex proteins 1/2 (TSC) 
which increases the Rheb-GDP levels, the removal of AMPK activity will lead to 
increased mTOR/p70S6K activity which is implicated in inhibitory serine phosphorylation 
of IRS and interference in the insulin signaling pathway. As mentioned above, 
resveratrol is a polyphenol found in grapes and red wine that activates AMPK, a 
molecule shown by many studies to be an excellent therapeutic target in regulating 
glucose homesotais. It is possible that other polyphenols found in various food 
components including herbs may act as activators of AMPK and have positive effects on 
glucose homeostasis. 
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1.7 Role of Obesity in Insulin Resistance and Type 2 Diabetes Mellitus  
Obesity, and particularly intra-abdominal adiposity, is considered to be amongst the 
most important acquired risk factors for type 2 diabetes with over 80% of people with 
type 2 diabetes being obese (93). Obesity is also associated with reductions in insulin 
responsiveness of target tissues (reduced insulin sensitivity) (22,94). Prospective 
epidemiological studies have suggested that elevated plasma FFA levels, as seen in 
obesity, is an independent predictor of progression to T2DM (95) in Caucasians and 
Pima Indians (96). Therefore, the link between obesity and T2DM appears to be 
elevated fasting plasma FFA concentrations which are commonly seen in obese 
individuals and in individuals with T2DM (95).  
In streptozotocin (STZ)-induced diabetic rats exposed to nicotinic acid and 
phenylisopropyladenosine, potent antilipolytic agents, there was a reduction in plasma 
FFA levels which was accompanied by a significant decrease in plasma glucose 
concentrations secondary to both increased basal and insulin-stimulated glucose uptake 
as demonstrated in isolated adipocytes in vitro (97). Lipodystrophic (fatless) mice, which 
are characterized as severely insulin resistant, had a twofold increase in myocellular lipid 
content paralled by reduced insulin-stimulated IRS-1 and PI3K activity in muscle tissue 
(98). Upon transplantation of normal adipose tissue in these mice, intracellular lipid 
content and insulin signaling were concurrently restored to normal levels (98). Similarly, 
transgenic mice with muscle-specific overexpression of plasma membrane associated 
lipoprotein lipase (a member of the lipase gene family responsible for hydrolyzing 
triglycerides in lipoproteins into FFAs and glycerol) had a threefold increase in muscle 
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triglyceride content and were insulin resistant due to decreases in insulin-stimulated 
skeletal muscle glucose transport (99). Furthermore, attenuation of insulin-stimulated 
IRS-1 associated PI3K activity was attributed to intramyocellular derivatives of 
triglyceride lipolysis including diacylglycerol (DAG) and fatty acyl coenzyme A content 
(99). Therefore, the abovementioned in vivo animal models of chemically-induced and 
genetic obesity demonstrate the temporally causative relationship of elevated FFA 
levels and reduced activity of the insulin signaling pathway (reduced glucose transport). 
 In obese diabetic and non-diabetic subjects, overnight administration of 
Acipimox, a long-acting nicotinic acid analogue, decreased fasting plasma FFA levels by 
60-70% which was accompanied by a twofold increase in insulin-stimulated glucose 
uptake (assessed by euglycemic-hyperinsulinemic clamp) in the obese, non-diabetic and 
a partial improvement in the obese, diabetic subgroups (100). Lean offspring of type 2 
diabetic parents who were characterized as insulin-resistant had increased 
intramyocellular triglyceride content compared to healthy controls as assessed by 
nuclear magnetic resonance spectroscopy (NMR) (101). Similarly, lipid and heparin 
infusion-induced increase in plasma FFA levels in healthy volunteers was associated with 
a proportionate increase in intramyocellular triglyceride content and a significant 
increase in muscle tissue insulin resistance (95). Thus, the findings of the close 
relationship of FFAs and tissue insulin resistance are corroborated in human studies.     
1.7.1 Role of Free Fatty Acids in Skeletal Muscle Insulin Resistance  
Triglycerides in muscle are in a constant state of turnover and its metabolites from 
lipolysis including FFA, fatty acyl coenzymes A, ceramides, and diacylglyercol (DAG) 
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impair insulin action in this tissue (23,102). Lipid infusion into normal rats for five hours 
caused a 40-50% reduction in muscle glucose oxidation and glycogen synthesis through 
impairment of glucose transport and this was accompanied by a fall in insulin-mediated 
tyrosine phosphorylation of IRS-1, and 50% reduction in IRS-1 associated PI3K activity 
(103). Both obese Zucker rats (104) and insulin resistant obese humans (with or without 
diabetes) (105) showed reduced levels of insulin-stimulated IRS-1 tyrosine 
phosphorylation and PI3K activity in muscle tissue. Elevated plasma FFA in humans 
abolished insulin induced IRS-1 associated PI3K activity (106). Additionally, increased 
long chain fatty acyl CoAs’ (LCACoAs) have been implicated in the compromised insulin 
signaling pathway in muscle tissue through direction inhibition of hexokinase, the 
enzyme involved in converting glucose to glucose-6-phosphate which can subsequently 
undergo glycolysis and/or glycogenesis (107). In conclusion, both animal and human 
studies have demonstrated a strong negative correlation between increased 
intramuscular lipid levels including triglycerides (108,109), DAG (110,111) and LCACoAs 
(112) and insulin-stimulated glucose metabolism.  
1.7.2 Role of Free Fatty Acids in Liver Insulin Resistance 
FFA-induced IR is not limited to the muscle tissue but also affects the liver. The 
relationship between elevated plasma FFA, FFA oxidation and hepatic glucose 
production (HGP) are as follows: 1) increased plasma FFA by mass action enhance 
hepatocyte FFA uptake leading to increased lipid oxidation and accumulation of acetyl 
CoA. An increase in acetyl CoA causes activation of pyruvate carboxylase and 
phosphophenolpyruvate carboxykinase (PEPCK), the rate limiting enzymes in 
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gluconeogenesis (113) as well as glucose-6-phosphatase, the rate controlling enzyme for 
glucose release from hepatocytes (114). Therefore, the cumulative effects of increased 
FFA influx in hepatocytes lead to increased glucose production and release into the 
circulation. Additionally, increased FFA oxidation provides a source of energy (glycerol) 
and reduced NADH to drive gluconeogenesis (42).  
The single gateway hypothesis introduced by Bergman & coworkers outlines that 
hepatic glucose output is indirectly associated with the hormonal regulation of lipolysis 
in adipocytes (115). Visceral fats which are inherently less sensitive to insulin action and 
specifically its antilipolytic effects, release FFAs into the portal vein which drains into the 
liver. Hepatocyte FFA accumulation causes hepatic glucose production and hepatic 
insulin resistance (IR). Normally, insulin acts on hepatocytes to decrease the 
transcription of genes encoding gluconeogenic enzymes such as 
phosphophenolpyruvate carboxykinase (PEPCK), fructose 1,6-bisphosphate and glucose-
6-phosphatase (G6Pase) while increasing transcription of glycolytic enzymes including 
glucokinase; and lipogenic enzymes such as fatty acid synthase and acetyl CoA 
carboxylase. The cumulative actions of insulin on the liver are to decrease hepatic 
gluconeogenesis and increase hepatic lipogenesis. Elevated FFA levels cause liver IR by 
activating certain serine/threonine kinases that interfere with the insulin signaling 
pathway thereby compromising insulin’s anti-gluconeogenic and anti-glycogenolytic 
effects in this tissue. Moreover, FFA by upregulating gluconeogenic enzymes (PEPCK, 
G6Pase) cause increased hepatic glucose production.  
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1.7.3 Mechanism of Free Fatty Acid-Induced Insulin Resistance in Skeletal 
Muscle 
Long chain fatty acyl CoAs (LCACoAs) and diacylglycerol (DAG) activate protein kinase C-
ϴ (PKC-ϴ) which increases serine phosphorylation of IRS-1 (116,117). Additionally, a 
direct, negative effect of LCACoAs on glucose transport, glucose phoshorylation, and 
glycogen synthase have been demonstrated in muscle (107,118). In HFF rats, the level of 
triglycerides and DAG were elevated four- and twofold in muscle tissue respectively 
accompanied by chronic activation of the protein kinase C (PKC) isozymes, PKCϴ and 
PKCε compared to control animals (119). In addition, transgenic mice with inactivation 
of PKCϴ were demonstrated to be protected from lipid-induced defects in insulin action 
and signaling in skeletal muscle (99,120). Similarly, PKCϴ knockout mice escaped lipid 
infusion-induced decrease in insulin-stimulated skeletal muscle glucose uptake and also 
escaped the decrease in insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-1 
associated PI3K activity (120). 
Intramuscular ceramide concentrations are elevated in skeletal muscle obtained 
from insulin resistant rats (121) and humans (122). In rat L6 myotubes, exposure to 
palmitate, a saturated FFA, abrogated insulin-stimulated glucose transport which was 
accompanied by suppression of insulin-induced plasma membrane recruitment and 
phosphorylation of PKB/Akt (123). This inhibition of PKB/Akt was attributable to 
elevation of intracellular synthesis of ceramide from palmitate and a concomitant 
activation of PKCζ. Indeed, co-incubation with inhibitors of serine palmitoyl transferase 
(enzyme that synthesizes ceramide from palmitate) prevented PKCζ activation and 
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reversed the observed effects. Similarly, co-incubation with a PKCζ inhibitor, Ro31.8220, 
also restored normal insulin-signaling and response in myocytes (123). In addition, 
activation of serine kinase PKC-ε as a result of intracellular accumulation of lipid 
metabolites was associated with reduced tyrosine phosphorylation of IRS-2 in liver 
(124,125). Taken together, these studies indicate that elevated FFA and its metabolic 
derivatives potently activate PKC which may underlie the development of insulin 
resistance in muscle, liver and adipose tissue.  
In insulin resistant 3T3-L1 adipocytes, pretreatment with rapamycin, an inhibitor 
of mTOR, enhanced insulin stimulated 2-[3H]-deoxy-D-glucose uptake indicating that 
mTOR is implicated in downregulating the insulin signaling pathway (126). More 
importantly, palmitate was demonstrated to increase phosphorylation of mTOR which 
was associated with hyperphosphorylation of IRS-1 at serine residues 632/639 in rat 
hepatocytes (127) showing that FFA may cause insulin resistance through activation of 
this particular serine/threonine kinase. Similar findings have been substantiated in 
skeletal muscle cells and adipocytes (128). An in vitro study indicated that abolishment 
of p70S6K, a downstream target of mTOR, by siRNA approach significantly increased 
insulin-stimulated Akt phosphorylation and increased insulin sensitivity in mouse 
embryonic fibroblasts (128).  
HFF rats exhibited increased mTOR and its downstream target, p70 S6K activity 
in liver and skeletal muscle tissue suggestive of the importance of this pathway in the 
induction of insulin resistance in vivo (129).  In accordance, rapamycin (mTOR inhibitor) 
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administration in mice decreased serine phosphorylation of IRS-1 and prolonged insulin-
stimulated PI3K activity in skeletal muscle (129). Additionally, p70S6K knocknout mice 
administered a HFF exhibited decreased IRS-1 phosphorylation on ser307 and 
ser636/639 residues compared to their wild-type counterparts (130). Therefore in vitro 
and in vivo studies provide evidence for the involvement of mTOR, and p70 S6K in FFA-
induced insulin resistance.  
c-Jun-N-terminal kinase (JNK), a serine/threonine kinase belonging to the MAPK 
family, is activated by elevated FFA, cytokines (including TNF-α) and other stress stimuli 
leading to subsequent Ser307 phosphorylation of IRS-1 in muscle and adipose tissue 
causing impairment of insulin action (131,132). Both TNF-α, and FFA are potent 
activators of JNK (133). In murine models of dietary and genetic obesity, total JNK 
activity was increased in muscle, liver and adipose tissue (134). In these mice, there was 
also increased serine-307 residue phosphorylation of IRS-1 and subsequent reduced 
tyrosine phosphorylation upon insulin stimulation. Moreover, in JNK-1 deficient mice, 
obesity-related ser-307 phosphorylation of IRS-1 and insulin resistance was significantly 
reduced (134). Collectively, these studies implicate the abovementioned 
serine/threonine kinases in tissue insulin resistance and T2DM. 
1.7.4 Role of Obesity-Induced Inflammation in Insulin Resistance 
Obesity is a state of chronic, low-grade inflammation particularly in white adipose tissue 
(133). Obesity-derived inflammation is implicated in insulin resistance (IR) through 
disturbances in the insulin signaling pathway mediated by increased inflammatory 
pathways (29). The primary mechanism underlying obesity-derived inflammation in 
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muscle includes elevated levels of intracellular FFA levels’ and adipocyte-derived 
hormones’ and adipocytokines’ reduction of tyrosine phosphorylation by preferential 
phosphorylation of serine residues of IRS (135,136) and reduction of IRS to associate 
with the insulin receptor (131,136,137).  
Obesity is associated with increased activation of inflammatory pathways with 
tumor necrosis factor-α (TNF-α), an inflammatory cytokine, initially identified to be a 
link between obesity and inflammation (133). Indeed, TNF-α was demonstrated to be 
overexpressed in adipose tissue of obese rodents (138,139). Infusion of lipids, to mimic 
the increased FFA levels seen in obesity, and TNF-α in nonobese animals caused IR 
(140). In obese humans, TNF-α was shown to be overexpressed in adipose (141,142) as 
well as muscle tissue (143). In humans, the risk for diabetes is increased with chronic 
inflammatory diseases. For example, one-third of patients with chronic hepatitis C have 
type 2 diabetes with TNF-α implicated in this link (144). Thus, obesity-derived 
inflammation is associated with tissue insulin resistance and presents to be an 
important mediator of type 2 diabetes.  
In obesity-induced inflammation, adipocytes and surrounding macrophages exhibit 
abnormal production of pro-inflammatory cytokines including TNF-α, and interleukin-6 
(IL-6) implicated in tissue insulin resistance (145). Additionally, obesity-related decrease 
in adipocyte-derived protein, adiponectin and increase in resistin has also been 
associated with tissue insulin resistance. Inflammatory signals cause insulin resistance 
primarily through the inhibition of intracellular signaling downstream of the insulin 
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receptor (133). Several serine/threonine kinases including PKC, JNK, and IKK are 
activated by inflammatory stimuli and cause inhibition of insulin signaling (146). 
1.7.4.1 Role of Inflammatory Cytokines in Insulin Resistance 
Tumor Necrosis Factor-α (TNF-α) is an adipocyte-derived cytokine that has been 
demonstrated to impair the insulin signaling cascade through IRS serine 
phosphorylation. When infused in rodents, it causes severe IR. In Zucker rat model of 
obesity and insulin resistance, neutralization of TNF-α with a soluble TNF receptor 
(TNFR)-immunoglobulin G fusion protein, caused a significant increase in insulin-
stimulated autophosphorylation of the insulin receptor and phosphorylation of IRS-1 in 
muscle tissue isolated from rats which was associated with improved plasma glucose, 
insulin and FFA levels compared to control animals(147). Gene knockout of TNF-α in 
high-fat fed mice and genetically obese mice resulted in lower levels of plasma FFA 
which prevented obesity-associated reduction in the insulin receptor signaling in muscle 
tissue (148). There was a 46% increase in insulin-stimulated autophosphorylation of the 
insulin receptor in TNF-α knockout, obese mice compared to obese, control mice. The 
TNF-α knockout mice also had improved insulin sensitivity compared to obese control 
mice (148). In accordance, intravenous administration of TNF-α prevented insulin-
mediated increase in rat skeletal muscle glucose uptake by 61% (149).  
There was a 2.5 fold increase in TNF-α mRNA and a similar increase in TNF-α protein 
in fat tissue isolated from obese premenopausal women compared to lean controls 
(141). Moreover, there was a strong positive correlation between TNF-α mRNA 
expression level in fat tissue and the level of hyperinsulinemia (an indirect measure of 
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IR). Body weight reduction in these women was characterized by a 45% decrease in 
adipose TNF-α mRNA expression which was accompanied by improved insulin sensitivity 
(141). In Native Canadian population, circulating TNF-α concentrations was found to be 
positively correlated with IR (150). In obese nondiabetic subjects, adipose tissue 
secretion of TNF-α increased 7.5 fold compared to lean controls, and TNF-α secretion 
was inversely correlated with insulin sensitivity (151). TNF-α activates downstream 
enzymes such as the inhibitor of nuclear factor ҡ-B kinase (IKK-B) which can impair the 
insulin signaling pathway in two ways. It can directly phosphorylate IRS-1 on serine 
residues and thereby attenuate tyrosine phosphorylation (152). Additionally, it can 
phosphorylate the inhibitor of NF-kB (IkB), targeting this enzyme for ubiquitination 
pathway, thus activating NF-kB, a transcription factor involved in the induction of 
diabetogenic genes. In rats, a 5-hour lipid infusion decreased insulin-stimulated glucose 
uptake and activation of IRS-1 associated PI3K activity in skeletal muscle. Pretreatment 
with salicylate, a known inhibitor of IKK-β prevented these lipid-induced effects (99). 
Moreover, in mice lacking IKK-β, lipid infusion did not lead to decreased insulin-
stimulated glucose uptake and activation of IRS-1 associated PI3K activity as seen in wild 
type mice (99). HFF mice with liver-specific IKK-β gene deletion showed a less 
pronounced elevation in fasting blood glucose and insulin levels relative to control HFF 
mice (153). Cultured hepatocytes isolated from control mice, were transiently 
transduced with an adenovirus expressing a specific inhibitor of NF-ҡB which prevented 
interleukin-1β (IL-1β)-induced reduction in insulin sensitivity, diminished insulin 
receptor tyrosine phosphorylation and IRS-1 associated PI3K activity (153). Inhibition of 
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IKKB by high dose aspirin treatment (salicylates) in diabetic patients improved insulin 
signaling and action (154). Collectively, the abovementioned studies suggest that IKK-β 
activation causes insulin resistance through primarily NF-ҡB gene expression.  
Moreover, these studies strongly implicate the NF-ҡβ pathway in FFA- and 
inflammation-induced tissue IR.  
Apart from TNF-α, interleukin-6 (IL-6), another inflammatory cytokine stimulate 
both JNK and IKKB pathways leading to induction of IR (133,155). IL-6 is expressed in 
macrophages and adipocytes. This cytokine is implicated in rodent models of muscle IR 
(156). In obese, non-diabetic subjects, plasma IL-6 was significantly elevated compared 
to lean controls and there was a strong inverse relationship with insulin sensitivity (151).  
 Adiponectin, also referred to as ACRP30, AdipoQ, and gelatin-binding protein-28, is 
exclusively expressed in adipose tissue (157). The average levels of plasma adiponectin 
in human range from 3 to 30 µg/ml. In adipose tissue, adiponectin mRNA levels were 
lower in genetically obese mice than in wild-type mice (158). HFF adiponectin-knockout 
mice developed severe insulin resistance compared to HFF control mice (159). 
Furthermore, diabetic mice treated with adiponectin exhibited attenuated 
hyperglycemia compared to control animals (160).    
Using an enzyme-linked immunosorbent assay (ELISA), adiponectin levels were 
found to be lower in obese humans compared to lean controls (161). Similarly, plasma 
adiponectin levels were markedly decreased in T2DM and obese patients and the 
magnitude of reduction was correlated with severity of IR in peripheral tissues including 
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muscle and liver (162). Therefore, adiponectin levels appear to be reduced in animal 
models of obesity and T2DM as well as in obese and type 2 diabetic humans indicating 
that this adipocyte-derived cytokine plays a role in IR.  
It has been suggested that obesity-induced reduction in plasma adiponectin 
levels (hypoadiponectinemia) occurs through obesity-associated pro-inflammatory 
cytokine downregulation of adiponectin (157). Indeed, TNF-α (163) and IL-6 (164) 
treatment suppressed adiponectin mRNA and protein expression in 3T3-L1 adipocytes 
and primary human adipocytes implicating these pro-inflammatory cytokines in the 
negative regulation of adiponectin expression in vitro (165). 
Resistin is an adipose-derived peptide hormone that is implicated in obesity and 
T2DM. Increased resistin levels and expression in adipocytes have been demonstrated in 
human obesity and T2DM (166,167). Consistent with this, infusion of resistin into 
healthy animals causes severe hepatic IR but has no effect on muscle IR.  Elevated 
resistin is associated with hepatic but not muscle IR in T2DM humans (168).  
 Tissue IR is a precedent to IGT (prediabetes), which if left untreated, leads to the 
development of overt diabetes mellitus. Therefore, diabetes mellitus is the clinical 
manifestation of prolonged mishandling of glucose by target tissues. In the next section, 
an overview of diabetes mellitus will be presented to put into context the importance of 
tissue glucose transport and metabolism in the overall maintenance of whole body 
glucose homeostasis.  
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1.8  Diabetes Mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action or both (13). Diminished insulin 
secretion and insulin action lead to deregulation of glucose and fat metabolism in 
various tissues and failure to maintain euglycemia (28,31). This prolonged pathological 
state characterized by hyperglycemia and hyperlipidemia may lead to complications 
such as retinopathy, neuropathy, nephropathy, microvascular and macrovascular 
problems (42).   
Type 2 diabetes mellitus (T2DM) also known as non-insulin dependent diabetes or 
adult-onset diabetes accounts for 90-95% of total cases of diabetes mellitus (13). It is 
characterized by IR and usually relative versus absolute deficiency of insulin. IR, a 
condition in which major insulin target tissues such as skeletal muscle, fat and liver 
display diminished responsiveness to normal circulating levels of insulin, result in 
abnormal fat and glucose metabolism in these tissues and lead to an increase in blood 
glucose levels due to increased glucose production and decreased glucose utilization, 
(15). Although, IR in classic target tissues (muscle, liver, fat) may be the predominant 
contributors underlying T2DM, the pancreas, brain, gastrointestinal tract, and kidneys 
are additional tissues that become insulin resistant and contribute to the 
pathophysiology of T2DM (28).    
Evidence from genetic studies indicate that the majority of tissue IR present in 
T2DM is not associated with insulin receptor mutations but rather occurs as a result of 
post-receptor disturbances primarly involving aberrations in the insulin signaling 
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pathway (13,15,169). This is also reflected in type A insulin resistance or acanthosis 
nigricans and pediatric syndromes Leprechaunism and Rabson-Mendenhall syndrome 
which are characterized by impairments in insulin action caused by insulin receptor gene 
mutations resulting in metabolic disturbances ranging from hyperinsulinemia and 
modest hyperglycemia to severe diabetes. However, these account for only a small 
percentage of total diabetes cases (13,15).   
Furthermore, the diminished insulin secretion seen in T2DM is due to pancreatic 
β-cell dysfunction. The cellular mechanism underlying insulin secretion involves rising 
blood glucose levels which enters pancreatic β-cells through the facilitated glucose 
transporter, GLUT2 (14). Once inside the cell, glucose undergoes oxidation resulting in 
an increase in the ATP/ADP ratio which leads to closing of the ATP-sensitive K+-channels 
resulting in cell membrane depolarization and subsequent influx of Ca2+ leading to 
exocytosis of intracellular vesicles where insulin and C-peptide are concomitantly 
released into the circulation (15,170). This insulin secretory mechanism is compromised 
when the β cells are chronically exposed to elevated glucose levels (170).  Therefore, 
although acute hyperglycemia is a trigger for insulin release, chronic hyperglycemia 
leads to β-cell desensitization to glucose and β-cell exhaustion with resultant deficiency 
in serum insulin levels (171).  
As long as β-cell insulin secretion matches the varying degrees of hyperglycemia, 
normal glucose tolerance will be maintained with fasting plasma glucose levels 
maintained at 80-115 mg/dL (4.0-7.0 mM) (17,54,170). However, once the 
compensatory hypersecretion of insulin declines in response to chronic hyperglycemia, 
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glucose intolerance and subsequent overt diabetes ensues (17). Furthermore, the 
resultant high plasma glucose levels and poor metabolic control, resulting from 
declining pancreatic β-cell function, will negatively affect tissue insulin sensitivity, which 
is determined by the level of tissue responsiveness to insulin and further contribute to 
the functional decline of the insulin secreting cells. Given that tissue IR and insulin 
deficiency are closely interconnected, treatments aimed at alleviating IR in major target 
tissues are highly beneficial in preventing pancreatic β-cell deficiency and at the very 
least delaying the occurrence of T2DM.  
1.8.1 Treatments for Type 2 Diabetes Mellitus 
At present, there is no cure for diabetes mellitus as is true for many of the major chronic 
diseases inflicting the world’s population at large (42). For this reason, the majority of 
current therapeutic strategies for diabetes mellitus is aimed at management and 
alleviation of the pathological processes underlying this disease. For a T2DM individual, 
treatment would include drug interventions coupled with lifestyle modifications such as 
healthy diets, weight management, and regular physical activity (170). There are various 
classes of oral medications for treatment of T2DM that have different target tissues and 
mode of action. These include drugs that stimulate insulin release from β-cells 
(sulfonylureas, meglitinides); inhibit glucose absorption by the gut (α-glucosidase 
inhibitors); reduce hepatic glucose output through inhibition of gluconeogenesis and 
increase peripheral glucose transport (biguanides/metformin); and reduce insulin 
resistance at target tissues (thiazolidinediones or glitazones) (42,171). Given that the 
current strategy for treatment of T2DM is management, and treatments aimed at 
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improving tissue IR has proven to be promising, it is warranted to study novel 
compounds that can bypass tissue IR by exerting an insulin-like effect through either 
stimulation of the insulin signaling pathway or complementary and convergent 
pathways with similar effects, and/or by increasing insulin sensitivity, thus potentially 
widening the spectrum of treatment options for T2DM. Additionally, the study of such 
novel compounds and their mechanism(s) of action also provide indirect benefits in 
terms of further elucidation of signaling pathways involved in metabolism, their 
crosstalk and unifying factors.  
1.9 Phytotherapy  
The use of plants for healing purposes predates recorded history and forms the origin of 
much of modern medicine (172). Many conventional drugs originate from plant sources 
including aspirin (from willow tree bark), digoxin (from foxglove), quinine (from 
cinchona bark), and morphine (from the opium poppy). The development of drugs from 
plants continues, with drug companies engaged in large-scale pharmacologic screening 
of herbs (172,173). 
 Herbal medicine is still the mainstay of about 75-80% of the world’s population, 
mainly in the developing countries, for primary health care. In the last few years there 
has been a major rise in the use of herbs in the developed world. In Germay and France, 
many herbs and herbal extracts are used as prescription drugs and their sales in the 
countries of European Union were around 6 billion in 1991 and maybe over 20 billion 
dollars now (173). An herb can be any form of a plant or plant product, including leaves, 
stems, flowers, roots, and seeds which can be formulated as raw material or extracts. 
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Maceration of plants with water, alcohol or other solvents results in extraction of their 
active chemicals including fatty acids, sterols, alkaloids, flavonoids, glycosides, saponins, 
and others (172).  
1.10  Rosemary 
Rosemary (Rosmarinus officinalis) is a plant belonging to the labiate family (Lamiaceae). 
It is an aromatic evergreen shrub indigenous to the Mediterranean region and South 
America (174). The fresh and dried leaves are frequently used as a food preservative and 
in traditional Mediterranean cuisine as a flavoring agent. Historically, rosemary has been 
used medicinally to treat renal colic, dysmenorrhea, to stimulate hair growth and relieve 
symptoms caused by respiratory disorders (174,175). Today, rosemary extracts are 
often used in aromatherapy to treat anxiety-related conditions and increase alertness 
(175). Evidence indicates that rosemary possesses anti-inflammatory, anti-microbial, 
anti-tumorigenic, antioxidant and anti-hyperglycemic effects. 
 Rosemary contains subclasses of polyphenols including phenolic abietane terpenes, 
caffeoyl derivatives and flavones (176-179). Thus far, twelve phenolic terpenes have 
been isolated from rosemary including carnosol, carnosic acid, rosmanol, epirosmanol, 
isorosmanol, rosmaridiphenol, rosmadial and miltirone (179). Caffeoyl derivatives 
include caffeic acid, p-coumaric acid, rosmarinic acid, and ferulic acid (180,181) while 
flavonoids found in rosemary include apigenin, apigenin-7-O-glucoside, and luteolin 
(180,181). 
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Figure 5: Chemical Structures of Rosemary's Major Polyphenols 
The polyphenols found in highest quantity in rosemary are carnosic acid (CA), 
carnosol and rosmarinic acid (RA) (176,178,182,183) (Figure 5). The reported 
concentrations of CA, and RA found in rosemary range between 0.1-5.0% (184) and 
0.02-30.0% (185,186). The production of these polyphenols in the plant is influenced by 
intrinsic factors such as genetics, subspecies, and age as well as extrinsic factors such as 
climate (sunlight exposure) and cultivation conditions (soil quality, and water 
availalbility) or the isolation/extraction method (172,184). It has been reported that 
anatomical regions of this herbal plant have varying levels of total phenolic content 
whereby the leaves contain the highest concentration of polyphenols in comparison to 
stem, branch and flower regions (183). Furthermore, the choice of solvent and 
extraction method affects the chemical composition of the extract with the possibility of 
losing lipid-soluble chemicals by an aqueous-based extraction method and water-
soluble chemicals by nonpolar solvent- (ethanol, methanol) based extraction (174). 
Regardless of the extraction method used, both polar and non-polar based rosemary 
extracts, with differential concentrations of polyphenols, have been shown to have 
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antioxidant, anti-inflammatory, and anti-hyperglycemic effects. These biological effects 
are highly correlated with the polyphenolic content with carnosic acid, carnosol and 
rosmarinic acid shown to be responsible (187-192). 
1.10.1 Antioxidant Properties of Rosemary Extract: In Vitro Studies 
Numerous physiological and biochemical processes in the human body produce reactive 
oxygen species such as superoxide, and hydrogen peroxide as byproducts. 
Overproduction of such free radicals causes oxidative damage to biomolecules 
(membrane lipids, nucleic acids, and proteins) resulting in cellular damage and leading 
to many chronic diseases such as atherosclerosis, cancer, and diabetes (193). On the 
other hand, the intake of natural antioxidants has been associated with reduced risks of 
cancer, cardiovascular disease, and diabetes (173). Plants (fruits, vegetables, medicinal 
herbs etc.) contain a wide variety of free radical scavenging molecules, such as phenolic 
compounds, nitrogen compounds, vitamins, terpenoids, and some other endogenous 
metabolites, that have been found to be rich in antioxidant activity (172,193). A number 
of studies have shown rosemary’s antioxidant properties. A study examining aqueous, 
and methanol extracts of rosemary leaves using a cell-free assay [2,2-diphenyl-1-
picrylhdrazyl (DPPH) assay] found that the latter extract had a higher antioxidant activity 
attributable to its relatively high total phenolic content compared to the former extract 
(183) (Table 2). The DPPH assay is used for the assessment of radical scavenging 
properties. DPPH colour change from purple to yellow is the result of the reducing 
ability of antioxidants toward DPPH stable radical (194). The decrease in DPPH stable 
radical in response to antioxidants is assessed by absorbance at 515 nm (194). Similarly, 
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methanol extract of rosemary exhibited high antioxidant activity which was attributed 
to its high phenolic content (194-196). Additionally, methanol extract of rosemary was 
demonstrated to have anti-lipid peroxidation activity in a linoleic acid emulsion system 
further supporting its antioxidant properties (194). In contrast, aqueous extract of 
rosemary was found to have greater antioxidant activity compared to the methanol 
extract of rosemary which was attributed to greater phenolic content in the former 
extract (197) (Table 2). Aqueous extract of rosemary showed the highest inhibitory 
activity against the peroxidation of arachidonic acid in liposomes while the methanol 
extract displayed less pronounced protective effects (197). Another study reported 
antioxidant activity of aqueous rosemary extract that was dose-dependent using the cell 
free DPPH assay (198). Moreover, the aqueous extract of rosemary was examined in 
liposomes composed of egg lecithin with Fe3+/ascorbic acid/H2O2 and demonstrated to 
have strong inhibitory effects against the oxidation of liposome indicative of potent 
antioxidant activity (198).  
Several studies have indicated that rosemary extract’s antioxidant activity is mainly 
attributed to carnosic acid and carnosol (199). Carnosic acid is reported to be the most 
powerful antioxidant among phenolic diterpenes (200). One study reported that 
approximately 90% of the total antioxidant activity of rosemary extract is mainly derived 
from carnosic acid and carnosol (201). Romano et al. (192) found that the antioxidant 
power of methanol extract of rosemary leaves was more similar to the antioxidant 
power of carnosic acid than to that of rosmarinic acid suggesting that the extract derives 
its antioxidant activity predominantly from carnosic acid. Similarly, the relative 
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antioxidant activity of rosemary extract was contingent on the content of carnosic acid 
(202). In agreement, three commercial oil-soluble rosemary extracts standardized on 
increasing concentration of carnosic acid (25.9%, 36.2%, 42.2% of extract formulation) 
were demonstrated to have strong antioxidant activity with the extract containing the 
highest concentration of carnosic acid exhibiting greatest antioxidant activity (203) 
(Table 2, refer to page 51). 
In contrast, rosmarinic acid isolated from aqueous extract of rosemary leaves 
exhibited the strongest antioxidant activity assessed by a cell free DPPH assay across all 
micro-molar concentrations used compared to carnosic acid and carnosol (204). 
Similarly, it was demonstrated using the DPPH assay that the main active compound 
contributing to the antioxidant activity of methanol extract of rosemary is rosmarinic 
acid (205).  
The relative antioxidant activity of whole extract of rosemary and pure 
polyphenolic constituents was evaluated using the DPPH assay and the former was 
found to have greater antioxidant capacity (206). Additionally, the pure polyphenolic 
constituents CA and RA were demonstrated to be readily oxidized in solution compared 
to their levels in the whole rosemary extract (206,207). These findings indicate that the 
presence of the other polyphenols provides a protective effect on the stability of each 
compound in the extract. A commercial oil-soluble rosemary extract containing 40% 
carnosic acid exhibited greater antioxidant activity in comparison to pure carnosic acid 
(207) (Table 2). These findings indicate additivity/synergy of various polyphenols present 
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in rosemary extract whose overall antioxidant activity is greater than pure polyphenolic 
constituents.   
All of the above studies indicate that different rosemary extract formulations 
consistently exhibit in vitro antioxidant activity with carnosic acid, carnosol and 
rosmarinic acid being the principle phytochemicals contributing to rosemary’s 
antioxidant properties. 
Rosemary (Rosmarinus officinalis L.) Extract 
 
53 
 
Table 2: Phenolic Content and Antioxidant Activity of Rosemary Extract 
Study 
ID 
Rosemary Constituents Assessment Total Phenolic  Isolated Compounds Activity 
Content 
(194) Methanol extract of 
rosemary; CA; RA 
DPPH radical 
assay 
 
162 mg GAE/g Extract contained 6% 
CA & 8% RA 
Extract had potent DPPH scavenging activity. CA had 
stronger radical scavenging activity compared to RA. 
(195) Methanol (M), ethanol (E), 
water (W) extract of 
rosemary. 
 
DPPH radical 
assay 
M: 90 mg CAE/ g > 
E:78 mg CAE/g > W 
50 mg CAE/g 
 
n/a M>E>W in terms of antioxidant activity and phenolic 
content. 
(196)  Methanol extract of 
rosemary leaves 
DPPH radical 
assay 
98.31 mg GAE/g 
Flavonoid content: 
113.5 mg QE/g 
CA>RA> caffeic acid. Extract exhibited strong DPPH activity. Superoxide 
anion scavenging reduced by 69% at 300 µg/ml of 
extract. 
Extract exhibited antibacterial and antifungal 
activities. 
(197) Methanol (M) and water 
(W) extract of rosemary 
DPPH, 
superoxide, and 
hydroxyl radical 
tests 
W: 47.9 µg QE/mg  
M: 24.0 µg QE/mg 
n/a Both extracts had significant activity against both 
radicals. W>M in terms of antioxidant activity and 
phenolic content. 
(198) Aqueous extract of 
rosemary leaves (RL) 
DPPH 185.04 mg GAE/g n/a 100 ug/ml of RE displayed good radical scavenging. 
(199) 24 different pilot plant 
and commercial rosemary 
extracts 
Methyl linoleate 
in lipophilic 
solvent system. 
n/a CA, COH, RA amongst 
various other 
derivatives 
All formulations of rosemary tested had significant 
antioxidant activity. Extracts containing a higher 
percentage of RA displayed greater ATOX activity 
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(192) Methanol extract of 
rosemary. 
DPPH assay n/a CA: 30%; COH: 16%; 
RA: 5% found in 
extract.  
RE>constituents in terms of ATOX activity. RA >CA in 
terms of ATOX activity. Concluded that extract’s 
ATOX is explained by combinatory ATOX activities of 
its main polyphenols CA & RA.  
(202) Super critical fluid extract of 
rosemary 
DPPH assay n/a CA: 3.12-30.0% in 
different extracts. 
Extract with higher percentage of CA displayed 
stronger ATOX activity.  
(203) Commercial oil soluble 
rosemary extract 
standardized on CA. 
Superoxide 
anion, hydroxyl 
and DPPH 
radical activity 
n/a VivOX20 <VivOX40 < 
Inolens 50 in terms of 
CA content. 
All extracts had significant ATOX with all 3 tests. 
Inolens 50 showed strongest activity. 
(204) Rosemary  derived CA, COH 
& RA (0.01, 0.1, 1.0 µM) 
DPPH radical 
assay 
n/a CA, COH, & RA All 3 compounds showed dose dependent DPPH 
activity. RA: most potent across [µM]. 
 
(205) Methanol extract of 
rosemary. 
DPPH assay n/a RA: 2.2-9.7 mg/g wet 
weight of rosemary 
RA exhibited strongest antioxidant activity amongst 
various phenolic compounds tested.  
(206) Methanol (M), & water (W) 
extract of rosemary leaves 
(L), flower (F), and branch (B) 
parts 
DPPH radical 
assay; 
Folin-Ciocalteau 
method; HPLC 
analysis 
 
M: 20 g GAE/ 100 g 
(200 mg GAE/g)* 
W: 3 g GAE/100 g  
(30 mg GAE/g) 
 
L & F contained higher 
phenolic content. M 
contained CA, COH, & 
RA. 
W contained RA. 
M had greater antioxidant activity compared to W.  
(207) Commercial V40 rosemary 
extract 
DPPH radical 
assay 
n/a CA in larger quantity. 
COH in trace amounts. 
No RA. 
V40 greatest antioxidant activity and CA among 
pure compounds tested. RE displayed antilisterial 
activity greater than CA. 
CA, carnosic acid; CAE, chlorogenic acid equivalents; COH, carnosol; DPPH; 2,2-diphenyl-1-picrylhydrazyl; GAE, gallic acid equivalents; QE, quercetin 
equivalents; n/a, not applicable
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1.10.2 Antioxidant Properties of Rosemary Extract: In Vivo Studies 
Membrane phospholipids of red blood cell (RBC) are more susceptible to peroxidation 
and formation of phospholipid hydroperoxidses (PLOOH), key products of oxidative 
damage. Supplementation with 1% (w/w of diet) rosemary extract for one week in mice 
lowered the level of RBC PLOOH by 65-74% compared to the control group indicating 
high antioxidant activity of rosemary (208) (Table 3). Another study examined whether 
two concentrations (0.2% and 0.02%) of a rosemary extract containing 20% carnosic acid 
could enhance antioxidant status in aged rats by assessing its effects on the activities of 
catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD) and nitric 
oxide synthase activity (NOS) as well as lipid peroxidation (191). Ageing causes changes 
in rodent antioxidant enzymes such as increased activity of CAT especially in heart and 
brain tissue. While there were no significant changes in SOD and GPx activity in 
response to rosemary extract supplementation, CAT activity in brain and heart tissues of 
rats was found to be diminished clearly indicating the antioxidant potential of the 
extract because the extract reversed the effects of ageing and the associated higher 
levels of reactive oxygen species (ROS) production on inducing increased CAT activity 
(191) (Table 3). Supplementation with 0.02% rosemary extract decreased NOS activity in 
heart, indicative of its protective role in this tissue. Furthermore, there was a significant 
dose-dependent inhibition of lipid peroxidation in the cerebral cortex of rats (191). The 
administration of 200 mg/kg of aqueous extract of rosemary to STZ-induced diabetic 
rats caused a significant restoration of total antioxidant capacity (enzymatic and non-
enzymatic antioxidants) compared to control animals (209). Similarly, rosemary extract 
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significantly protected against increases in lipid peroxidation markers such as 
malondialdehyde (MDA) and decreases in plasma antioxidant enzymes including SOD, 
CAT and GPx and non-enzymatic antioxidants including ascorbate and glutathione in 
STZ- diabetic rats (210) and alloxan-induced diabetic rabbits (211). Currently, there are 
no studies directly examining the antioxidant effects of rosemary extract or its major 
constituents in humans. However, there have been a few studies indirectly examining 
the effects of rosemary supplements with non-conclusive results. An observational, 
prospective, monocenter study examined the effect of 21 days of oral supplementation 
of aqueous rosemary extract containing 77.7 mg rosemary extract with 0.97 mg 
carnosol, 8.60 mg carnosic acid, and 10.30 mg rosmarinic acid in twelve healthy young 
volunteers (212) (Table 3). There were no significant differences in serum SOD, 
intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), 
GPx, high-sensitivity capsular reactive protein (hs-CRP), TNF-α, and fibrinogen levels 
between extract supplemented group and control group. However, there was a 
significant decrease observed in plasminogen activator-inhibitor-1 (PAI-1) levels 
suggesting that rosemary extract may have anti-inflammatory and anti-blood clotting 
activity in vivo. Another observational study demonstrated rosemary extract and 
oleanolic acid, twice to thrice a day for four to eight weeks in patients with 
osteoarthritis, fibromyalgia, and rheumatoid arthritis, was protective against 
inflammatory rheumatic diseases (213) (Table 3). Thus, these studies provide strong 
evidence of antioxidant activites of rosemary extract in vivo (Table 3) and are in 
agreement with the in vitro (Table 2) studies. 
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   Table 3: Antioxidant Properties of Rosemary Extract: In Vivo Studies 
Reference Animals Treatment Assessment Results Conclusion 
(208) ddY mice 1% (w/w) of diet 
supplemented with 
hexane extract of 
rosemary.  
Lipid 
peroxidation 
(PLOOH) 
Extract significantly reduced RBC plasma 
PLOOH levels to 65-74% of control cells.  
Extract displays strong 
antioxidant effects.  
(191) 
 
 
Aged male 
wister rats (550-
700 g) 
Supercritical fluid 
extract of rosemary  
(SFE) with 20% CA 
supplemented in 
diet at 0.2% & 
0.02% 
Heart, and 
brain tissue 
CAT, GPx, 
SOD; NOS; LP 
Cortex: Dose-dependent inhibition of LP by 
extract Hippocampus: Decrease in LP at 
0.2% (p<0.05). CAT Heart and cortex: CAT 
activity significantly decreased. NOS 
activity decreased in heart at 0.02% 
extract.  
Extract decreased 
cerebral catalase 
activity, and LP; and 
decreased catalase and 
NOS activity in the heart.  
(209) STZ-induced 
adult male 
albino rats (150-
200 g) 
Aqueous extract of 
rosemary 
supplemented at 
200 mg/kg b.w for 
21 days. 
Total 
antioxidant 
activity (TAC) 
TAC significantly decreased in diabetic 
animals compared to control animals. 
Extract significantly increased TAC levels 
compared to treated normal animals. 
Extract displayed 
antioxidant properties in 
vivo. 
(210) 
 
 
 
STZ-induced 
diabetic adult 
male albino rats 
(150-200 g) 
Aqueous extract of 
rosemary 
supplemented at 
200 mg/kg b.w 
daily for 3 weeks. 
MDA, NO, 
CAT, SOD, 
GPx, vitamin 
C, glutathione 
levels (G) 
Diabetic rats displayed decreased levels of 
CAT, SOD, GPx, vitamin C, G & increased 
levels of MDA and NO compared to 
control. Extract increased all antioxidant 
enzyme activity and non-enzyme levels; 
and decreased MDA and NO levels 
(p<0.05).    
Extract displayed 
antioxidant properties in 
vivo.  
(211) Alloxan-induced, 
adult New 
Zealand rabbits 
(2.2-3.1 kg) 
200 mg/kg b.w of 
ethanolic extract of  
rosemary (RE) for a 
week 
MDA, SOD, 
CAT 
SOD, CAT significantly increased and MDA 
increased in diabetic rabbits compared to 
control. RE significantly inhibited serum 
MDA elevations by 33.3% and increased 
serum SOD and CAT activity by 24% and 
35% compared to diabetic control animals.  
Antioxidant effects 
demonstrated in vivo. 
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(212) 12 healthy, 
young 
volunteers 
21 days of 
rosemary extract 
supplementation. 
77.7 mg of crude 
extract: 0.97 mg 
COH, 8.60 mg CA, 
10.30 mg RA. 
Serum lipid 
profile, SOD, 
ICAM-1, 
VCAM-1, GPX, 
hs-CRP, TNF-α, 
PAI-1 and 
fibrinogen 
levels 
Amongst the various markers examined, 
the supplementation significantly 
decreased PAI-1 levels in treatment group 
compared to control. 
Rosemary may possess 
anti-clotting and anti-
inflammatory 
properties. 
(213) 
 
 
 
 
 
72 patients with 
rheumatic 
disease including 
osteoarthritis 
(OA), 
rheumatoid 
arthritis (RAT) 
and fibromyalgia 
(FM). 
Supplemented with 
440 to 880 mg of 
Met050, a 
proprietary 
standardized 
combination of 
rosemary extract & 
oleanolic acid, 2-3 
times a day for 8 
weeks.   
C-reactive 
protein (CRP) 
Significant decrease in CRP in treatment 
group particularly in those with initial 
serum CRP levels >7.0 mg/L. 
 
Meta050 may provide 
beneficial relief 
encountered in 
rheumatic diseases 
especially in patients 
with OA.  
      
BHT, butylated hydroxytoluene; CA, carnosic acid; CAT, catalase; COH, carnosol; FM, fibromyalgia; GPx, glutathione peroxidase; CRP, C-reactive protein; 
ICAM-1, intercellular adhesion molecule-1; LP, lipid   peroxidation; MDA, malondialdehyde; NOS, nitric oxide synthase; OA, osteoarthritis; PAI-1, 
plasminogen activator inhibitor-1; PLOOH, phospholipid hydroperoxides RA, rosmarinic acid; RAT, rheumatoid arthritis; RBC, red blood cell; SOD, 
superoxide dismutase; TAC, total antioxidant capacity; TBARS, thiobarbituric acid reactive substances; VCAM-1, vascular cell adhesion molecule-1.  
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1.10.3 Evidence of Anti-hyperglycemic Effects of Rosemary Extract: In 
Vitro Studies 
Rosemary extract and its phenolic compounds CA, and RA were shown to significantly 
suppress gluconeogenesis in HepG2 hepatocytes via inhibition of the cAMP/PKA/CREB 
pathway (214). Specifically, the cAMP responsiveness of the phosphophenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), the key gluconeogenic 
enzymes, were significantly inhibited by RE and its phenolic components (214). 
Moreover, rosemary extract was shown to significantly increase glucose consumption in 
hepatocytes in a dose-dependent manner (215). Additionally, exposure of hepatocytes 
to RE significantly increased phosphorylation of 5’ AMP-activated kinase (AMPK), an 
enzyme with regulatory effects on cellular lipid and glucose metabolism (Table 4)(215). 
Carnosic acid, a major polyphenolic constituent of RE, prevented palmitate-induced lipid 
accumulation in hepatocytes with concomitant activation of both AMPK and its 
downstream enzyme, acetyl coA carboxylase (ACC) (215). Furthermore, co-treatment 
with compound C, a specific inhibitor of AMPK, abolished these effects of carnosic acid 
suggesting that AMPK may be involved in the protective effects of carnosic acid against 
lipid accumulation in liver cells (216) (Table 4). Administration of ethanol extract of 
rosemary enriched with 40% CA in lean rats did not affect AMPK phosphorylation in 
adipose tissue and liver while muscle tissue was not examined (188) (Table 5). In 
contrast, in adipose tissue of leptin receptor deficient obese rats treated with rosemary 
extract, there was a decrease in phosphorylated AMPK levels compared to control obese 
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animals while this enzyme was undetectable in liver tissue (188). The authors indicated 
that the finding of increased phosphorylated AMPK levels in adipose tissue of control
 obese rats may have been a consequence rather than a cause of the higher levels of 
circulating adipokines in an attempt to attenuate the dysfunction and inflammation in 
this tissue of these animals.  
Apart from the abovementioned studies, rosemary extract’s polyphenolic constituents 
have been previously reported to modulate PPARγ, a transcription factor regulating genes 
involved in adipocyte differentiation, lipid metabolism and regulation of insulin sensitivity. 
PPARγ represent the major target for thiazolidinediones, the anti-diabetic class of drugs. 
Extracts of rosemary were found to increase human PPARγ activity in an in vitro cell-free 
assay and decrease adipocyte differentiation (217). Similarly, 80% aqueous ethanol extract 
of rosemary activated human PPARγ in a concentration-dependent manner with half 
maximal effective concentration (EC50) value of 22.8 ± 8.4 mg/L (218). Furthermore, 
carnosic acid and carnosol were determined to be the principle constituents contributing to 
PPARγ activation (218). In hepatocytes, CA at 10 and 20 μM concentrations was 
demonstrated to abolish the palmitate-induced reduction in mRNA and protein levels of 
PPARγ through increased activation of the EGFR/MAPK pathway leading to reduced lipid 
accumulation (189). Similarly, rosemary extract and carnosic acid were demonstrated to 
inhibit 3T3-L1 adipocyte differentiation, in part through inhibition of PPARγ expression 
(187). Thus, rosemary and its polyphenolic constituents have been shown to modulate 
PPARγ expression and activity, which may have secondary implications for increased 
insulin sensitivity.   
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Rosemary extract’s polyphenolic constituents may also provide protection against 
chemically-induced reactive oxygen species production and cell death. RA exhibited 
significant cytoprotective effects against mycotoxin-induced reactive oxygen species (ROS) 
production, protein and DNA synthesis inhibition, and induction of apoptosis through 
inhibitory effects on caspase-3 activation in human hepatocytes (219). Similarly, RA 
inhibited lipopolysaccharide (LPS)- and phorbol 12-myristate 13-acetate (PMA)-induced 
reactive oxygen and nitrogen species production and  cell death in RAW264.7 macrophages 
(220). The proposed underlying mechanism was reported to be inhibition of LPS-induced Iҡ-
Bα phosphorylation of Ser32 and Ser36 residues (220). On the other hand, 50-100 µM CA 
caused a decrease in intracellular ATP levels without affecting caspase3/7 activity and 
lactate dehydrogenase (LDH) release in human hepatocytes indicating that CA may be acting 
as a mitochondrial toxin, indicating that it may inhibit a component of the mitochondrial 
respiratory complex (221).  
Digestive enzymes convert starch to maltose and iso-maltose which then travel to 
the small intestine where they are converted along with sucrose to monosaccharides 
(glucose and fructose) and absorbed by intestinal α-glucosidase (sucrase and maltase) 
thereby increasing blood glucose levels. Inhibitors of α-glucosidase are used in the 
management of hyperglycemia present in T2DM. Rosemary extract was found to have  
significant α-glucosidase inhibitory activity (222) which was the most potent among 31 
other extracts of herbs and spices tested (223) (Table 4). Moreover, rosmarinic acid, a 
major polyphenolic constituent of rosemary extract, was demonstrated to significantly 
inhibit porcine pancreatic amylase activity in vitro (224), although the same has not 
been reported for CA, another major polyphenolic constituent of rosemary extract.  
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These studies indicate that rosemary extract and its polyphenols may play a role in 
carbohydrate digestion and absorption in the bloodstream and exert beneficial effects in 
pathological states such as insulin resistance and T2DM. From the above studies, it is 
evident that only a limited number of studies have examined the potential anti-
hyperglycemic effects of rosemary extract in in vitro systems. There are no studies 
examining the direct effect of rosemary extract or any of its constituent polyphenols on 
glucose uptake and metabolism in skeletal muscle cells or adipocytes, key insulin target 
tissues. On the other hand, extracts of sage, an herb classified in within the rosemary 
family of Lamiaceae, were shown to significantly enhance insulin-stimulated glucose 
uptake in a dose-dependent manner in adipocytes (217) (Table 4). 
Other effects of rosemary extract that may contribute to regulation of glucose 
homeostasis may be due to its effects on lipid/fat metabolism. Lipids are stored in cells 
particularly adipocytes in the form of triglycerides (TG). The breakdown of TG is 
controlled by enzymes called lipases. Excessive activation of hormone sensitive lipase 
leads to increases in plasma lipid levels such as free fatty acids (FFA) contributing to 
insulin resistance and T2DM. The effects of rosemary extract were assessed on hormone 
sensitive lipase (HSL), and pancreatic lipase (PL) and was shown to significantly inhibit 
both enzymes in a dose-dependent manner (225). Pure rosmarinic acid was shown to 
inhibit PL and HSL in a dose-dependent manner (225). Moreover, the extract had greater 
inhibitory activity compared to purified compounds suggesting that the extract contains 
a variety of constituents that may contribute synergistically in the inhibition of these 
enzymes (225). Additionally, in vitro analysis indicated that carnosic acid rich rosemary 
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extract inhibited PL activity by 70% (190). These studies clearly indicate that RE and its 
constituents CA and RA have antilipolytic activity in vitro. 
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Table 4: Anti-hyperglycemic Effects of Rosemary Extract and/or its Polyphenolic Constituents: In Vitro Studies 
Study ID Cell/Model Treatment Effects Effects on Signaling Molecules  
(214) HepG2 hepatocytes Methanol rosemary 
extract 
Rosemary extract and its polyphenolic 
constituents suppressed gluconeogenesis 
through inhibition of the cAMP/PKA/CREB 
pathway. 
Supressed cAMP responsiveness of PEPCK 
and G6Pase promoters in hepatocytes by > 
60% quantified by the luciferase reporter 
gene 
(226) HepG2 hepatocytes 0.4, 2, 10, 50 µg/ml 
methanol rosemary 
extract 
2-50 µg/ml increased glucose consumption by 6 
%, 13 %, 21% 
10-50 µg/ml ↑AMPK & ACC 
phosphorylation 
 
(216) HepG2 hepatocytes 10-20 µM CA Inhibited palmitate-induced cellular fat 
accumulation.  
CA ↑AMPK phosphorylation in a time-
dependent manner.  
↓PPARγ (↑EGFR/MAPK signaling) 
(218) Cos7 cells transfected 
with hPPARγ  
80% aqueous ethanol 
rosemary extract 
Rosemary extract activated PPARγ in a 
concentration-dependent manner, with EC (50) 
values of 22.8 +/- 8.4 mg/L. CA & COH, active 
principles of extract had EC (50) values of 19.6 
+/- 2.0 μM, and 41.2 +/- 5.9 μM  respectively. 
↑PPARγ activation. 
(187)  3T3-L1 adipocytes Acetone rosemary 
extract; CA 
Rosemary extract (10-30 μg/ml) & CA (0.3-20 
μM) significantly inhibited adipocyte 
differentiation.  
↓PPARγ expression. 
(219) HepG2 hepatocytes RA (25-50 µM) RA significantly reduced AFB1- & OTA-induced 
ROS production, DNA & protein sythnesis 
inhibition, & apoptosis. 
↓activation of caspase 3 
(220) RAW264.7 
macrophages 
RA (10-50 µM) RA significantly reduced LPS-induced NO 
production, and decreased iNOS protein 
expression; PMA-induced ROS production.  
↓Iҡ-Bα phosphorylation at Ser32 & Ser36 
residues 
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CA, carnosic acid; COH, carnosol, RA, rosmarinic acid; PPAM, porcine pancreatic α-amylase; PL, AGc, α glucosidase, porcine pancreatic lipase; HSL, hormone 
sensitive lipase; PPARγ, peroxisome proliferator activated receptor-γ; EGFR, epidermal growth factor receptor; MAPK, mitogen activated protein kinase; AMPK, 
AMP-activated protein kinase; ACC, acetyl coA carboxylase.  
 
 
(221) 
 
HepG2 hepatocytes 
 
50-100 μM CA 
 
CA caused hepatoxicity, with associated 
decrease in ATP levels and lack of caspase 3/7 
activity or LDH release after 4 hours of 
treatment indicating that CA may be acting as a 
mitochondrial toxin.  
 
↓ATP levels 
↔ caspase 3/7 
↔ LDH levels  
(223) Rat intestinal α- 
glucosidase (AGc) 
50 % ethanol rosemary 
extract 
Inhibited AGc with IC50 value of 683-711 µg/ml  
(227) PPAM 100 mg of different RA 
extract in 3 mL of 50% 
ethanol. Oregano (7% 
RA) (O); Lemon balm 
(50% RA) (LB); Pure RA 
(97%) (PRA) 
PRA, LB, O inhibited amylase activity by 85%, 
50%, & 42%. Inhibitory amylase activity was 
correlated with RA content of extracts 
 
(225) Porcine pancreatic 
lipase (PL);  Rodent 
hormone sensitive 
lipase (HSL) 
6.3-200 ug/ml of 
methanol rosemary 
extract & its constituent 
RA 
Both inhibited PL & HSL activity. *Extract > 
inhibitory activity versus pure RA 
 
(190) Human PL 100 µg/ml rosemary 
extract rich in CA 
Inhibited human PL (70%)   
(217) 3T3-L1 adipocytes Extract of sage Increased insulin-stimulated glucose uptake in a 
dose-dependent manner 
↑PPARγ transactivation 
↓adipocyte differentiation 
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1.10.4 Evidence of Anti-Hyperglycemic Effects of Rosemary Extract: In 
Vivo Studies   
In streptozotocin-(STZ) induced diabetic rats, aqueous rosemary extract resulted in 
significant improvements in fasting plasma glucose levels (228) (Table 5). Administration 
of 50% ethanol extract of rosemary in streptozotocin (STZ)-induced diabetic rats 
significantly decreased plasma glucose levels (223). This effect was due to inhibition of 
glucosidase enzymes involved in glucose absorption (Table 5). In a more recent study, 
daily administration of 200 mg/kg b.w of aqueous extract of rosemary for three weeks 
caused significant reductions in blood glucose levels of both normal and STZ-induced 
diabetic rats (210) (Table 5). Similar effects were seen on blood glucose levels in STZ-
induced diabetic rats given aqueous rosemary extract (1.16 g/ml) for 4 weeks (229). In 
addition, the extract significantly reduced plasma triglycerides, cholesterol and LDL 
while increasing plasma HDL levels (229). In agreement with the above studies, blood 
glucose levels as well as total cholesterol and triglyceride levels were significantly 
reduced in STZ-induced diabetic rats given aqueous rosemary extract 2 weeks before 
and 2 weeks after STZ injection (209,230). Insulin resistance and Type 2 diabetes is 
associated with increased plasma lipid levels in humans and studies both in vitro and in 
vivo provide clear evidence that enhanced lipid levels can cause insulin resistance  as 
discussed in  section 1.7. Therefore, the significant reduction in plasma lipid levels seen 
in the abovemetioned studies using the STZ-induced diabetic animals provide strong 
evidence for RE’s indirect anti-diabetic effects. Furthermore, administration of aqueous 
extract of rosemary prior to streptozotocin injection in rats significantly protected 
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against STZ-induced elevations in blood glucose levels which was correlated with a 
significant protection against pancreatic β-cells (231). In addition, rosmarinic acid, a 
major polyphenolic constituent of rosemary, was demonstrated to significantly increase 
total antioxidant capacity and estrogen levels in STZ-induced diabetic female rats 
suggesting that it may have indirect effects on hyperglycemia-induced reactive oxygen 
species production and associated T2DM complications (232). Although, the 
abovementioned studies used STZ-induced diabetic animals to investigate the effects of 
RE, its effects on different insulin target tissues and the mechanism involved are not 
clear largely due to the fact that the different studies examined different parameters 
and there was a lack of systematic examination of factors involved in glucose 
homeostasis. All of the studies are summarized in Table 5 (refer to pages 71-74) to 
provide an overview of the existing literature on the topic and simultaneously reveal 
potential areas of interest for future research to better clarify rosemary extract’s effects 
on glucose homeostasis and its mechanism of action.   
In addition to the STZ-induced diabetic model, the alloxan-induced diabetes animal 
model is also used extensively. Alloxan causes diabetes by rapid depletion of pancreatic 
β-cells leading to inflammation and sustained hyperglycemia secondary to a reduction in 
insulin release into circulation. In alloxan-induced diabetic rabbits, 200 mg/kg b.w of 
ethanol extract of rosemary lead to a significant reduction in fasting plasma glucose 
levels (211) (Table 5). Another recent study evaluated the effects of rosemary extract on 
blood glucose levels and liver function and structure in alloxan-induced diabetic rats 
(233). Diabetic rats were supplemented with powdered rosemary extract added as 20% 
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of diet or 20% aqueous rosemary extract was orally administration through a tube (233) 
(Table 5). There was a significant decrease in fasting plasma glucose levels in both 
treatment groups compared to control. Additionally, aqueous extract of rosemary was 
demonstrated to have regenerative properties against alloxan-induced hepatocyte 
vacuolar degeneration, necrosis, small hemorrhages and dilatation of hepatic sinusoids 
indicating hepatoprotective effect of this herbal extract (233). Moreover, administration 
of 100-200 mg/kg b.w of rosmarinic acid to alloxan-induced rats for eight weeks 
significantly inhibited glomerular hypertrophy, glomerular number loss and 
glomerulosclerosis compared with diabetic control indicating rosmarinic acid’s 
renoprotective properties (234). 
Oral administration of carnosic acid (0.05% (w/w)) to obese leptin receptor 
deficient (db/db) mice for five weeks resulted in significant protection against fat-
induced fasting and non-fasting hyperglycemia. Carnosic acid also significantly inhibited 
weight gain, decreased regional areas of visceral fat, and prevented against fat 
accumulation in white adipose tissue as well as liver. Moreover, animals supplemented 
with carnosic acid exhibited decreased serum levels of triglycerides, cholesterol, and 
alanine aminotransferase; as well as significantly decreasing hepatic lipids (189) (Table 
5).  
Apart from animal models of genetic and chemically-induced obesity and T2DM, 
the effects of rosemary extract have been examined in dietary animal models of obesity 
and T2DM. The preventive effects of aqueous rosemary extract standardized to contain 
20% carnosic acid on glycemic levels, and lipid homeostasis was examined in mice that 
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were started on a high-fat diet (HFD) as juveniles (190). Daily, dietary supplementation 
of 500 mg/kg b.w of rosemary extract standardized to contain 20% carnosic acid for 16 
weeks significantly protected against HFD-induced elevations in plasma glucose levels 
and total cholesterol levels compared with HFD control mice (190). Notably, fasting 
insulinemia remained low during the length of the study and no significant differences 
were observed between the groups. Correlating with the observed reductions in total 
cholesterol levels, HFD mice supplemented with rosemary extract displayed significant 
decreases in fat mass and one to twofold increase in total fecal content compared to 
HFD-fed control mice (190). Similarly, daily administration of 100 mg/kg b.w of aqueous 
rosemary extract to high-cholesterol fed mice for 36 days resulted in significant declines 
in tryiglycerides, plasma total cholesterol, LDL-C, and increase in HDL levels compared to 
control mice (235). Furthermore, administration of aqueous extract of rosemary and 
non-esterified phenolic extract of rosemary at concentrations of 70 mg/kg b.w and 140 
mg/kg b.w to diet-induced hypercholesterolemic rats for four weeks resulting in 
significant reduction in total cholesterol and non-HDL-c levels compared with control 
rats only in response to the former herbal supplementation (Afonso et al., 2013). 
However, there were no effects on triglyceride and HDL-C levels. In addition, high-
fructose fed (HFR) mice given daily dose of 100 mg/kg b.w of rosmarinic acid for 60 days 
significantly prevented against HFR-induced glucose intolerance compared to HFR 
control mice (236). Glucose disposal in the diaphragm of mice in vitro also increased 
significantly in response to rosmarinic acid and rosmarinic acid in combination with 
insulin compared to control. 
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 In contrast, obese mice and their lean counterparts fed 0.5% ethanol extract of 
rosemary enriched with carnosic acid (40%) incorporated in their standard chow for 64 
days did not show significant differences in their glucose levels compared to control 
rats, although circulating insulin levels were found to be significantly decreased only in 
the lean rats (188) (Table 2). Noteworthy, the plasma glucose levels in all animals were 
within normal physiological range with a non-significant, slight increase in obese 
counterparts. The study also demonstrated a significant inhibition of gastric lipase (GL) 
in the stomach and pancreatic lipase (PL) in small intestine of rats consuming the 
rosemary extract (237). Furthermore, there was a significant attenuation of circulating 
plasma TNF-α, IL-1β, leptin and elevation of adiponectin levels, adipocytokines implicated in 
peripheral tissue insulin resistance and T2DM (188).  
Thus the anti-hyperglycemic effects of rosemary extract are observed in animal 
models of obesity and T2DM. The mechanisms underlying the anti-hyperglycemic 
effects of rosemary extract in vivo, however, remain to be determined.
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Table 5: Anti-hyperglycemic Effects of Rosemary Extract and/or its Polyphenolic Constituents: In Vivo Studies 
Study Animal Model Dose Glucose Insulin Other Measures 
(228) STZ-induced diabetic Swiss 
albino mice (25-30 g) 
Ad libitum (10 g leaves in 1 
L boiling water) for 3 
months 
↓FPG in healthy and 
diabetic animals 
 ↔ alkaline phosphatase, bilirubin, 
ALT, AST, creatinine, urea-N, total 
protein, albumin 
(223) STZ-induced diabetic male 
ddY mice (19-21 g) 
20 mg/mice of 50% 
ethanol & aqueous 
rosemary extract 
↓ Plasma glucose 
levels.  
 
 Both exerted strong α-glucosidase 
(AGc) inhibitory activity 
(210) STZ-induced diabetic male 
albino rats (150-200 g) 
Oral 200 mg/kg/day of 
aqueous rosemary extract 
for 3 weeks 
↓ FPG  ↑CAT, SOD, GPx, vitamin C, vitamin 
G 
↓MDA 
↓NO 
(229) STZ-induced diabetic male 
albino rats (140-155 g) 
Oral 1.11 g/ml of aqueous 
rosemary extract for 4 
weeks 
↓ FPG (20%)  ↓ total cholesterol, TAG, LDL-c (22%, 
24%, 27%) 
↑ HDL-c (18%) 
(230) STZ-induced diabetic male 
albino rats (150-200 g) 
Oral 200 mg/kg/day of 
aqueous rosemary extract 
for 2 weeks prior to STZ 
injection; for 3 weeks after 
STZ injection. 
 
↓FPG (36.9%)   ↑Hb levels 
↓total cholesterol, TG, LDL-c (72.9%, 
33%, 79%). 
↑HDL-c (40%) 
↓ serum AST, CDK, LDH 
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(209) STZ-induced diabetic male 
albino rats (150-200 g) 
Oral 200 mg/kg/day of 
aqueous rosemary extract 
for 21 days 
↓FPG  ↓total cholesterol, TAG 
↑TAC 
(231) STZ-induced diabetic male 
albino rats (150-200 g) 
Oral 200 mg/kg/day of 
aqueous rosemary extract 
for 2 weeks prior to STZ 
injection; & for 3 weeks 
after STZ injection 
↓FPG in both groups ↑serum insulin & 
C-peptide  
↓ serum AST, ALT, ALP,  
↑total protein, albumin 
(232) STZ-induced diabetic, 
female albino Wistar rats 
(250 g) 
Oral 5 mg/rat RA for 8 
weeks 
  ↓MDA 
↑Total antioxidant capacity.  
(211) 
 
 
Alloxan-induced diabetic 
New Zealand rabbits (2.2-
3.1 kg) 
Oral 50, 100, 200 mg/kg of 
ethanol rosemary extract 
for 6 hours (acute); for 1 
week (subacute) 
 
Healthy animals 
Acute: ↓FPG (14.5%) 
↓ OGTT glucose 
levels  
Diabetic animals 
Acute: ↓FPG (22.3) 
Subacute: ↓ FPG 
(29.5%) 
 
↑insulin levels in 
healthy & diabetic 
animals  
*200 mg/kg 
extract for 1 week 
increased plasma 
insulin levels by 
77.8% 
↓MDA (33.3%) 
↑SOD, & CAT activity (24%, 35%) 
(233) Alloxan-induced Sprague-
Dawley male albino rats 
(130-200 g) 
20% of diet powdered 
rosemary; 20% of 
rosemary extract 
administered through the 
tube 
 
↓FPG  Significant regenerative properties 
against alloxan-induced hepatocyte 
vacuolar degeneration, necrosis, 
small hemorrhages, and dilatation of 
hepatic sinusoids 
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(234) Alloxan-induced Sprague-
Dawley uninephrectomized 
rats 
100-200 mg/kg/day of RA 
for 8 weeks 
  Inhibited glomerular hypertrophy, 
glomerular number loss, & 
glomerulosclerosis. ↓serum MDA, 
creatinine, urea 
(237) Female Zucker lean (fa/+) 
and obese (fa/fa) rats 
(105.5-148.5 g) 
0.5% w/w of aqueous 
rosemary extract enriched 
with CA for 64 days  
↔ plasma glucose 
levels  
*(levels were normal 
range throughout 
entire study period ) 
↓insulin levels in 
lean animals. 
 
Inhibited gastric lipase activity in 
both lean (70%) and obese animals 
(80%) 
↓total cholesterol, TAG, LDL-c 
↑HDL-c 
(189) Male ob/ob mice 0.05% w/w CA for 5 weeks  ↓BPG 
↓OGTT glucose 
levels 
 ↓ total cholesterol, TAG 
↓ALT 
↓hepatic lipids and total TAG 
content (28%, 47%)  
(190) HFD-treated male C57BL/6J 
mice 
Oral 500 mg/kg/day of 
aqueous rosemary extract 
standardized to contain 
20% CA for 16 weeks  
↓FPG (72%)  ↓ total cholesterol (68%) 
↑total fecal content (1-2 fold) 
(235) Diet-induced HC female 
BALB/c mice 
Oral 100 mg/kg/day of 
aqueous rosemary extract 
for 36 days; 10, 50, 100 
mg/kg/day of rosemary 
extract for 8 weeks 
 
 
  ↓total cholesterol, TAG, LDL-c 
↑HDL-c 
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(238) Diet-induced HC Wistar rats 
(101 g) 
Oral 70 & 140 mg/kg/day 
of aqueous rosemary 
extract (AQ); 7 & 14 
mg/kg/day of non-
esterified phenolic extract 
of rosemary (NEPF) 
  ↓total cholesterol, non-HDL-c 
(39.8%, 44.4%) 
(236) Fructose-fed (FF) swiss 
albino mice (25-30 g) 
Oral 100 mg/kg/day of RA 
for 60 days 
↓FPG levels  
↓OGTT glucose 
levels 
↓ plasma insulin 
levels 
↑diaphragm glucose utilization* (RA 
plus insulin resulted in greater 
effects) 
↓Glycated plasma Hb levels 
 
(237) Female Zucker lean (fa/+) 
and obese (fa/fa) rats 
(105.5-148.5 g) 
0.5% w/w of ethanolic 
rosemary extract enriched 
with CA for 64 days  
↔ plasma glucose 
levels  
*(levels were normal 
range throughout 
entire study period ) 
↓insulin levels in 
lean animals. 
 
Inhibited gastric lipase activity in 
both lean (70%) and obese animals 
(80%) 
↓total cholesterol, TAG, LDL-c 
↑HDL-c 
(188) Female Zucker lean (fa/+) 
and obese (fa/fa) rats 
(105.5-148.5 g) 
0.5% w/w of ethanolic 
rosemary extract enriched 
with CA for 64 days 
  ↓leptin, TNF-α, IL-1β (lean rats) 
↓AMPK phosphorylation in adipose 
tissue of obese rats. 
Undetectable Phospho-AMPK in liver 
or hypothalamus of both obese and 
lean rats. 
 
 AGc, α-glucosidase activity; ALT, alanine aminotransferase; CA, carnosic acid; COH, carnosol; FF, fructose-fed; FPG, fasting plasma glucose; HFD, high-fat diet; 
HC, hypercholesterolemia; HDL-c, high-density lipoprotein; LDL-c, low-density-lipoprotein; MDA, malondialdehyde; RA, rosmarinic acid; SGLT, sodium glucose 
cotransporters; STZ, streptozotocin; TAC, total antioxidant capacity; TC, total cholesterol; TG, triglyceride;    
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Chapter 2 
2.1 Research Proposal 
The vast majority of pharmacological treatments for insulin resistance and T2DM 
including biguanides, thiazolidinediones, sulfonylureas and α-glucosidase inhibitors are 
lacking in drug efficacy, and/or have unwanted side-effects. Biguanides (metformin) are 
insulin-sensitizing or insulin-mimetic drugs without affecting insulin secretion (42). The 
major adverse effects of metformin are lactic acidosis. Thiazolidinediones (TZDs) are a 
new class of oral antidiabetic drugs that improve metabolic control in patients with type 
2 diabetes through the improvement of insulin sensitivity (239). TZDs exert their 
antidiabetic effects through a mechanism that involves activation of the gamma isoform 
of the peroxisome proliferator-activated receptor (PPAR-γ), a nuclear receptor. TZDs 
improve insulin resistance in muscle, adipose tissue and liver through PPAR-γ induction 
of genes involved in glucose and lipid metabolism including glucokinase and the GLUT4 
glucose transporter. The major adverse effects associated with TZDs are edema and 
fluid retention (239). Sulfonylureas are antidiabetic drugs that stimulate β-cells of the 
pancreas to release insulin. Several studies have also shown that sulfonylureas can midly 
reduce endogenous glucose output and improve peripheral insulin resistance (42). The 
adverse effects associated with sulfonylureas are severe hypoglycemia, gastrointestinal 
intolerance, hemolytic anemia and cholestatic jaundice due to hepatotoxicity. Alpha-
glucosidase inhibitors delay the digestion of complex carbohydrates and disaccharides 
(starch, sucrose) to monosaccharides by reversibly inhibiting α-glucosidases within the 
intestinal brush border which results in reduced glucose absorption and attenuated rise 
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of postprandial hyperglycemic. The currently available α-glucosidase inhibitors are 
acarbose, miglitol and voglibose. The major adverse effects associated with acarbose 
therapy are gastrointestinal complaints including flatulence and abdominal discomfort.  
There is growing interest in search of new compounds found in plant extracts and 
herbal supplements in the treatment of insulin resistance and T2DM (173,225). The 
plant polyphenol resveratrol found in high concentrations in red wine has been 
demonstrated to increase glucose uptake in vitro (88) and reduce blood glucose levels in 
different animal models of type 2 diabetes (90,91,240). Resveratrol has been shown to 
activate AMPK in myotubes (88) and as previously mentioned the beneficial effects of 
resveratrol against fat-induced insulin resistance are abolished in animals lacking AMPK 
(91) providng strong evidence that AMPK activation is very important.  
Rosemary extract has been demonstrated to decrease plasma glucose levels in 
animal models of obesity and diabetes, an effect similar to resveratrol. Studies have 
indicated that rosemary extract has in vitro and in vivo antioxidant activity. Given that 
oxidative stress and increased production of reactive oxygen species (ROS) is linked to 
insulin resistance (IR) and T2DM (36), rosemary extract’s reported antioxidant activity 
may indirectly affect glucose homeostasis and exert beneficial effects in pathological 
states of IR and T2DM. Moreover, previous in vivo studies have demonstrated that RE 
protects against hyperlipidemia and hyperglycemia in genetic, chemically-induced and 
dietary animal models of obesity and T2DM. Daily administration of RE significantly 
improved plasma glucose levels in streptozotocin (STZ)-induced diabetic rats 
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(210,223,229); and in alloxan-induced diabetic rats (231) and rabbits (211). In genetically 
obese mice, carnosic acid, a polyphenolic component of RE protected against fat-
induced fasting and non-fasting hyperglycemia and hyperlipidemia (189). Similarly, in a 
dietary rodent model of obesity, RE significantly protected against high-fat diet (HFD) 
induced elevations in plasma glucose and total cholesterol levels (190). Collectively, 
these studies (refer to Table 5) demonstrate RE’s in vivo anti-hyperglycemic properties. 
However, there are currently no studies that delineate the mechanism underlying the 
reported in vivo effects of RE. It is possible that the antihyperglycemic effects of the 
extract of rosemary in vivo may be due to effects on skeletal muscle; however, the exact 
action of rosemary extract and its polyphenolic constituents on glucose uptake in 
muscle tissue, quantitatively the most important insulin target tissue, have not been 
examined.  
2.2 Hypotheses 
Rosemary extract (RE) and its two major polyphenolic constituents carnosic acid (CA) 
and rosmarinic acid (RA) increase skeletal muscle glucose uptake via activation of AMPK. 
2.3 Objectives/Aims 
1. Examine the effects of rosemary extract (RE) on glucose uptake in skeletal 
muscle cells.  
2. Examine the effects of pure rosemary extract constituents including carnosic acid 
(CA), and rosmarinic acid (RA) on glucose uptake in skeletal muscle cells.  
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3. Investigate the intracellular signaling molecules and signaling cascade activated 
by rosemary extract (RE).  
3.1 Examine the effects of rosemary extract and its main polyphenols on 
activation of Akt and determine the role of Akt.  
3.2 Examine the effects of rosemary extract and its main polyphenols on 
activation of AMPK and determine the role of AMPK. 
3.3 Examine the effects of rosemary extract (RE) and its main polyphenols on 
glucose transporter GLUT1 and GLUT4 translocation 
2.4 Methodology 
2.4.1 Materials 
Minimum essential media (α-MEM), fetal bovine serum (FBS), trypsin, and antibiotic 
were purchased from GIBCO Life Technologies (Burlington, ON, Canada). Akt, and AMPK 
(Total and Phospho-specific) antibodies, horse-radish peroxidase (HRP)-conjugated anti-
rabbit secondary antibody, and LumiGLOW reagents were purchased from New England 
Biolabs (Mississauga, ON, Canada).  Insulin (Humulin R) was purchased from Eli Lilly and 
Company (Indianapolis, IN, USA). Bovine serum albumin and compound C were 
purchased from Calbiochem (Gibbstown, NJ, USA). Bradford protein assay dye reagent 
concentrate, polyvinylidene difluoride (PVDF) membranes, molecular weight protein 
standards, and electrophoresis reagents were purchased from BioRad. [3H]-2-deoxy-D-
glucose were purchased from PerkinElmer (Boston, MA). Cytochalasin B, and cold 2-
deoxy-D-glucose were purchased from Sigma Chemicals (St. Louis, MO). Dimethyl 
sulfoxide (DMSO) hybri-max was purchased from Sigma Life Sciences. Rosmarinic acid 
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(≥98%, powder, from Rosmarinus officinalis) and carnosic acid (≥91%, powder, from 
Rosmarinus officinalis) were purchased from Sigma Aldrich. Whole dried rosemary 
(Rosmarinus officinalis L.) leaves were purchased from Compliments/Sobeys 
(Mississauga, ON, Canada). Parental, GLUT1 and GLUT4 overexpressing L6 cells were a 
kind gift from Dr. A Klip (Hospital for Sick Children, Toronto, ON, Canada).  
2.4.2 Cells 
L6 cells which are an immortalized myogenic cell line derived from rat hindlimb skeletal 
muscle, undergo proliferation as mononucleated myoblasts when grown in 10% FBS 
containing α-minimum essential media (α-MEM) and spontaneously differentiate into 
multinucleated myotubes when placed in 2% FBS containing media. L6 cells express 
insulin receptor, insulin-like growth factor-1 receptor (IGF-1), and facilitated glucose 
transporters (GLUTs) namely GLUT1, GLUT3, and GLUT4 (241). During differentiation 
from myoblasts into myotubes, insulin receptor and insulin-sensitive glucose transporter 
(GLUT4) expression increases resulting in established insulin responsiveness. Following 
cell treatment with insulin, all three GLUT isoforms translocate to the plasma membrane 
but the largest relative change occurs with the GLUT4 (242). In accordance with relative 
change in GLUT expression between myoblasts and myotubes, glucose transport activity 
also differs as the cells differentiate. Basal glucose transport is highest in myoblasts and 
decreases as the cells differentiate into myotubes while insulin-stimulated glucose 
uptake is observed only upon cell alignment and increases as they differentiate to the 
myotube stage (243). 
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 Cultured cells are extensively used to study metabolic and hormonal processes. The 
advantages of studying molecular mechanisms of hormone action and transport 
function/regulation in a cell culture system are the homogeneity of muscle cell 
population with limited intercellular space unlike intact tissue preparation, as well as a 
closely controlled external environment without influences by other factors found in in 
vivo studies (241). Additionally, cell cultures have an extended viability and provide a 
conducive model to examine acute and chronic effects of a particular 
substance/chemical under investigation.  
 Isolation of human skeletal muscle strips is possible only during a surgical procedure 
and therefore availability is greatly limited. Additionally, there is a risk of compromising 
membrane integrity upon removal of muscle tissue (242). In primary cell culture, 
stimulation of glucose transport in response to physiological concentrations of insulin 
has been demonstrated ineffective (241). Furthermore, there is difficulty associated 
with establishing primary muscle cell culture and is not generally used. 
 Other than L6 skeletal muscle cells, mouse C2C12 cells, which express both the 
glucose transporters GLUT1 and GLUT4 have been used as an in vitro model of skeletal 
muscle (241).  
L6 cells display greater ratios of GLUT1 and GLUT3 and lower GLUT4 transporter 
expression compared to adult rat muscles resulting in an inequitable representation of 
adult skeletal muscle, however these cells express many morphological and functional 
characteristics of skeletal muscle. Most importantly, the L6 cell line is amongst few cell 
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lines that differentiate in culture, and the only cell line that express GLUT1, GLUT3 and 
GLUT4 (241,242).  
 L6 cells are extensively used and represent the best available cell culture model of 
skeletal muscle (242). These cells grow in monolayers, which makes them readily 
accessible to substrates rendering them a good model for studying the influence of 
substances/chemicals on glucose transport. 
 In addition to using the parental L6 cell line, the L6 GLUT4myc and GLUT1myc 
overexpressing cell lines were used in the present study. The L6 GLUTmyc 
overexpressing cell line was constructed by inserting a human c-myc epitope tag within 
the first exofacial loop of the GLUT1 or GLUT4 trasnporter (241,244). These cells 
differentiate normally from myoblasts to fused myotubes, at which stage they respond 
to insulin with a two-fold stimulation of glucose uptake. Additionally while the 
GLUT4myc cell line responds to insulin treatment with a two-fold increase in GLUT4 
translocation, there is a modest increase in GLUT1 translocation in GLUT1myc cells. The 
Michaelis-Menten constant (Km) of glucose uptake is similar in L6 GLUTmyc cells to that 
of the parental cells (71,241). Similar to L6 parental cells, L6 GLUTmyc cells respond to 
insulin by IRS-1 phosphorylation and subsequent PI3k and Akt/PKB activation, which are 
necessary for stimulation of glucose uptake.  
2.4.3 Cell Culture Technique 
L6 rat skeletal muscle cells were grown in α-MEM (pH 7.4) containing 5 mM glucose, 
10% (v/v) FBS, and 1% (v/v) antibiotic-antimycotic solution (100 U/ml penicillin, 100 
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µg/ml streptomycin, and 250 ng/ml amphotericin B) in a humidified atmosphere of 5% 
CO2, 95% air at 37oC. Cells were grown in 250 cm3 flasks and seeded into 12-well tissue 
culture plates for glucose uptake measurements and 6-well plates for immunoblotting 
analysis. Upon reaching 100% confluency, the cells were exposed to 2% (v/v) FBS to 
allow the cells to differentiate from mono-nucleated myoblasts into multi-nucleated 
myotubes. Myotubes were used for all experiments. Prior to treatments, myotubes 
were growth-arrested by incubation with serum-free α-MEM media for 2.5-3 hours. 
Serum deprivation decreases the rate of basal glucose transport so that the cells are not 
at maximum capacity before stimulation, thereby making an increase in glucose 
transport in response to treatments more detectable (Mitsumoto et al., 1991). 
2.4.4 Preparation of Rosemary Extract (RE) 
A methanol extract of rosemary (RE) was prepared. Whole dried rosemary (Rosmarinus 
officinalis L.) leaves (purchased from Compliments/Sobey’s, Mississauga, ON, Canada), 
were ground and passed through a mesh sieve and extracted following protocols 
established by the National Cancer Institute of the U.S. (223,226). The ground plant (5 g) 
was steeped overnight (16 hours) in dichloromethane-methanol (1:1) (30 mL). The 
filtrate was collected under slight vacuum followed by a MeOH (30 mL) extraction for 30 
min. The solvent was removed by rotary evaporation. Aliquots were prepared in 
dimethyl sulfoxide (DMSO) (10 mg/ml) and stored at -20 ˚C (226). Preparation of the 
rosemary extract was performed in collaboration with Dr.Stamatatos’s chemistry lab at 
Brock University.  
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2.4.5 Analysis of Rosemary extract (RE) Using High Performance Liquid 
Chromatography (HPLC) Technique  
Methanol extract of rosemary, and standards (carnosic acid and rosmarinic acid) 
(purchased from Sigma Aldrich) were dissolved in sterile DMSO at a concentration of 2 
mg/mL.  Before HPLC analysis, all the samples were filtered through a 0.45 µM filter. 
Aliquots of 2.5 µL were injected into a reverse phase Agilent 110 series HPLC instrument 
equipped with an autosampler. Separation and quantification were achieved at 25 oC by 
using a mobile phase consisting of solvent A and solvent B. Solvent A was 0.1% formic 
acid in HPLC grade water, and solvent B was acetonitrile. A linear gradient of 95% 
solvent A and 5% solvent B was achieved over 30 minutes. The flow rate was 0.4 ml min-
1 and the detection was set at 254 nm. Identification of individual compounds was based 
on the comparison of the actual retention time to those of reference authentic 
standards (carnosic acid, rosmarinic acid). Quantification of each compound was 
performed by the calculation of the peak areas after HPLC separation. Mean total 
content was expressed in % (g/100 g dry weight extract). It should be noted that the 
HPLC analysis was performed in collaboration with Dr.Hudlicky’s chemistry lab at Brock 
University.  
2.4.6 Cell Treatment 
L6 myotubes were treated with different concentrations of methanol extract of 
rosemary leaves with different exposure times. The concentrations used were 0.1, 1.0, 
5.0, 10, 20, 30, 40, 50 ug/ml of methanol extract of rosemary leaves. The exposure times 
were 0.5, 1, 2, 4, 6, 16 hours. Cells were exposed to 100 nM insulin (30 min. exposure) 
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or 5 mM metformin (16 hours exposure) (211,228,236). L6 myotubes were also exposed 
to 0.1, 0.3, 2.0 µM carnosic acid (CA), and 2.0, 5.0 µM rosmarinic acid (RA) for four 
hours. Selection of these concentrations was derived from the HPLC analysis of the 
extract and other in vitro studies that used these compounds. A vehicle-treated control 
(% of DMSO) was used in parallel with the treated groups.  
2.4.7 Glucose Uptake Assay 
The radiometric glucose uptake assay measures specific carrier (GLUT)-mediated 
glucose transport utilizing a radiolabelled, non-metabolizable glucose analog, [3H]-2-
deoxy-D-glucose. At the end of the incubation period, the cells were rinsed three times 
with HEPES-buffered saline solution (HBS; 14mM NaCl, 5mM KCl, 20 mM HEPES, 2.5mM 
MgSO4 and 1mM CaCl2, pH 7.4). Subsequently, 2-deoxy-D-glucose uptake 
measurements were carried out by exposing cells to 250µl of HEPES-buffered saline 
containing 10µM [3H]-2-deoxy-D-glucose for 10 minutes. Nonspecific uptake of 2-deoxy-
D-glucose were determined in the presence of 10µM cytochalasin B (GLUT inhibitor), 
and subtracted from total uptake (absence of CB) to determine specific carrier-mediated 
glucose transport. The transport assay was terminated by washing the cells three times 
with 1 ml ice-cold 0.9% NaCl solution. Cells were solubilized by 1 ml of 0.05N NaOH 
solution. Cell lysates were collected into scintillation vials followed by addition of 10 ml 
of scintillation fluid. All experiments were assayed in triplicates and performed 4-8 
times. 50µl of cell lysates were pipetted into 2 ml eppendorf tubes and stored at -20oC 
for analysis of cellular protein content using the Bradford Protein Assay method. 
Radioactivity was measured using the Beckman Scintillation Counter. 
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2.4.8 Cell Lysis 
L6 cells were grown in 6-well plates until they were fully confluent, followed by 
treatments as indicated in the cell treatment section. After treatments, cells were be 
washed two times with PBS and placed on ice. PBS was removed and 100µl of cell lysis 
buffer was added to each well of the 6-well plates. Cells were lysed and collected into 
1.5 mL eppendorf tubes, and an equal amount of SDS (sodium dodecyl sulfate) sample 
buffer was added to each tube. The cell lysates were then boiled for 5 minutes and 
stored in the freezer at -20°C. 
2.4.9 Protein Assay 
Protein assay dye (BioRad) was prepared (1 part dye concentrate: 4 parts DD H20) and 
filtered for protein concentration determination. BSA protein standards (0, 0.1, 0.2, 0.4, 
0.6, 0.8, 0.9, 1.0mg/ml) were used to create a standard protein curve. 10µL of each 
protein standard and lysed samples was pipetted into separate wells of a 96-well plate 
in triplicate. 200µL of protein assay dye was then added into each well. The absorbance 
was measured using a microplate reader at 595nm, and the final concentration of the 
protein samples was calculated in Microsoft Excel 2010. 
2.4.10 Western Blot Analysis 
At the end of the treatment period, the cells were rinsed three times with HBS and then 
lysis buffer (20mM Tris (pH 7.5), 150mM NaCI, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 
2.5mM NA407P2, 1mM β-glycerolphosphate, 1mM Na3V04, 1µg/ml leupeptin, 1mM 
PMSF) was added and the lysate was scraped off and solubilized in electrophoresis 
sample buffer, followed by separation by sodium dodecyl sulfate polyacrylamide gel 
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(10%) electrophoresis. The samples were subsequently transferred electrophoretically 
to PVDF membranes. The membranes were incubated for 1 h at room temperature with 
5% (w/v) nonfat dry milk in Tris- buffered saline and then overnight at 4°C with the 
primary antibody. The following primary antibodies were used: Phospho- Akt (Ser473) 
polyclonal antibody (1:1000 dilution), Total- Akt polyclonal antibody (1:1000), Phospho-
AMPKα1/2 polyclonal antibody (1:1000), Total-AMPkα1/2. Immunoblotting of total and 
phosphorylated forms of the specific protein were performed on separate PVDF 
membranes. The primary antibody was detected with either the HRP-conjugated anti- 
rabbit secondary antibody (1 :2000) or the HRP- conjugated anti-mouse secondary 
antibody (1 :2000), and LumiGLOW reagent (New England Biolabs) using Alpha Innotech 
FluorChem (quantitative imaging system for fluorescent and chemiluminescent blots; 
Johannesburg, S.A). 
2.4.11 Measurement of GLUT1myc and GLUT4myc Translocation  
The amount of myc-tagged GLUT1 and GLUT4 at the surface of intact cells was 
measured by an antibody-coupled colorimetric assay as previously described (245). 
Following the treatment period, the monolayer of myotubes was fixed with 3% 
paraformaldehyde for 10 minutes at 4oC, incubated with 1% glycine for 10 minutes to 
reduce the remaining paraformaldehyde, blocked with 5% goat serum in PBS, and then 
exposed to anti-myc antibody (1:500) for 60 minutes, and followed by incubation with 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:1000) for 45 minutes, 
all at 4oC. Cells were washed extensively, and 1 ml of OPD reagent was added for 30 
minutes at room temperate. The reaction was stopped by 0.25 ml of 3 N HCL. The 
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supernatant was collected, transferred to a 96-well ELISA plate and the absorbance was 
measured at 492 nm. Nonspecific IgG binding, as measured by a HRP-conjugated goat 
anti-rabbit IgG was subtracted from experimental values. Values were expressed as 
percentage of control.  
2.4.12 Statistical Analysis 
 Statistical analysis was performed using the SAS software 9.3. All data from several 
experiments were pooled and then presented as mean ±SE. The means of the groups 
(treatments compared to control group) were compared with one-way analysis of 
variance (ANOVA) followed by Tukey’s post hoc test for multiple comparison
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Chapter 3: Results 
3.1 Effects of rosemary extract (RE) on glucose uptake in L6 skeletal 
muscle cells.  
We investigated whether rosemary extract (RE) stimulates glucose uptake in L6 skeletal 
muscle cells. For this purpose L6 myotubes were treated with 0.1, 1.0, 5.0, 10, 20, 30, 
40, and 50 µg/ml of RE for 4 hours followed by glucose uptake measurements. An 
incubation time of 4 hours was initially chosen based on another study that has 
investigated the effects of methanol extract of rosemary in HepG2 cells (226). RE at 0.1 
and 1.0 µM did not have a significant effect on glucose uptake (119± 4.73% and 
129%±6.54% of control, p>0.05 respectively). However, RE at 5 µg/ml and 10 µg/ml 
significantly increased glucose uptake (184±5.05% and 178±7.84% of control, p<0.001 
respectively) (Figure 6). Concentrations at 20 µg/ml resulted in significant increase in 
glucose uptake (145±5.05% of control, p<0.01) while concentrations higher than 20 
µg/ml did not have significant effects (data not shown; 30 μg/ml: 134±6.69%, 40 μg/ml: 
124±14.81%, 50 μg/ml: 95±12.89% of control, p>0.05). Microscopic examination of cell 
morphology did not reveal any changes with any concentrations used, indicating no 
changes in cell viability. Although no microscopic evidence of toxicity were observed at 
RE concentrations of 30-50 µg/ml, the lack of stimulation of glucose uptake may indicate 
an excessive pharmacological dose with possible associated cytotoxic effects and 
therefore such high doses are not recommended to be used in future studies.  
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Figure 6: Effects of rosemary extract (RE) on glucose uptake in L6 myotubes: Dose-
response. Serum deprived L6 myotubes were incubated with the indicated 
concentrations of RE for 4 hours. 2-deoxy-D-glucose uptake was measured according to 
the methods. Data are expressed as percentage of control. Results are the mean ± SE of 
six to eight independent experiments. ** P<0.01, ***P<0.001, vs. control. 
Next, in order to examine whether the effect of RE in increasing glucose uptake in 
myotubes is time-dependent, the cells were incubated with 5 µg/ml of RE for 0.5, 1, 2, 4, 
6 & 16 hours followed by glucose uptake measurements (Figure 7). Incubation of 
myotubes with RE for 0.5 & 1 hour did not result in a significant increase in glucose 
uptake (115±4.10%, 123±5.21%, p>0.05). However, RE at 2, 4, 6 and 16 hours increased 
glucose uptake time-dependently (154±5.93%, 184±5.07%, 197±7.28% and 157±8.66% 
of control, p<0.001 respectively). Maximum stimulation was seen with 6 hours 
(197±7.28% of control, p<0.001 respectively). Importantly, longer incubation time with 
RE (16 hours) resulted in a significant increase in glucose uptake. 
Rosemary (Rosmarinus officinalis L.) Extract 
 
90 
 
 
Figure 7: Effects of rosemary extract (RE) on glucose uptake in L6 myotubes: Time-
course. Serum deprived L6 myotubes were incubated with 5 µg/ml of RE for the 
indicated times. 2-deoxy-D-glucose uptake was measured according to the methods. 
Data are expressed as percentage of control (0 hrs). Results are the mean ± SE of eight 
to ten independent experiments. *** P<0.001 vs. control.  
We next examined whether this effect of RE is similar to insulin. Insulin (100 nM, 30 
minutes) significantly stimulated glucose uptake in myotubes (207±5.26% of control, 
p<0.001) (Figure 8). Similarly, RE at 5 µg/ml for four hours caused a significant increase 
in glucose uptake (184±5.07% of control, p<0.001) which was comparable to insulin 
(Figure 8). Furthermore, this effect of RE is comparable to metformin (2 mM for 16 
hours), an oral anti-diabetic drug (216±8.77%, P<0.001). These results indicate that RE 
significantly stimulates glucose uptake in a dose- and time-dependent manner that is 
independent of insulin. Importantly the increase in glucose uptake by RE is to the same 
level as the increase seen with maximum insulin and metformin stimulation.  
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Figure 8: Stimulation of skeletal muscle glucose uptake by insulin, metformin, and 
rosemary extract (RE). L6 myotubes were incubated with 100 nM insulin (30 minutes), 2 
mM metformin (16 hours) or 5 µg/ml of RE (4 hours). 2-deoxy-D-glucose uptake was 
measured according to the methods. Data are expressed as percentage of control. 
Results are the mean ± SE of four to eight independent experiments. ***P<0.001 vs. 
control. 
3.2 Effects of rosemary extract (RE) on insulin-stimulated glucose uptake 
in L6 skeletal muscle cells.  
Next, we examined the effect of rosemary extract (RE) on insulin-stimulated glucose 
uptake. Myotubes were treated with or without 5 µg/ml RE (4 hours) and different 
concentrations of insulin (1 nM, 3 nM, 10 nM, 100 nM) were added in for the last 30 
minutes followed by glucose uptake measurements.  
Insulin increased glucose uptake in a dose-dependent manner (157±9.30%, 
161±7.92%, 188±11.45%, 203± 9.5% of control, p<0.001) (Figure 9). Pre-treatment with 
RE did not affect the insulin response in any of the concentrations used (181±5.84%, 
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185±5.01%, 194±6.35% and 199±7.55% of control, p>0.05) (Figure 9). There was a 
tendency of RE to increase glucose uptake at insulin concentrations of 1 nM and 3 nM 
but it did not reach significance. The results indicate that RE does not have additive or 
synergistic effects on insulin-stimulated glucose uptake. 
 
Figure 9: Effect of rosemary extract (RE) on insulin-stimulated glucose uptake. Serum 
deprived L6 myotubes were incubated with 5 µg/ml RE for 4 hours and then exposed to 
different insulin concentrations for the last 30 minutes followed by glucose uptake 
measurements. Data are expressed as percentage of control. Results are the mean ± SE 
of three to five independent experiments. 
3.3 Effects of the PI3K inhibitor wortmannin  on rosemary extract (RE)-
induced glucose uptake. 
PI3K has been established as a key molecule involved in the insulin signalling cascade 
that leads to glucose uptake in skeletal muscle and its activity is required in this action. 
Therefore we investigated whether PI3K may be a mediator of RE-stimulated glucose 
uptake by using the PI3K inhibitor, wortmannin. Myotubes were pre-treated with 100 
nM of wortmannin for 15 minutes followed by treatment with or without 5 µg/ml RE for 
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4 hours or 100 nM insulin for 30 minutes. After treatments, glucose uptake 
measurements were performed.  
Insulin significantly increased glucose uptake (210±9.47% of control, p<0.001), and 
this effect was significantly reduced by wortmannin pre-treatment (140±6.08% of 
control, p<0.001) (Figure 10). RE significantly increased glucose uptake (208±13.62% of 
control, p<0.001) but this was not affected by wortmannin pretreatment (201±9.32% of 
control, p>0.05) (Figure 10). These results suggest that PI3K is not involved in the 
regulation of glucose uptake by RE.  
 
Figure 10: Effect of wortmannin on insulin- and rosemary extract (RE)-induced glucose 
uptake. Cells were pre-incubated in the absence or presence of 100 nM wortmannin for 
15 minutes followed by treatment with or without 5 µg/ml of RE for 4 hours or 100nM 
of insulin for 30 minutes. 2-deoxy-D-glucose uptake was measured according to the 
methods. Data are expressed as percentage of control. Results are the mean ± SE of six 
to seven independent experiments. ***P<0.001 vs. control. ###P<0.001 vs. treatments 
alone (without inhibitors).   
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3.4 Effect of rosemary extract (RE) on Akt phosphorylation 
Although the use of wortmannin, the PI3K inhibitor, indicated that the PI3K-Akt cascade 
may not be activated by RE, we wished to confirm these findings and therefore we next 
examined the effects of RE on Akt, the molecule downstream of PI3K. Phosphorylation 
of Akt on Ser473 residue leads to its activation and ser473 phosphorylation has been 
established as an indicator of Akt activity (246). Therefore, the effect of RE was 
examined using phospho-specific antibodies against Akt (Ser473) in western blot 
analysis. As shown previously in our lab (88,247) and others, insulin treatment (100 nM 
for 15 minutes) strongly stimulates phosphorylation of Ser473 residue of Akt 
(260±11.5%, p<0.05) (Figure 11). RE at 5 µg/ml and 10 µg/ml (4 hours) did not affect Akt 
phosphorylation (Figure 11). The action of insulin on Akt phosphorylation is an acute 
event. It is possible that RE may activate Akt and we missed such activation by looking at 
4 hour time point (Figure 11). To ensure that we did not miss potential earlier 
phosphorylation of Akt by RE, cells were exposed to 5 µg/ml of RE for 0.25, 0.5, 1, 2, and 
4 hours and Akt phosphorylation was examined. RE did not lead to phosphorylation of 
Akt at any of the time points (Figure 12). Insulin consistently phosphorylated Akt. 
Metformin, resveratrol and AICAR were also used and none of them, as it is previously 
established, induced Akt phosphorylation (Figure 12). Total Akt levels were not changed 
by any treatment (Figure 11 & 12). These results indicate that the effect of RE on 
glucose uptake is Akt-independent. 
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Figure 11: Effect of rosemary extract (RE) on Akt phosphorylation. L6 myotubes were 
serum-deprived for 2 hours followed by treatment with 100 nM insulin for 15 minutes, 5 
µg/ml or 10 µg/ml of RE for 4 hours. Whole cell lysates were prepared and 
immunoblotted for Akt and Phospho-Akt (Ser473). 
   
 
 
Figure 12: Effect of rosemary extract (RE) on Akt phosphorylation: Time-Course.  L6 
myotubes were serum-deprived for 2 hours followed by treatment with 100 nM insulin 
(15 minutes), 2 mM metformin (MET) (120 minutes), 2mM AICAR (120 minutes), 100 µM 
resveratrol (RSV) (120 minutes), or 5 µg/ml of RE for the indicated times Whole cell 
lysates were prepared, resolved by SDS-PAGE and immunoblotted for specific antibodies 
that recognize Akt or Phospho-Akt (Ser473). (A) Representative immunoblots. (B) 
Immunoblots were scanned to quantitate the density of the bands. Values are arbitrary 
densitometric units compared to control. Results are the mean± SE of 3-4 experiments. 
*p<0.05 compared to control (B). 
 
B 
A 
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3.5  Effects of  the AMPK inhibitor compound C (CC) on rosemary extract 
(RE)-induced glucose uptake. 
As previously discussed (section 1.6), activation of AMPK in skeletal muscle has been 
shown to be another mechanism stimulating glucose uptake. This mechanism is 
employed by exercise/contraction, and various compounds including metformin, AICAR, 
and the polyphenol resveratrol. Therefore AMPK may be a mediator of RE-stimulated 
glucose uptake. We investigated the possible involvement of AMPK by using the AMPK 
inhibitor compound C. Myotubes were pre-treated with 25 µM compound C for 30 
minutes followed by treatment with or without 5 µg/ml RE, or 2 mM metformin (2 
hours). After treatments glucose uptake measurements were performed. 
 
 
Figure 13: Effect of compound C (CC) on metformin and RE-induced glucose uptake. 
Cells were incubated in the absence or presence of 25 µM compound C (CC) for 30 
minutes followed by the addition of 2 mM metformin (MET) for 2 hours or 5 µg/ml of RE for 4 
hours. 2-deoxy-D-glucose uptake was measured according to the methods. Data are expressed 
as percentage of control. Results are the mean ± SE of six to seven independent experiments. 
***P<0.001 vs. control. #P<0.05, ###P<0.001 vs. treatments alone (without inhibitors). 
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independent experiments. ***P<0.001 vs. control. #P<0.05, ###P<0.001 vs. treatments 
alone (without inhibitors). 
Metformin treatment increased glucose uptake (216±8.77% of control, p<0.001) 
which was inhibited by pre-treatment with compound C (106.2±5.59% of control, 
p>0.05) (Figure 13). RE significantly increased glucose uptake (208±8.11% of control, 
p<0.001) and this effect was significantly reduced by pre-treatment with compound C 
(142±2.40% of control, p<0.05 respectively). These results indicate that AMPK is 
involved in the regulation of glucose uptake by RE. 
3.6 Effects of rosemary extract (RE) on AMPK 
Next, we examined whether RE phosphorylates and activates AMPK. Myotubes were 
treated with 2 mM metformin (2 hours), 2 mM AICAR (2 hours), 100 µM resveratrol (2 
hours), 100 nM insulin (15 minutes) or 5 µg/ml and 10 µg/ml RE for 4 hours. Western 
blot analysis revealed that RE significantly increased AMPK phosphorylation to levels 
similar to those seen with AICAR (Figure 14).  We also examined whether the activation 
of AMPK by RE is time-dependent. Myotubes were treated with 5 μg/ml of RE for 15 
minutes, 30 minutes, 1 hour, 2 hours, and 4 hours. A significant increase in AMPK 
phosphorylation was observed at 2 hours (157.3±11.3%, p<0.05) of RE treatment and 
remained elevated at 4 hours (190.3±17.6%, p<0.05) (Figure 15). Metformin, AICAR and 
resveratrol significantly increased AMPK phosphorylation (196±27.5%, 238±28.4% and 
212±29.3%), while insulin treatment did not have any effects (67±11.2%, p>0.05) (Figure 
15). Total AMPK levels were not changed by any treatment (Figure 14 & 15). Together, 
these results (Figure 12-14) suggest that RE stimulates glucose uptake through AMPK 
activation. 
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Figure 14: Effect of rosemary extract on AMPK phosphorylation. L6 myotubes were 
serum-deprived for 2 hours followed by treatment with 2 mM AICAR for 2 hours, 5 
µg/ml or 10 µg/ml of RE for 4 hours. Whole cell lysates were prepared, resolved by SDS-
PAGE and immunoblotted for phospho-AMPK (Thr172) and total AMPK.  
 
 
 
Figure 15: Effect of rosemary extract (RE) on AMPK phosphorylation: Time-Course. L6 
myotubes were serum-deprived for 2 hours followed by treatment with 2 mM 
metformin (MET) (120 min.), 2 mM AICAR (120 min.), 100 µM resveratrol (RSV) (120 
min.), or 5 µg/ml of RE for the indicated times. Whole cell lysates were prepared, 
resolved by SDS-PAGE and immunoblotted for total and phospho-AMPK (Thr172). (A) 
Representative immunoblots. (B) Immunoblots were scanned to quantitate the density 
of the bands. Values are arbitrary densitometric units compared to control.  Data are 
the mean ± SE of 3-4 experiments. *p<0.05. 
 
A 
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3.7  High performance liquid chromatography (HPLC) analysis of rosemary 
extract (RE) 
Previous studies have shown that the major polyphenols in rosemary extract are 
carnosic acid (CA), and rosmarinic acid (RA) (177,182). Therefore, we wished to 
investigate whether the rosemary extract (RE) prepared in our lab and used in the 
experiments up to now (Figure 6-15) contained CA and RA and determine its relative 
quantity in the extract.  To this end, high performance liquid chromatography analysis 
(HPLC) was performed. RE, and standards of CA and RA were prepared at a 
concentration of 2 mg/ml to be used in HPLC. The standards of CA and RA were run in 
HPLC machine followed by RE. The retention time of the peak corresponding to CA from 
the standard (CA) was used to determine the presence of CA in the extract (Figure 16). 
The area under the peak corresponding to CA in the extract was used to quantify the 
relative amount of CA found in the extract (Figure 16). Similar analytical methods were 
used for RA (Figure 16).   
HPLC analysis revealed that the RE contained 2.12±0.22% CA and 13.39±0.23% of RA 
(Table 6). These concentrations of CA and RA are well within the range of previously 
reported concentrations and are in agreement with previous studies (178,179,184-
186,206). Based on these values and the molecular weight of CA and RA (CA MW: 
332.42 g/mol, RA MW: 360.31 g/mol) 5 µg/ml of RE (maximum stimulation of glucose 
uptake) corresponds to 0.3 µM CA and 2.0 µM RA (Table 6). Therefore, we wished to 
examine whether 0.3 µM CA and 2.0 µM RA would have an effect on glucose uptake. 
However, because the major polyphenolic content of rosemary extract varies depending 
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on soil, climate, geographical location, extraction method and storage  (refer to section 
1.10), in order to account for this variability and based on previous reports, we decided 
to use additional CA (0.1 μM, 2.0 μM) and RA (5.0 μM) concentrations and examine their 
effect on glucose uptake.   
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Figure 16: High performance liquid chromatography (HPLC) analysis of rosemary 
extract (RE). HPLC of RE and standards (carnosic acid & rosmarinic acid) were performed 
and the quantification of carnosic acid (CA) and rosmarinic acid (RA) in RE was 
determined by the retention times. A) Chromatograph of RE. B) Chromatograph of CA. 
C) Chromatograph of RA.
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Table 6: Relative concentrations of carnosic acid (CA) and rosmarinic acid (RA) 
identified in rosemary extract (RE) 
*In 5 µg/ml of RE which elicited maximum increase in glucose uptake in myotubes, the corresponding 
concentrations of CA and RA were measured/calculated.
3.8  Effects of rosemary extract (RE)’s major polyphenolic compounds 
carnosic acid (CA) and rosmarinic acid (RA) on glucose uptake.  
The effects of carnosic acid (CA) and rosmarinic acid (RA) were evaluated on glucose 
uptake in myotubes. Myotubes were incubated with indicated concentrations of CA and 
RA for 4 hours (Figure 17). CA at 0.1 µM did not significantly increase glucose uptake 
(128±4.33% of control, p>0.05 respectively). However, CA at 0.3 and 2.0 µM significantly 
increased glucose uptake (147± 7.72%, and 226±9.62% of control, p<0.01 and p<0.001 
respectively) (Figure 17). RA at 2.0 µM did not significantly increase glucose uptake 
(121±5.04% of control, p>0.05 respectively), while RA at 5.0 µM also increased glucose 
uptake (180±8.00% of control, p<0.001). The degree of glucose uptake in myotubes 
elicited by RE treatment (184±5.07% of control) was greater than CA (0.3 µM) or RA (2.0 
µM) alone indicating that the two compounds (CA, RA) may act synergistically. This 
could be tested by examining the combined effects of CA and RA at concentrations 
found in RE on glucose uptake and determine whether the level of glucose uptake seen 
with RE is comparable to that of combined CA and RA.  
Compound MW 
(g/mol) 
Retention 
Time (min) 
Relative Mean 
Quantity in RE 
(%) 
Concentration 
(µg/mg RE) 
Concentration in 
5 µg/ml of RE 
(µM)* 
Carnosic acid 
(CA) 
332.42 24.197  2.12±0.22 21.2±2.2 0.3±0.031 
Rosmarinic 
acid (RA) 
360.13 11.859 13.39±0.23 133.9±2.3 2.0±0.034 
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Figure 17: Effects of carnosic acid (CA) and rosmarinic acid (RA) on glucose uptake. 
Serum deprived L6 myotubes were incubated with 5 µg/ml RE, carnosic acid (CA) or 
rosmarinic acid (RA) at the indicated concentrations for 4 hours. 2-deoxy-D-glucose 
uptake was measured according to the methods. Data are expressed as percentage of 
control. Results are the mean ± SE of three to four independent experiments. *P<0.05, 
***P<0.001 vs. control. 
3.9  Effects of carnosic acid (CA) and rosmarinic acid (RA) on insulin-
stimulated glucose uptake.  
Next we investigated whether CA and RA affects insulin-stimulated glucose uptake. 
Myotubes were treated with or without 2.0 µM CA and 5.0 µM RA (4 hours) followed by 
treatment with the indicated concentrations of insulin for the last 30 minutes (Figure 
18). Glucose uptake measurements were performed following treatments.  
 Insulin dose-dependently increased glucose uptake (157±9.29%, 161±7.92%, 
188±11.45%, 203±9.5% of control, p<0.001) (Figure 18). RA significantly increased 
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insulin-stimulated glucose uptake at 3 nM insulin concentration (214±11.68% of control, 
p<0.01). RA did not increase insulin-stimulated glucose uptake at insulin concentrations 
of 1 nM, 10 nM, and 100 nM (179±2.33%, 210±12.86% and 203±10.17% of control, 
p>0.05). CA significantly increased insulin-stimulated glucose uptake at submaximal 
insulin concentrations (1 nM, 3 nM, 10 nM) (249±24.31%, 252±26.83%, 286±23.79% of 
control, p<0.001, p<0.05, p<0.05) (Figure 18) without a significant effect on the maximal 
insulin (100 nM) response (272±29.57% of control, p>0.05). These results indicate a 
potential of CA and RA to affect insulin-stimulated glucose uptake. 
 
Figure 18: Effect of carnosic acid (CA) and rosmarinic acid (RA) on insulin-stimulated 
glucose uptake.  Serum deprived L6 myotubes were incubated with 2.0 µM CA or 5.0 
µM RA for 4 hours and then exposed to different insulin concentrations for the last 30 
minutes followed by glucose uptake measurements. Data are expressed as percentage 
of control. Results are the mean ± SE of three to five independent experiments. *P<0.05, 
** P<0.01, ***P<0.001 vs. insulin treatments alone.   
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3.10 Effects of wortmannin, the PI3K inhibitor, on carnosic acid (CA)- and 
rosmarinic acid (RA)-induced glucose uptake. 
We investigated whether PI3K may be a mediator of CA-, and RA-stimulated glucose 
uptake by using the PI3K inhibitor, wortmannin. Myotubes were pre-treated with 100 
nM of wortmannin for 15 minutes followed by treatment with or without 2.0 µM CA and 
5.0 µM RA (4 hours) or 100 nM insulin (30 minutes). After treatments, glucose uptake 
measurements were performed.  
 
Figure 19: Effect of wortmannin on carnosic acid (CA) and rosmarinic acid (RA)-induced 
glucose transport. Cells were incubated in the absence or presence of 100 nM 
wortmannin (WORT) for 15 minutes followed by the addition of 100nM insulin for 30 
minutes, 2.0 µM CA, or 5.0 µM RA for 4 hours. 2-deoxy-D-glucose uptake was measured 
according to the methods. Data are expressed as percentage of control. Results are the 
mean ± SE of six to seven independent experiments. ***P<0.001 vs. control.  ###P<0.001 
vs. treatments alone (without inhibitors). 
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In agreement with our data presented in figure 10, insulin significantly increased 
glucose uptake (210±9.47% of control, p<0.001), and this effect was significantly 
reduced by wortmannin pre-treatment (140±6.08% of control, p<0.001) (Figure 19). 
Similar to figure 10, RE significantly increased glucose uptake (208±13.62% of control, 
p<0.001) but this was not affected by wortmannin pretreatment (201±9.32% of control, 
p>0.05) (Figure 19). Furthermore, both CA (180±8.00% of control, p<0.001) and RA 
significantly increased glucose uptake (180±8.00% of control, p<0.001) and this effect 
was not altered by wortmannin (210±3.27%, 196±9.99% of control, p>0.05). These 
results suggest that PI3K is not involved in CA- and RA-induced glucose uptake.  
3.11 Effects of carnosic acid (CA) and rosmarinic acid (RA) on Akt 
phosphorylation. 
Next, we also examined the effects of CA and RA on Akt. As shown in figure 11 and 12, 
insulin treatment (100 nM for 15 minutes) strongly stimulated phosphorylation of 
Ser473 residue of Akt (260±11.5%, p<0.05) (Figure 20). However, CA and RA did not 
have effects on Akt phosphorylation (Figure 20). Metformin, AICAR, resveratrol and RE 
did not affect Akt phosphorylation (Figure 20). Total Akt levels were not changed by any 
treatment (Figure 20). These results indicate that the effect of CA and RA on glucose 
uptake is Akt-independent. 
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Figure 20: Effect of carnosic acid (CA) and rosmarinic acid (RA) on Akt phosphorylation. 
L6 myotubes were serum-deprived for 2 hours followed by treatement with 100 nM 
insulin (15 minutes), 2 mM metformin (MET) (120 minutes), 2mM AICAR (120 minutes), 
100 µM resveratrol (RSV) (120 minutes), 5 µg/ml of RE (2 hours), 2.0 µM CA (2 hours) or 
5.0 µM RA (2 hours). Whole cell lysates were prepared, resolved by SDS-PAGE and 
immunoblotted for specific antibodies that recognize total and phospho-Akt (Ser473) 
(A). Representative immunoblots. (B) Immunoblots were scanned to quantitate the 
density of the bands. Values are arbitrary densitometric units compared to control. Data 
are the mean ± SE of 3-4 experiments. *p<0.05 compared to untreated control.   
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3.12 Effects of compound C (CC), the AMPK inhibitor, on carnosic acid (CA) 
and rosmarinic acid (RA)-induced glucose uptake. 
Metformin significantly increased glucose uptake (216±8.77% of control, p<0.001) and 
this effect was significantly reduced by pre-treatment with compound C (106±5.59% of 
control, p>0.05) (Figure 21) in agreement with our data in figure 13. CA significantly 
increased glucose uptake (226±9.62%, p<0.001) which was significantly inhibited by pre-
treatment with compound C (160±10.0% of control, p<0.05, p<0.01 respectively). 
However, RA-stimulated increase in glucose uptake (180±8.0% of control, p<0.001) was 
not altered by compound C (158±3.32% of control, p>0.05). These results indicate that 
AMPK is involved in the regulation of glucose uptake by CA but not RA.  
 
Figure 21: Effect of compound C (CC) on carnosic acid (CA) and rosmarinic acid (RA)-
induced glucose transport. Cells were incubated in the absence or presence of 25 µM 
compound C (CC) for 30 minutes followed by the addition of 2mM metformin (2 hours), 
2.0 µM CA, and 5.0 µM RA for 4 hours. 2-deoxy-D-glucose uptake was measured over a 
10-minute period, using liquid scintillation counter. Readings are expressed as 
percentage increase of control. Results are the mean ± SE of six to seven independent 
experiments. ***P<0.001 vs. control.  ###P<0.001 vs. treatments alone (without 
inhibitors). 
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3.13 Effects of carnosic acid (CA) and rosmarinic acid (RA) on AMPK 
phosphorylation 
The effect of CA and RA on AMPK phosphorylation was examined. Metformin, AICAR 
and resveratrol significantly increased AMPK phosphorylation (196±27.5%, 238±28.4% 
and 212±29.3% of control, p<0.05) while insulin treatment did not have any effects 
(67±11.2% of control, p>0.05). RE treatment significantly increased AMPK 
phosphorylation (Figure 22). CA and RA treatment for 2 hours increased AMPK 
phosphorylation (164.0±12.7%, and 166.3±27.6% of control, p<0.05). 
 
 
 
 
Figure 22: Effect of carnosic acid (CA) and rosmarinic acid (RA) on AMPK 
phosphorylation. L6 myotubes were treated with 2 mM metformin (MET) (120 
minutes), 2 mM AICAR (2 hours), 100 µM resveratrol (RSV) (120 minutes), 5 µg/ml of RE, 
2.0 µM CA and 5.0 µM RA (2 hours). (A) Representative immunoblots. (B).Densitometry. 
Results are the mean± SE of 3-4 independent experiments *p<0.05 versus control. 
B 
A 
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Immunoblots were scanned to quantitate the density of .mmmmmmmmmmmmmm 
Values are arbitrary densitometric units compare 
3.14 Effects of RE and its polyphenolic constituents CA, and RA on GLUT4 
translocation  
Insulin-stimulated glucose transport requires GLUT4 translocation. To elucidate the 
mechanism by which RE and its polyphenolic constiuents CA and RA altered glucose 
uptake, we measured surface GLUT1 and GLUT4 levels under the various treatments. L6 
GLUT1myc and GLUT4myc cells stably express GLUT1 or GLUT4 tagged with an exofacial 
c-myc epitope. GLUT1myc and GLUT4myc segregate, cycle and respond to insulin in a 
manner similar to endogenous GLUT4 (71). The amount of GLUT1myc and GLUT4myc 
incorporated into the plasma membrane was quantitated by immunologically labelling 
the myc epitope at the surface of intact cells.  
 Acute maximal insulin treatment stimulated GLUT4 translocation to 217±11.26% of 
untreated control cells (p<0.001) (Figure 23). Additionally, metformin (1 mM, 6 hours) 
treatment caused a significant increase in GLUT4myc number on the plasma membrane 
(175±7.18%, p<0.001). However, unlike insulin and metformin, RE treatment did not 
cause a significant increase in recruitment of GLUT4myc to the plasma membrane 
(106±3.71% of control, p>0.05) (Figure 23). These results suggest that RE-stimulated 
glucose uptake is not due to GLUT4 translocation. Although RE did not significantly 
affect GLUT4 recruitment to the plasma membrane, we wished to examine the effects 
of RE’s major polyphenols, CA and RA on these parameters. Neither CA nor RA caused a 
significant increase in GLUT4 (113±3.53%, 115±2.86% of control, p>0.05) (Figure 23) 
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recruitment to the plasma membrane. These results indicate that RE-, CA- and RA-
stimulated glucose uptake is not due to GLUT4 translocation.  
 
Figure 23: Effect of RE, CA, or RA on plasma membrane GLUT4 levels in GLUT4myc 
overexpressing myotubes. L6 GLUT4myc cells were treated with insulin (100 nM, 20 
minutes), metformin (1 mM, 6 hours), RE (5μg/ml, 4 hours), CA (2.0 μM, 4 hours) or RA 
(5.0 μM, 4 hours) followed by GLUT4 transporter translocation measurements. Results 
are mean±SE of 6-8 independent experiments performed in triplicate and expressed as 
percentage of control. ***p<0.001 vs control. 
3.15 Effects of RE and its polyphenolic constituents CA and RA on GLUT1 
translocation 
Skeletal muscle cells also express the basal glucose transporter isoform, GLUT1. Since RE 
and its polyphenolic constituents CA and RA did not affect the translocation of the 
insulin-sensitive glucose transporter, GLUT4, we wished to examine the effects of these 
treatments on GLUT1 translocation.  
 Acute maximal insulin (10-7 M, 20 minutes) stimulation alone significantly increased 
the amount of GLUT1myc epitope at the surface of intact cells to 139±1.44% of 
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untreated control cells (p<0.001) (Figure 24). Metformin (1 mM, 6 hours) treatment also 
caused a significant increase in GLUT1 recruitment to the plasma membrane (134±7.8% 
of control, p<0.001). However, unlike that of insulin, RE (5 μg/ml, 4 hours) did not cause 
a significant increase in recruitment of GLUT1myc to the plasma membrane (113±5.52% 
of control, p>0.05) (Figure 24). Furthermore, neither CA nor RA caused a significant 
increase in GLUT1 (114±4.14%, 116±2.51% of control, p>0.05) (Figure 24) recruitment to 
the plasma membrane. These results indicate that RE-, CA- and RA-stimulated glucose 
uptake is not due to GLUT1 translocation.  
 
Figure 24: Effect of RE, CA and RA on plasma membrane GLUT1 in GLUT1myc 
overexpressing myotubes. L6 GLUT1myc cells were treated with insulin (100 nM, 20 
minutes), metformin (1 mM, 6 hours), RE (5μg/ml, 4 hours), CA (2.0 μM, 4 hours) or RA 
(5.0 μM, 4 hours) followed by GLUT1 transporter translocation measurements. Results 
are mean±SE of 6-8 independent experiments, ***p<0.001 vs. control. 
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3.16 Effect of RE and its polyphenolic constituents CA and RA on glucose 
uptake in GLUT4myc overexpressing cells. 
Since RE-, CA- and RA-stimulated glucose transport was observed in parental L6 cells and 
GLUT4 translocation was examined in GLUT4myc overexpressing cells, it was critical to 
examine whether RE, CA and RA also stimulated glucose uptake in a similar fashion in 
the GLUT4myc tagged cell line. We measured insulin-, metformin-, RE-, CA- and RA-
stimulated glucose transport in overexpressing GLUT4myc tagged cells.  
 
Figure 25: Effects of rosemary extract (RE), carnosic acid (CA), and rosmarinic acid (RA) 
on glucose uptake in L6 GLUT4myc tagged myotubes. GLUT4myc overexpressing 
myotubes were incubated with insulin (100 nM, 30 minutes), metformin (2 mM, 2 
hours), RE (5 μg/ml, 4 hours), CA (2.0 μM, 4 hours) or RA (5.0 μM, 4 hours) 2-deoxy-D-
glucose uptake was measured according to the methods. Results are the mean ±SE of 3-
4 independent experiments. ***p<0.001 versus control. 
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As previously seen in the parental L6 cell line, insulin (10-7M, 30 min) induced a 2- 
fold increase in glucose transport (233 ± 11.7% of control, p<0.001) in GLUT4myc 
overexpressing L6 cells (Figure 25). Additionally, metformin significantly increased 
glucose transport (189±7.36% of control, p<0.001). Treatment with RE (5 μg/ml, 4 
hours) did result in a significant increase in glucose uptake (172±7.19% of control, 
p<0.001) (Figure 25). Additionally, both CA and RA significantly stimulated glucose 
transport in GLUT4myc (188±10.0%, 178±8.62% of control, p<0.001). Take together, 
these results (Figure 23 & 25) indicate that RE and its polyphenolic constituents CA and 
RA significantly stimulate glucose uptake in L6 GLUT4myc cells by a mechanism that is 
independent of GLUT4 translocation.  
3.17 Effect of RE and its polyphenolic constituents CA and RA on glucose 
uptake in GLUT1myc overexpressing cells 
Similarly, since RE-, CA- and RA-stimulated glucose transport was observed in parental 
L6 cells and GLUT1 translocation was examined in GLUT1myc overexpressing cells, it was 
critical to examine whether RE, CA and RA also stimulated glucose uptake in a similar 
fashion in the GLUT1myc tagged cell line. We measured insulin-, metformin-, RE, CA, 
and RA-stimulated glucose transport in overexpressing GLUT1myc tagged cells.  
As previously seen in the parental L6 cell line, insulin (10-7M, 30 min) induced a 
nearly 2- fold increase in glucose transport (194± 14.2% of control, p<0.001) (Figure 26) 
in GLUT1myc overexpressing L6 cells which was comparable to the level seen in parental 
cells (207±5.26% of control, p<0.001) (Figure 8). Additionally, metformin significantly 
increased glucose transport (183±21.6% of control, p<0.001) (Figure 26). Treatment with 
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RE (5 μg/ml, 4 hours) did result in a significant increase in glucose uptake (167±8.82% of 
control, p<0.001) (Figure 26). Both CA (2.0 μM, 4 hours) and RA (5.0 μM, 4 hours) 
significantly stimulated glucose transport in GLUT1myc cells (201±9.87%, 154±6.35% of 
control, p<0.001). Take together, these results (Figure 24 & 26) indicate that RE and its 
polyphenolic constituents CA and RA significantly stimulate glucose uptake in L6 
GLUT1myc cells by a mechanism that is independent of GLUT1 translocation. 
 
Figure 26: Effects of rosemary extract (RE), carnosic acid (CA) and rosmarinic acid (RA) 
on glucose uptake in L6 GLUT1myc tagged myotubes GLUT1myc overexpressing 
myotubes were incubated with insulin (100 nM, 30 minutes), metformin (2 mM, 2 
hours), RE (5 μg/ml, 4 hours), CA (2.0 μM, 4 hours) or RA (5.0 μM, 4 hours) 2-deoxy-D-
glucose uptake was measured according to the methods. Results are the mean ±SE of 3-
4 independent experiments. ***p<0.001 versus control.  
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Chapter 4: Discussion 
4.1 Rosemary extract significantly increases skeletal muscle glucose 
uptake. 
Skeletal muscle is responsible for 75-80% of total body glucose uptake and disposal in 
the postprandial state; therefore, from a quantitative standpoint, it represents a major 
tissue in glucose homeostasis (13,15,28). Glucose enters skeletal muscle by facilitated 
transport mediated by the family of plasma membrane proteins, glucose transporters 
(GLUTs). These GLUTs recycle between intracellular compartments and the plasma 
membrane (2). Insulin acts on skeletal muscle and increases glucose uptake in this tissue 
by increasing plasma membrane availability of the specific GLUT isoform, GLUT4. The 
PI3K-Akt pathway, which is utilized by insulin, is a well-established pathway involved in 
the regulation of skeletal muscle glucose transport. The failure of skeletal muscle to 
respond to insulin, termed skeletal muscle insulin resistance (IR), largely contributes to 
manifestation of chronically elevated plasma glucose levels (hyperglycemia), and type 2 
diabetes (T2DM). The underlying cellular mechanism of skeletal muscle IR is an 
attenuated PI3K-Akt signaling (15). Various anti-diabetogenic stimuli such as exercise, 
and the oral anti-diabetic drug, metformin increase skeletal muscle glucose uptake by 
utilizing an insulin-independent (PI3K-Akt independent) pathway. It is well-established 
that both exercise and metformin-induced increase in skeletal muscle glucose uptake is 
mediated by the AMPK pathway (86,248). This pathway is known to regulate glucose 
and lipid metabolism and act as an energy sensor for the cell. Apart from these two 
factors, certain polyphenols have been demonstrated to increase skeletal muscle 
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glucose transport. Resveratrol, a polyphenol found in red wine, and naringenin, a 
polyphenol found in citrus fruits, have been shown to increase skeletal muscle glucose 
transport in vitro (88,247). There are also numerous in vivo studies that strongly support 
the anti-hyperglycemic effects of resveratrol (89,240). Given that skeletal muscle 
glucose transport is an indispensable process involved in whole body glucose 
homeostasis and the consequent repercussions (hyperglycemia, T2DM) involved in the 
failure of this tissue to increase postprandial glucose uptake (insulin resistance), 
compounds that target this process provide a therapeutic value in this sense. Compeling 
evidence showing that polyphenols such as resveratrol and narigenin that have been 
shown to exhibit anti-hyperglycemic benefits, supports the need to explore other food 
components or herbs that may possess similar properties. Rosemary (Rosmarinus 
officinalis), an herb that is used extensively in the Mediterranean diet, has been 
reported to have bioactive properties as a potent antioxidant (refer to section 1.10.3) 
and anti-hyperglycemic agent (refer to section 1.10.6). Therefore, we sought to directly 
examine the effects of rosemary extract (RE) in skeletal muscle cells as well as explore 
the mechanisms involved. 
 In the present study, we used the rat L6 skeletal muscle cell line, which is a well-
established model of skeletal muscle extensively used in studies of insulin signaling and 
glucose transport. 
 Our findings are the first to show that RE stimulates glucose uptake in L6 skeletal 
muscle cells and that this effect occurs in a dose- and time-dependent manner. This 
effect did not require the presence of insulin as the cells were incubated in media 
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without FBS and therefore without any insulin. Maximum stimulation was seen with 5 
µg/ml and 10 µg/ml RE with 4 hours of incubation time. Doses higher than 10 µg/ml (20 
µg/ml) did not result in any further increase. Microscopic examination of cells at 
concentrations ranging from 0.1 to 50 µM of RE tested did not show observable changes 
in cell morphology or viability indicating a low in vitro cytotoxicity profile of RE. 
Additionally, there were no reported changes in cell morphology in response to longer 
(6-16 hours) incubation times with 5 µg/ml RE. Although no microscopic evidence of 
toxicity were observed at RE concentrations of  30-50 µg/ml, the lack of stimulation of 
glucose uptake may indicate an excessive pharmacological dose with possible associated 
cytotoxic effects and therefore such high doses are not recommended to be used in 
future studies. Future studies could employ the lactate dehydrogenase (LDH) assay or 
the MTT assay to further substantiate the cytotoxicity characteristics of RE and its 
polyphenols carnosic acid and rosmarinic acid.  
RE increased glucose uptake in myotubes in a time-dependent manner. Within 2 
hours, RE (5 µg/ml concentration) significantly increased glucose uptake in myotubes 
which continued to increase at 4 and 6 hours. Longer incubation with RE (16 hours) did 
not result in any further increase in glucose uptake. Our observation that longer 
exposure (16 hours) of myotubes to RE resulted in attenuation of glucose uptake 
compared to a 4 hour time point may be explained by initiation of intracellular negative 
feedback mechanisms that tend to reduce glucose uptake.  
Interestingly, the increase in glucose uptake with RE was similar to that seen with 
maximum insulin stimulation. Additionally, the extent of RE-induced glucose uptake was 
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comparable to the oral anti-diabetic drug, metformin. This is the first study to report the 
novel finding that RE increases glucose uptake in myotubes to levels comparable to 
insulin and metformin. RE required a longer incubation time to increase glucose uptake 
to levels comparable to those reached by maximum insulin stimulation. It is possible 
that this time-dependent action of RE on glucose uptake is due to RE utilizing a different 
signaling cascade than that of insulin. Interestingly, the effects of RE are similar to 
metformin, a drug stimulates glucose uptake by activating an insulin-independent 
signaling cascade and has a kinetically prolonged onset of action in comparison to 
insulin.   
Upon finding that RE enhances basal glucose uptake, the effect of RE on insulin-
stimulated glucose uptake was assessed. Interestingly, RE did not lead to significant 
increases in insulin-stimulated glucose uptake suggesting that RE- and insulin-stimulated 
pathways may converge at some point.  
Previous in vivo studies have demonstrated that RE protects against hyperlipidemia 
and hyperglycemia in genetic, chemically-induced and dietary animal models of obesity 
and T2DM. Daily administration of RE significantly improved plasma glucose levels in 
streptozotocin (STZ)-induced diabetic rats (210,223,229); and in alloxan-induced 
diabetic rats (233) and rabbits (211). In genetically obese mice, carnosic acid, a 
polyphenolic component of RE protected against fat-induced fasting and non-fasting 
hyperglycemia and hyperlipidemia (189). Similarly, in a dietary rodent model of obesity, 
RE significantly protected against high-fat diet (HFD) induced elevations in plasma 
glucose and total cholesterol levels (190). Collectively, these studies (refer to Table 5) 
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demonstrate RE’s in vivo anti-hyperglycemic properties. However, there are currently no 
studies that delineate the mechanism underlying the reported in vivo effects of RE. Our 
in vitro study for the first time shows a direct effect of RE in skeletal muscle and suggest 
that the in vivo anti-hyperglycemic effects of RE may be due to its direct effect on 
skeletal muscle glucose uptake.  
 Rosemary contains various subsets of polyphenols including phenolic diterpenes, 
phenolic triterpenes and flavonoids (178,179,182,183). The major polyphenols found in 
rosemary are carnosic acid (CA), carnosol (COH) and rosmarinic acid (RA). It has been 
reported that CA and COH are found at 1.5-5.0% in rosemary (214,249); and RA is found 
at 0.3-30.0% (184,186). These chemical compounds have been demonstrated to exert 
antioxidant properties (refer to section 1.10.3). Since rosemary extract (RE) was shown 
in this study to increase skeletal muscle glucose uptake, we wished to determine 
whether this effect of RE was attributable to the effects of its major polyphenols on 
skeletal muscle glucose uptake. Therefore, we sought to determine the relative 
concentration of CA and RA in the rosemary extract (RE) used in the present study. High 
performance liquid chromatography analysis of RE indicated that it contained 
approximately 2.12±0.22% of CA and 13.39±0.23% of RA. These concentrations of CA 
and RA are well within the range of previously reported concentrations from other 
studies (178,179,183,206,249,250). CA and RA separately prepared in DMSO were 
exposed to cells. Both CA and RA significantly increased glucose uptake in skeletal 
muscle cells at concentrations corresponding to that found in the whole rosemary 
extract (RE). Higher concentrations of CA and RA had an even greater effect on skeletal 
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muscle glucose uptake. These novel findings indicate that polyphenolic compounds 
found in RE increase skeletal muscle glucose uptake and possess anti-hyperglycemic 
properties. Moreover, it also suggests that the positive effects of RE on skeletal muscle 
glucose uptake is attributable to its polyphenolic components. Interestingly, the degree 
of glucose uptake in myotubes elicited by RE treatment was greater than CA and RA 
alone which suggests that CA and RA may be acting on a mutual signaling pathway 
which is stimulated more so in the presence of both CA and RA rather than these 
bioactive compounds alone. Additionally, microscopic examination of cells did not 
indicate signs of cytotoxicity with all concentrations of CA and RA tested. Notably, an in 
vitro study examining the cytotoxicity of CA in human hepatocytes reported that 50 to 
100 µM CA treatment for 24 hours appears to be cytotoxic causing nuclei to be not 
observed, cytoplasm to become granular and filled with vacuoles, and cause changes in 
cell morphology (221). The cell viability EC50 for CA was determined to be 95 µM with 24 
hour incubation in human hepatocytes. Futhermore, Dickman’s study also reported that 
CA at concentrations of ≥ 50 µM to decreased intracellular ATP levels without affecting 
caspase3/7 activity and lactate dehydrogenase (LDH) release which led authors to 
conclude that CA may be acting as a mitochondrial toxin (221). These levels (50-100 μM) 
of CA are much higher than those used in the present study and therefore this is in 
support of the observation that cell viability was not affected in the present study. On 
the other hand, an in vivo 30-day toxicity study determined that 150-300 mg/kg body 
weight of CA treatment did not have adverse effects on histopathological and 
hematological factors in the rat and concluded that CA has a low oral toxicity profile 
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(216). Furthermore, the acute, median lethal dose (LD50) for CA was determined to be 
7100 mg/kg body weight (216).  
We also examined the effects of CA and RA on insulin-stimulated glucose uptake. 
Based on the observation that higher concentrations of CA and RA had a greater effect 
on basal skeletal muscle glucose uptake compared to concentrations of CA and RA 
found in RE, we chose to use the former concentrations to determine whether these 
polyphenolic compounds have an effect on insulin-stimulated glucose uptake. It should 
be noted that these concentrations of CA and RA have been found in extracts of 
rosemary by others (176,178,179,182,183,206). This is the first study to report that both 
CA and RA significantly increased insulin-stimulated glucose uptake. This finding 
indicates that CA and RA, major polyphenolic components of RE, possess insulin-
sensitizing properties and deserve further extensive investigation in vivo.     
4.2 Elucidating the mechanism of action of RE and its bioactive 
compounds  
Insulin activates the PI3K-Akt pathway in target tissues and the phosphorylation of the 
proximal enzyme Akt leads to increased GLUT4-containing vesicles translocation which 
results in greater plasma membrane availability of GLUT4 and increased glucose uptake 
(15,71). In this study, we examined the potential role of PI3K, a lipid kinase situated 
upstream of Akt, in mediating the effects of RE and its bioactive compounds CA, and RA. 
In order to do this, we used wortmannin, which is a microbial secondary metabolite that 
irreversibly inhibits PI3K (128). Our results indicated that the effect of RE and its 
bioactive compounds on glucose uptake is PI3K independent since inhibition of PI3K by 
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wortmannin did not affect RE-, CA- or RA-stimulated glucose uptake while insulin-
stimulated glucose uptake was significantly reduced. We further examined the effect of 
RE and its bioactive compounds on Akt phosphorylation. Full activation of Akt requires 
phosphorylation of its residues Thr308 and Ser473 and as a result phosphorylation of 
Akt at either of these residues has been generally accepted as an indication of Akt 
activation (15). In contrast to insulin, neither RE nor its bioactive compounds, CA and 
RA, induced Akt phosphorylation. These data indicate that the PI3K-Akt pathway is not 
involved in RE-, CA- and RA-induced glucose uptake. Studies with resveratrol, another 
polyphenol, have demonstrated that it increases glucose uptake in L6 myotubes (88) in 
an Akt-independent manner. Similarly, the polyphenol narigenin was shown to increase 
glucose uptake in L6 myotubes in an Akt-independent manner (247). Our data indicate 
that RE and its bioactive compounds CA and RA have similar effects on skeletal muscle 
glucose uptake to that of resveratrol and narigenin and these effects are achieved in a 
PI3K-Akt independent manner.  
 An alternative way of stimulating glucose uptake in skeletal muscle is through 
activation of AMPK. AMPK is a serine/threonine kinase and activation of this enzyme 
requires phosphorylation at its Thr172 residue which has been acknowledged as 
indication of its activation (67). Activators of AMPK include an increase in intracellular 
AMP: ATP ratio and its upstream kinases LKB1 and CaMKK (38). We report here that RE 
increased AMPK phosphorylation in a time-dependent manner in skeletal muscle cells. 
We also found that CA and RA significantly increased AMPK phosphorylation/activation 
in skeletal muscle cells. Furthermore, inhibition of AMPK with compound C (an ATP-
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competitive inhibitor of AMPK) significantly reduced RE- and CA-stimulated skeletal 
muscle glucose uptake while RA-induced glucose uptake was unaffected. These results 
indicate that AMPK is involved in RE-stimulated glucose uptake. While, both CA and RA 
activate AMPK, AMPK appears to be involved in CA-stimulated glucose uptake however, 
RA does not require AMPK to increase skeletal muscle glucose uptake. Previously, an in 
vitro study demonstrated that RE increased AMPK phosphorylation in hepatocytes 
(226). Similarly, carnosic acid was shown to activate AMPK in hepatocytes in a time-
dependent manner (189). Our present in vitro study for the first time shows that RE and 
its bioactive compounds CA and RA increased AMPK phosphorylation in skeletal muscle. 
In particular, compound C did not alter RA-stimulated glucose uptake indicating that 
AMPK may not be involved in its action on the glucose transport in skeletal muscle cells. 
The role of AMPK in RE, CA and RA stimulated glucose uptake could be strengthened by 
small interference RNA (siRNA) knockdown and/or dominant negative AMPK mutants in 
order to confirm or rule out its involvement. Furthermore, RA may affect other well-
established signalling molecules that regulate glucose uptake such as protein kinase C 
(PKC), the CAP/Cbl pathway, or p38 mitogen activated protein kinase (p38 MAPK) which 
has been shown to regulate GLUT4 activation in L6 myotubes and 3T3-L1 adipocytes 
(251,252). Future studies could investigate the effects of RE and its major polyphenols 
on the abovementioned signaling molecules with the western blotting technique.  
  Given that AMPK activation can occur by increased AMP: ATP ratio, and upstream 
kinases including LKB1 and CaMKK, it will be important to determine whether the 
bioactive compounds found in RE affect any of these mechanisms in leading to 
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increased activity of AMPK. Currently, there are no reported studies examining the 
effects of RE’s or its bioactive compounds on the mechanism of AMPK activation. RE or 
its bioactive compounds CA and RA may allosterically modulate AMPK activity, increase 
the activity of upstream kinases (LKB1 and CaMKK) (41), or alternatively cause an 
increase in the AMP: ATP ratio secondary to inhibition of the mitochondrial complex 1 
(78,86,253). Indeed, metformin, an anti-diabetic drug, has been demonstrated to 
activate AMPK by inhibiting the mitochondrial complex 1 (85,254).  
As mentioned before, skeletal muscle glucose uptake is mediated by the glucose 
transporters (GLUTs). During basal conditions, GLUT1 is predominantly responsible for 
transporting glucose in skeletal muscle (2). On the other hand, GLUT4 becomes the 
major glucose transporter in skeletal muscle in response to insulin (2,76). The degree of 
skeletal muscle glucose uptake dictated by the GLUTs is determined by a combination of 
regulatory mechanism including GLUTs intrinsic activity, translocation and stability (half-
life) (3). Since we report that RE and its bioactive compounds CA and RA increase 
skeletal muscle glucose uptake, we sought to determine their effects on GLUT1 and 
GLUT4 translocation. These transporters are expressed in L6 myotubes and have been 
shown to be affected by insulin and metformin. We measured surface GLUT1 and GLUT4 
levels with L6 GLUT1myc and GLUT4myc cells that stably express GLUT1 or GLUT4 
respectively, tagged with an exofacial myc epitope. The amount of GLUT1myc and 
GLUT4myc incorporated into the plasma membrane was quantitated by 
immunologically labelling the myc epitope at the surface of intact cells.  
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To date, the study of GLUTs translocation has been performed using subcellular 
fractionation, immunodetection by light and electron microscopy or GLUT 
photolabelling (255). These methodological approaches however are limited in 
providing an accurate quantification of GLUT translocation due to low yield of plasma 
membrane of treated cells and incomplete separation of the individual membrane 
compartments. Furthermore, fractionation does not distinguish between GLUT vesicles 
incorporated into the plasma membrane from those docked but unfused or occluded 
(256). These shortcomings are circumvented with the use of the L6 cell line expressing 
GLUTs harboring a myc epitope in the exofacial loop of the transporter at the cell 
surface of intact cells which can be detected using immunofluorescent and 
immunochemical labelling techniques of the myc epitope. To note, the intracellular 
distribution, recycling, exocytotic and endocytotic rates and insulin-response of 
GLUTmyc are identical to those of GLUT (255). Furthermore, this system enables the 
direct comparision of the fold GLUTs translocation with the fold stimulation of glucose 
uptake in response to insulin and as a result facilitate predictions about the intrinsic 
activity of GLUTs (255,256). 
First of all, insulin treatment stimulated GLUT1 and GLUT4 glucose transporter 
translocation in agreement with other studies in L6 myotubes (257-260), and human 
primary myotubes (261,262). RE and its major polyphenolic constituents CA and RA did 
not cause significant increases in GLUT1 and GLUT4 translocation despite significant 
increases in glucose transport by these treatements in GLUT1 and GLUT4 overexpressing 
cells. These findings indicate that RE-, CA- and RA-stimulated glucose uptake is not due 
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to GLUT1 or GLUT4 translocation. The dissociation of glucose transport and glucose 
transporter (GLUTs) translocation could suggest that RE and its polyphenolic 
constituents CA, and RA may have a sole or combined effect on 1) the intrinsic activity of 
the GLUT1 and GLUT4 transporters, 2) the intrinsic activity of other glucose transporters 
expressed in the L6 cell line (GLUT3), 3) the translocation of GLUT3 4) the stability/half 
life of the glucose transporters (GLUTs -1,-3, -4).  
 
Figure 27: Schematic representation of the proposed in vitro mechanism of action of 
rosemary extract (RE) and its polyphenolic constituents, carnosic acid (CA) & 
rosmarinic acid (RA), on skeletal muscle glucose uptake. Akt (PKB), protein kinase B; 
AMPK, AMP-activated Kinase (heterotrimer αβγ subunits); AS160, Akt substrate of 160 
kDa; GLUT4, glucose transporter; IRS, Insulin receptor substrate; PDK; phosphoinositide-
dependent kinase-1; PI3K, phosphatidylinositol-3-kinase; PIP3, phosphatidylinositol 
(3,4,5)-trisphosphate. 
It is possible that RE and its polyphenolic constituents may affect the intrinsic activity of 
GLUTs (GLUT1, GLUT3, GLUT4) that are already present at the plasma membrane. 
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Alternatively, RE and its polyphenolic constituents may prolong the half-life of glucose 
transporters (GLUT1, GLUT3, GLUT4) by reducing the degradation rate and stabilizing 
GLUTs at the plasma membrane.  
 The increase in glucose uptake seen by RE, CA and RA in the present study may 
involve changes in hexokinase activity, a rate-limiting enzyme responsible for the initial 
phosphorylation of glucose and subsequent trapping of glucose inside the cell. This 
mechanism was reported to be utilized in myotubes which displayed increased glucose 
uptake in response to troglitazone, an antidiabetic drug belonging to the 
thiazolidediones class of drugs, whereby this drug caused activation of AMPK, secondary 
to alterations to the mitochondrial membrane potential, which was associated with 
increased glycolytic flux and increased hexokinase activity (245). It is possible that RE 
and its polyphenolic constituents CA and RA have an effect similar to troglitazone.  
  The bioavability of CA and RA have been reported in a limited number of 
studies. This information is relevant because these in vivo studies demonstrate that RE’s 
major polyphenols, CA and RA, have significant in vivo bioavailibity as well as being 
detectable in tissues; and provide strong evidence for the in vitro findings that these 
polyphenols have significant effects on skeletal muscle cell glucose uptake. Intragastric 
administration of 90 mg/kg of CA in rats was determined to result in a bioavailability of 
65% with a slow absorption (Tmax=125.6 min), and maximum plasma concentration of 42 
mg/L (263). The plasma half-life of CA was longer with intragastric (961 min) versus 
intravenous administration (68 min) (263). Another study showed a bioavailability of 
40% in rats with intragastric administration of 65 mg/kg of CA with a maximum time 
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(Tmax) of 137 min and maximum concentration (Cmax) of 35 mg/L (264) which is in 
agreement with the previous study. CA was also detected in small intestines, as well as 
in liver and muscle tissue in trace amounts 24 hours post-administration (264). 
Furthermore, CA was predominantly found in free form in plasma and excreted in feces 
verus urine of animals (264). Furthermore, a recent in vivo study showed that oral 
administration of RE rich in CA at doses of 80-120 mg (29-49 mg CA) in the rat provides 
bioactive concentrations of CA and carnosol in the small and large intestines (up to 
several hundred µg/g), in the liver (1-15 µg/g) and in plasma (2-30 µM) (265). According 
to the European Food Safety Authority, the predicted maximal exposure to CA as a food 
additive is approximately 0.2 mg/kg body weight/day (266). Based on average body 
weight, total plasma volume, and 65% bioavailability, maximal plasma concentrations 
are calculated to approximately reach 3 nM (221). Therefore, the doses reported by 
Vaquero et al. (265) in rats, equivalent to a human dose of 50-100 mg of RE or 20-40 mg 
of CA/kg body weight per day, can only be attained through the consumption of 
nutraceuticals or supplements rich in these compounds. These doses are within the 
range of those established by the European Food Safety Authority as nonobserved 
adverse effect levels on 90 day feeding studies in rats (266). 
  In rats, oral administration of 50 mg/kg body weight of RA reaches maximum 
plasma concentration of 4.63 µM post 30 minutes and is found in free, methylated and 
conjugated forms of RA as well as its metabolites including caffeic acid, ferulic acid, and 
m-courmaric acid and are excreted in urine (267). Similarly, RA reached maximum serum 
concentration of 1.36 µM (0.5 mg/L) post 10 minutes in rats administered 100 µmol/kg 
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(36 mg/kg) body weight (268). In healthy men, single intake of perilla extract containing 
200 mg of RA, RA was detected in plasma 30 minutes post-intake with total RA reaching 
maximum plasma concentrations of 0.87-1.43 µM (267). Furthermore, metabolites of 
RA including caffeic acid, ferulic acid, and coumaric acid were detected in plasma and 
the main method of excretion was through the urinary route, (268). The relative 
potency of RA’s metabolic derivatives as compared to RA itself remains to be 
determined.  
The mechanism behind how CA and RA enter cells has not yet been directly 
examined. Nonetheless, extrapolations can be made from the chemical nature of these 
polyphenols. Since CA is a lipid-soluble molecule (177), it is possible that it may diffuse 
through the cell membrane and accumulate in the cytosol in this manner. In contrast, 
RA is a water-soluble molecule (250) and therefore, it may require a protein channel or 
transporter to enter the cell. Previous studies have indicated that RA is hydrolyzed 
neither chemically under the conditions of the gastrointestinal tract (GI) model nor by 
secreted enzymatic activity (lipase and pancreatic enzymes) but rather is degraded into 
its metabolic derivatives  m-coumaric and hydroxylated phenylphropionic acids by gut 
microflora before absorption and metabolization (268,269). RA’s metabolic derivatives 
were demonstrated to be absorbed and distributed within the body through the 
monocarboxylic acid transporter (MCT) (268,269). Additionally, it has been suggested 
that RA is absorbed in human intestinal Caco-2 cells through paracellular diffusion (270).  
 Based on the available data that RE and its bioactive compounds CA and RA both 
have a low toxicity profile and significant bioavailability, it would be important to study 
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the anti-hyperglycemic effects of these RE bioactive compounds in vivo. Although 
previous animal studies have shown that RE has anti-hyperglycemic effects, its 
mechanism of action was not determined. In the present study, we found that RE and its 
bioavailable polyphenolic compounds CA and RA increase skeletal muscle glucose 
uptake in a dose- and time-dependent manner. The reported improvements in plasma 
glucose levels of animals treated with RE could in fact be a result of RE’s direct effects 
on skeletal muscle glucose uptake. Furthermore, we report that RE, CA and RA activate 
AMPK in skeletal muscle. RE and CA-stimulated glucose uptake requires AMPK activity 
which requires further investigation. It remains to be determined how RE’s bioactive 
compounds lead to activation of AMPK.  
4.3 Limitations and Future Directions 
A limitation of the study is that RE contains various polyphenols which may be acting 
additively or synergistically to exert their effects and their identification and specific 
effects was not possible. Although, the effects of the major polyphenols found in RE, CA 
and RA, were tested on skeletal muscle glucose uptake, their combined effects were not 
assessed to determine whether they are acting additively or synergistically to exert their 
effects. Another limitation is that this study was done in an in vitro model of rat skeletal 
muscle which has limited applicability and generalizability to human skeletal muscle. 
Nonetheless, this particular skeletal muscle cell line is a well-established and extensively 
used in vitro model of skeletal muscle (41,44,241,271) and provides an appropriate, 
preliminary in vitro model for studying novel compounds with insulin-like effects.  
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It will be pertinent to examine the direct effects of RE, CA and RA in human skeletal 
muscle both in vitro and in vivo. Furthermore, the effects of RE, CA and RA could be 
evaluated in animals in vivo using tracer methods to examine if skeletal muscle glucose 
uptake is affected in response to these treatments.  
Based on microscopic analysis, RE and its polyphenolic constituents CA and RA did 
not have adverse effects on cell morphology or viability. Future studies should assess 
the cytotoxicity effects of RE and its polyphenols CA and RA using the lactate 
dehydrogenase (LDH) assay or the [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
bromide (MTT) assay.  
 It was found that RE and its polyphenolic constituents CA and RA require AMPK in 
order to increase skeletal muscle glucose uptake which needs to be further confirmed 
with a small interference RNA (siRNA) approach. In addition, their effects on skeletal 
muscle glucose uptake could be assessed in cells deficient in AMPK (91). Neither RE nor 
its polyphenolic constituents (CA, RA) affected GLUT1 or GLUT4 plasma membrane 
translocation suggesting that they may be modulating these glucose transporters’ 
intrinsic activity which needs to be examined. This potential effect could be determined 
by pretreating cells with indinavir, a chemical inhibitor of GLUT4, and determining the 
extent of glucose uptake in response to the various treatments compared to the control 
group (88,272). Cells would be pretreated with indinavir which would result in inhibiting 
glucose uptake through GLUT4 and this approach would enable the determination of 
the contributory roles of the different GLUT isoforms expressed in L6 cells (GLUT1, 
GLUT3, GLUT4) in increasing skeletal muscle cell glucose uptake in response to RE, CA 
Rosemary (Rosmarinus officinalis L.) Extract 
 
133 
 
and RA. Additionally, studies examining the effects of RE, CA and RA on GLUT half-life 
could be performed in the future by using [35S]-methionine labelling and glucose 
transporter immunoprecipitation (273). Furthermore, the effect of RE, CA and RA on 
GLUT3 translocation could be examined in the future using subcellular fractionation 
studies and an antibody specific for GLUT3. An alternative approach will be to create 
GLUT3myc overexpressing cells and employ enzyme-linked immunosorbent assay using 
anti-myc antibody to quantify cell surface GLUT3. In addition, GLUT1, GLUT3 and/or 
GLUT4 protein total membrane content should be measured using membrane 
fractionation and immunoblotting technique to determine whether RE and it’s 
polyphenols CA and RA have effects on total protein expression of these glucose 
transporters. 
 It is important to note that the possibility exists that by having used [3H]-2-deoxy-D-
glucose, a non-metabolizable analogue of glucose, that can still be phosphorylated by 
hexokinase, the increases in glucose uptake in response to the various treatments may 
not solely be representative of glucose transport but glucose phosphorylation as well. 
The use of 3-0-methylglucose, which is a non-metabolizable glucose analogue that 
cannot be phosphorylated by hexokinase, in the future could provide a better insight in 
this matter. If an increase in 3-0-methylglucose uptake was observed, it would be solely 
attributable to glucose transport. 
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4.4  Summary/Conclusion 
Skeletal muscle is important in glucose homeostasis and it is quantitatively the most 
important insulin-target tissue. Impaired insulin action in this tissue leads to insulin 
resistance and type 2 diabetes mellitus. In recent years, activation of the energy sensor, 
5’ AMP-activated kinase (AMPK), has been viewed as a targeted approach to counteract 
insulin resistance. Chemicals found in plant extracts such as polyphenols have attracted 
attention for their potential use for treating IR. Recent in-vitro and in-vivo studies 
indicate that rosemary extract (RE) has anti-diabetic properties, although its effects on 
muscle and exact mechanisms involved are not known.  
In the present thesis, we examined the effects of RE and the mechanism of 
regulation of glucose uptake in skeletal muscle cells. RE stimulated glucose uptake in L6 
myotubes in a dose- and time-dependent manner. Maximum stimulation was seen with 
5 µg/ml of RE for 4 h (184±5.07% of control, p<0.001), a response comparable to 
maximum insulin stimulation (191±5.26% of control, p<0.001). Furthermore, carnosic 
acid (CA) and rosmarinic acid (RA), major polyphenols found in RE, increased glucose 
uptake indicating that these compounds may be responsible for the RE effects. RE along 
with CA, and RA did not affect Akt phosphorylation while significantly increasing AMPK 
phosphorylation. Furthermore, RE-, and CA-induced glucose uptake was significantly 
reduced by the AMPK inhibitor, compound C while remaining unchanged by the PI3K 
inhibitor, wortmannin. RE, CA and RA did not affect GLUT4 and GLUT1 plasma 
membrane translocation in L6 GLUT4myc and GLUT1myc overexpressing myotubes 
while glucose uptake in these cells was similar to the parental L6 cells signifying that 
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these treatments may be affecting the intrinsic activity of these glucose transporters, 
which will require further examination. Our study is the first to show a direct effect of 
RE and it polyphenolic constituents CA and RA on skeletal muscle glucose by a 
mechanism that involves AMPK activation. Our findings are very important and suggest 
a potential use of RE to regulate glucose homeostasis and counteract insulin resistance.   
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